Articles: Background

Articles
Global, regional, and national incidence, prevalence, and

years lived with disability for 301 acute and chronic diseases
and injuries in 188 countries, 19902013: a systematic
analysis for the Global Burden of Disease Study 2013
Global Burden of Disease Study 2013 Collaborators*
Summary
Background Up-to-date evidence about levels and trends in disease and injury incidence, prevalence, and years lived
with disability (YLDs) is an essential input into global, regional, and national health policies. In the Global Burden of
Disease Study 2013 (GBD 2013), we estimated these quantities for acute and chronic diseases and injuries for
188 countries between 1990 and 2013.
Methods Estimates were calculated for disease and injury incidence, prevalence, and YLDs using GBD 2010 methods
with some important renements. Results for incidence of acute disorders and prevalence of chronic disorders are new
additions to the analysis. Key improvements include expansion to the cause and sequelae list, updated systematic
reviews, use of detailed injury codes, improvements to the Bayesian meta-regression method (DisMod-MR), and use of
severity splits for various causes. An index of data representativeness, showing data availability, was calculated for each
cause and impairment during three periods globally and at the country level for 2013. In total, 35 620 distinct sources of
data were used and documented to calculated estimates for 301 diseases and injuries and 2337 sequelae. The comorbidity
simulation provides estimates for the number of sequelae, concurrently, by individuals by country, year, age, and sex.
Disability weights were updated with the addition of new population-based survey data from four countries.
Published Online
June 8, 2015
http://dx.doi.org/10.1016/
S0140-6736(15)60692-4
See Online/Comment
http://dx.doi.org/10.1016/
S0140-6736(14)62254-6
*Collaborators listed at the end
of the Article
Correspondence to:
Prof Theo Vos, Institute for
Health Metrics and Evaluation,
2301 5th Avenue, Suite 600,
Seattle, WA 98121, USA
[email protected]
Findings Disease and injury were highly prevalent; only a small fraction of individuals had no sequelae. Comorbidity
rose substantially with age and in absolute terms from 1990 to 2013. Incidence of acute sequelae were predominantly
infectious diseases and short-term injuries, with over 2 billion cases of upper respiratory infections and diarrhoeal
disease episodes in 2013, with the notable exception of tooth pain due to permanent caries with more than 200 million
incident cases in 2013. Conversely, leading chronic sequelae were largely attributable to non-communicable diseases,
with prevalence estimates for asymptomatic permanent caries and tension-type headache of 24 billion and 16 billion,
respectively. The distribution of the number of sequelae in populations varied widely across regions, with an expected
relation between age and disease prevalence. YLDs for both sexes increased from 5376 million in 1990 to
7648 million in 2013 due to population growth and ageing, whereas the age-standardised rate decreased little from
11487 per 1000 people to 11031 per 1000 people between 1990 and 2013. Leading causes of YLDs included low back
pain and major depressive disorder among the top ten causes of YLDs in every country. YLD rates per person, by
major cause groups, indicated the main drivers of increases were due to musculoskeletal, mental, and substance use
disorders, neurological disorders, and chronic respiratory diseases; however HIV/AIDS was a notable driver of
increasing YLDs in sub-Saharan Africa. Also, the proportion of disability-adjusted life years due to YLDs increased
globally from 211% in 1990 to 312% in 2013.
Interpretation Ageing of the worlds population is leading to a substantial increase in the numbers of individuals with
sequelae of diseases and injuries. Rates of YLDs are declining much more slowly than mortality rates. The non-fatal
dimensions of disease and injury will require more and more attention from health systems. The transition to nonfatal outcomes as the dominant source of burden of disease is occurring rapidly outside of sub-Saharan Africa. Our
results can guide future health initiatives through examination of epidemiological trends and a better understanding
of variation across countries.
Funding Bill & Melinda Gates Foundation.
Introduction
The Global Burden of Disease Study 2013 (GBD 2013) is
the rst of a series of yearly updates for the GBD studies
that began with estimates for 1990 and were most
recently updated to 2010. The 2010 update (GBD 2010)
systematically quantied prevalence of 1160 sequelae of
289 diseases and injuries across 21 regions.1 National

estimates for 187 countries were also derived on the basis
of global and regional statistical analyses.1 The metrics of
years lived with disability (YLDs), equal to the sum of
prevalence multiplied by the general publics assessment
of the severity of health loss, was used to explore patterns
www.thelancet.com Published online June 8, 2015 http://dx.doi.org/10.1016/S0140-6736(15)60692-4
Articles
See Online for appendix
over time, age, sex, and geography.1 Results for specic

diseases and impairments have been extensively
reported.246 These results drew attention to the
importance of disability from musculoskeletal disorders,
mental and substance use disorders, and various other
non-communicable diseases.1 In developing countries,
disorders such as anaemia and neglected tropical
diseases remained important contributors to health
loss.18,43,47 More generally, the analysis showed the global
transition towards a rapid increase in YLDs due to global
population growth and ageing, combined with little
progress in reduction of age-specic YLD rates.
In view of the ambitious goal of the GBD 2010, to
synthesise the global evidence for the countryagesex
year prevalence of all major disorders, several specic
estimates were critiqued. Specic data sources, modelling
assumptions, and aspects of the general approach were
challenged and there was widespread recognition that
more and higher quality data could improve the
estimates.4852 Disability weights that were used to
calculate YLDs were based on surveys of the general
public in ve countries (Bangladesh, Indonesia, Peru,
Tanzania, and the USA) and an open internet survey. The
validity of disability weights was questioned for selected
states including hearing loss, vision loss, drug use, spinal
cord lesion, intellectual disability, and musculoskeletal
disorders.53,54 Some investigators questioned whether
disability weights should be used to measure health or
the loss of wellbeing associated with health states.53,55
Additionally, the YLD uncertainty intervals were large for
several disorders because of scarce data, hence there was
a need to statistically adjust for dierent case denitions,
measurement methods, and wide uncertainty intervals
for disability weights. Wide uncertainty intervals reduced
the number of signicant dierences for some disorders
reported across time and countries. Broad interest and
crucial discourse about GBD also drew attention to many
unpublished data sources in specic countries that could
be used to strengthen the analysis.
With the prominent role attached to quantication of
disease burden for health research and policy nationally
and globally, up-to-date estimates based on the latest
evidence for descriptive epidemiology constituted an
essential global public good.2227,32,5660 The GBD 2013
provides an opportunity to incorporate constructive
criticism about GBD 2010 data sources, model
development, methods, and interpretation. Additionally,
the GBD 2013 shows methodological advances and
includes new data for disability weights, capturing
many new published or unpublished data sources for
the disorders included in the GBD. Here, we report
data, methods, and results from the analysis of
188 countries for 1990 to 2013 for 301 diseases and
injuries and their 2337 sequelae. We report incidence
for acute sequelae, prevalence for chronic sequelae,
total prevalence by cause, in addition to YLDs for all
causes. Because prevalence and YLDs for the entire
period from 1990 to 2013 were reanalysed using

consistent data and methods, these results supersede
any previous publications about GBD.
Methods
Overview
Our general approach was similar to that for GBD 2010.
The analysis of incidence and prevalence for HIV/AIDS,
tuberculosis, and malaria for GBD 2013 have already
been reported in detail.61 Key changes from GBD 2010
were the inclusion of new data through updated
systematic reviews and the contribution of unpublished
data sources from many collaborators; elaboration of the
sequelae list to include asymptomatic states, such as
Plasmodium
falciparum
parasitaemia
(without
symptoms); use of more detailed nature-of-injury codes;
improvements to the Bayesian meta-regression method;
increased simulation size for comorbidity; estimation of
the prevalence of injuries by cohort; and use of a novel
method to estimate the distribution of mild, moderate,
and severe anaemia by cause.
Cause and sequelae list changes

Based on feedback about GBD 2010, and input from the
GBD 2013 collaborators, we expanded the cause and
sequelae list (appendix pp 6089). There were several key
changes. First, we included asymptomatic states as
explicit sequelae so that overall disease prevalence
estimates were available, which might be useful for
disease targeting, health service planning, or mass
treatment strategies. Asymptomatic sequelae, by
denition, were not associated with ill health and
therefore were not assigned disability weights. Second, to
deal with the challenge that some of the nature-of-injury
categories used in the GBD 2010 were highly
heterogeneous, these categories were expanded from
23 to 47. Third, we added several new causes and sequelae.
All these additions to the cause list were done to either
reduce the size of the large residual categories, such as
other injuries, or recognition of substantial
epidemiological heterogeneity within a disease category
(appendix pp 6089). With these changes, the cause list
was expanded from 289 to 301 causes and from 1160 to
2337 sequelae. Most of the increase in sequelae was due
to the expansion of the nature-of-injury sequelae, which
applied to each of the external causes of injuries. The
appendix pp 9096 provides a list of the International
Statistical Classication of Diseases and Related Health
Problems, Tenth Revision (ICD-10) and International
Classication of Diseases, Ninth Revision (ICD-9) codes
for all GBD causes and the nature-of-injury categories.
Data sources
GBD 2010 collaborators undertook systematic reviews
for most of the causes and sequelae. For some sequelae,
the majority of the data came from household survey
microdata reanalysis and administrative data such as
Articles
hospital discharges. For others, most of the data were

extracted from publications. Documentation of the GBD
2010 systematic reviews, however, was not centralised
and only some of these reviews have been published. For
this study, we updated systematic reviews through
Aug 31, 2013. In some cases, studies published after
Aug 31, 2013, were identied and included on the basis of
GBD collaborator input; no data or studies were extracted
after Nov 30, 2014. Household surveys including the
demographic and health surveys, multiple indicator
cluster surveys, living standards measurement surveys,
reproductive health surveys, and various national health
surveys included in the Global Health Data Exchange
were systematically screened for data relevant to
sequelae. For some diseases, case notications reported
to WHO were used as inputs and updated until the end
of 2013. The appendix pp 97653 provides a full list of
citations for sources organised by country that were used
for this analysis.
We computed an index of the geographical and
temporal representativeness of the data sources available
for non-fatal health outcomes for each cause or
impairmentthe data representativeness index (DRI).
The overall DRI simply counts the fraction of countries
that have any incidence, prevalence, remission, or excess
mortality data available for causes that are prevalent in
that country. We did not count cause of death data in this
measure, even if it was used in the estimation of
incidence or prevalence. We computed the same measure
for three periods: before 1998, 19982005, and 2006
onwards. Table 1 provides the overall DRI and periodspecic DRI measures for each cause and table 2 provides
the same information for estimation of total impairment
prevalence. The DRI was also computed for level 1 and
level 2 causes (aggregate causes; see appendix pp 6089)
by counting data availability for any cause within that
aggregate. This metric represents the availability of data
and does not incorporate any assessment of data quality.
The all-cause DRI was 100% overall and for each period,
indicating that there was at least data for one cause for all
188 countries in each period. At more detailed levels,
however, there was wide variation in the DRI across
causes and time. DRI ranged from less than 2% for eight
causes, including glucose-6-phosphate dehydrogenase
deciency trait and other mental and substance use
disorders, to 100% for Chagas disease, African
trypanosomiasis, and food-borne trematodiases. Causes
with required infectious disease case reporting had high
DRI values. Other disorders, such as cancers, had DRI
values above 70% due to the network of population-based
cancer registries. Although the time trend varied by
disease, many of the highest DRI values were from 1998
to 2005. The lag in data analyses and publications might
explain lower DRI values for 2006 to present.
Data representativeness can also be assessed at the
country level. Figure 1 shows a map of the percentages of
causes for which there were data available in each of the
188 countries between 1990 and 2013. The DRI values

ranged from 6% in South Sudan to 92% in the USA.
Many developed countries had data for more than 65% of
causes; Brazil, India, and China have similar levels. Low
levels of data availability were noted in several
sub-Saharan African countries, central Asia, the
Caribbean, and the Balkans. There was substantial
Before 1998
All causes
Communicable, maternal, neonatal, and
nutritional diseases
HIV/AIDS and tuberculosis
For the Global Health Data

Exchange see http://ghdx.
healthdata.org
19982005
200613
Total
1000%
1000%
1000%
1000%
995%
1000%
1000%
1000%
995%
910%
968%
989%
Tuberculosis
569%
915%
984%
995%
HIV/AIDS
798%
803%
798%
803%
HIV/AIDS resulting in mycobacterial infection
33%
11%
05%
33%
798%
803%
798%
803%
979%
995%
1000%
1000%
Diarrhoeal diseases
319%
585%
383%
670%
Intestinal infectious diseases
181%
250%
106%
346%
165%
106%
64%
202%
48%
80%
48%
90%
Lower respiratory infections
309%
612%
489%
734%
Upper respiratory infections
309%
282%
250%
447%
Otitis media
181%
117%
59%
234%
Meningitis
303%
367%
223%
479%
367%
HIV/AIDS resulting in other diseases

Diarrhoea, lower respiratory, and other
common infectious diseases
Typhoid fever
Paratyphoid fever
Other intestinal infectious diseases
Pneumococcal meningitis
261%
213%
85%
Haemophilus inuenzae type B meningitis
261%
218%
80%
372%
Meningococcal meningitis
255%
202%
85%
356%
255%
202%
80%
346%
Encephalitis
Other meningitis
197%
207%
154%
303%
Diphtheria
574%
612%
596%
713%
Whooping cough
973%
963%
936%
984%
Tetanus
644%
654%
612%
750%
Measles
973%
979%
989%
989%
Varicella and herpes zoster

Neglected tropical diseases and malaria
144%
176%
27%
213%
973%
989%
979%
995%
Malaria
378%
319%
234%
426%
Chagas disease
421%
1000%
579%
1000%
Leishmaniasis
414%
441%
441%
526%
276%
322%
336%
401%
Visceral leishmaniasis
296%
336%
342%
408%
African trypanosomiasis
Cutaneous and mucocutaneous leishmaniasis
944%
1000%
1000%
1000%
Schistosomiasis
500%
500%
212%
45%
Cysticercosis
43%
16%
05%
64%
Cystic echinococcosis
69%
181%
144%
202%
379%
379%
197%
500%
345%
276%
259%
448%
Lymphatic lariasis
Onchocerciasis
Trachoma
Dengue
504%
548%
548%
600%
Yellow fever
909%
955%
886%
955%
Rabies
495%
612%
596%
676%
(Table 1 continues on next page)
Articles
Before 1998
19982005
200613
Total
(Continued from previous page)

Intestinal nematode infections
927%
883%
701%
993%
Ascariasis
927%
883%
701%
993%
Sequelae incidence and prevalence
Trichuriasis
927%
883%
701%
993%
Hookworm disease
920%
883%
693%
985%
1000%
353%
59%
1000%
330%
516%
473%
606%
101%
277%
223%
335%
48%
154%
154%
186%
Maternal hypertensive disorders
128%
340%
367%
468%
Obstructed labour
101%
234%
239%
293%
Complications of abortion
32%
133%
138%
160%
Other maternal disorders
681%
702%
585%
819%
Preterm birth complications
362%
452%
314%
553%
Neonatal encephalopathy due to birth asphyxia

and trauma
122%
144%
59%
202%
The appendix pp 65484 provides a brief description of

the modelling strategy used for each sequela and cause.
The most extensively used estimation method was the
Bayesian meta-regression method DisMod-MR 2.0. For
some causes such as HIV or hepatitis B and C, diseasespecic natural history models were used in which the
underlying three state model in DisMod-MR 2.0
(susceptible, cases, or dead) was insucient to capture
the complexity of the disease process. For some diseases
with a range of sequelae dierentiated by severity, such
as chronic obstructive pulmonary disease (COPD) or
diabetes mellitus, DisMod-MR 2.0 was used to metaanalyse the data for overall prevalence. Separate DisModMR 2.0 models were then used to analyse data for the
proportion of cases with dierent severity levels or
sequelae. Likewise, DisMod-MR 2.0 was used to
meta-analyse data for the proportions of liver cancer and
cirrhosis due to underlying causes such as hepatitis B,
hepatitis C, and alcohol use. For acute sequelae, we
report incidence (dened as a duration of 3 months or
less) at the cause level in table 3, because incidence is the
preferred measure for disorders of short duration.
DisMod-MR 2.0 represents a major advance in the
computational speed, geographical disaggregation of
full internally consistent posterior estimation, and
display of data results compared with DisMod-MR 1.0,
which was used in GBD 2010. Through cross-validation
tests, Flaxman and colleagues reported62 that the logrates specication of models worked as well or better
than the negative binomial specication used in
DisMod-MR 1.0. Based on these ndings, and the
substantial improvements in computational speed for
log-rate models, this specication was the default
method for DisMod-MR 2.0. The appendix pp 36
provides details of the DisMod-MR 2.0 likelihood
estimation. The DisMod-MR 1.0 sequence of global
estimation, regional estimation, and country prediction,
which we call an analytical cascade, is illustrated in the
appendix p 734. DisMod-MR 2.0 uses a more complete
cascade (appendix p 735). At the global level, a mixedeects non-linear regression with all available country
data was used to generate initial global estimates that
are passed to the next level of the DisMod cascade to
inform the model for each super region. In turn, a
super-region
specic
mixed-eects
non-linear
regression was used to estimate for regions. The same
regression method was used for estimation of further
geographical disaggregation. The analyst could choose,
depending on data density, to branch the cascade in
terms of time and sex at dierent levels. In GBD 2010,
DisMod-MR 1.0 was used to generate ts for three
periods only: 1990, 2005, and 2010 because of long
Food-borne trematodiases
Other neglected tropical diseases
Maternal disorders
Maternal haemorrhage
Maternal sepsis and other infections
Neonatal disorders
Neonatal sepsis and other infections

Haemolytic disease and other neonatal jaundice
Other neonatal disorders
48%
32%
05%
69%
426%
404%
351%
553%
936%
957%
910%
989%
Protein-energy malnutrition
926%
957%
910%
989%
Iodine deciency
378%
223%
27%
452%
Vitamin A deciency
208%
50%
08%
225%
Iron-deciency anaemia
Other nutritional deciencies
824%
830%
771%
926%
372%
431%
197%
564%
11%
37%
00%
37%
Chlamydial infection
165%
266%
138%
404%
Gonococcal infection
Nutritional deciencies
Other communicable, maternal, neonatal, and

nutritional diseases
Sexually transmitted diseases excluding HIV
Syphilis
154%
239%
80%
319%
Trichomoniasis
80%
181%
96%
266%
Genital herpes
245%
245%
32%
319%
43%
11%
05%
48%
569%
457%
197%
681%
564%
Other sexually transmitted diseases

Hepatitis
Hepatitis A
468%
277%
122%
Hepatitis B
362%
277%
53%
436%
Hepatitis C
266%
282%
85%
383%
207%
122%
59%
255%
881%
776%
853%
993%
Hepatitis E
Leprosy
Other infectious diseases
37%
21%
00%
43%
Non-communicable diseases
984%
995%
984%
995%
Neoplasms
739%
745%
691%
824%
Oesophageal cancer
654%
681%
612%
761%
Stomach cancer
654%
691%
617%
766%
Liver cancer
665%
713%
638%
787%
Liver cancer due to hepatitis B
170%
176%
96%
245%
Liver cancer due to hepatitis C
176%
176%
101%
245%
Liver cancer due to alcohol use
69%
96%
64%
112%
Liver cancer due to other causes
37%
53%
43%
59%
variation within regions; for example, Kenya had 49%,

whereas Djibouti had less than 10%, Laos had 14%, and
Thailand had 54%.
Articles
computational time. For GBD 2013, we generated ts

for 1990, 1995, 2000, 2005, 2010, and 2013.
DisMod-MR 2.0 internal validity was assessed by use of
R for adjusted data. Results for all DisMod-MR 2.0 models
are provided in the appendix pp 65484. Adjusted data
were the original study data transformed to the reference
case denition and measurement method, using the metaregression component of DisMod-MR 2.0 to make the data
from dierent studies with varying methods comparable.
External validity was also evaluated through crossvalidation on a small number of sequelae due to the
computational time and complexity for this analysis. We
selected ten DisMod-MR 2.0 models representing a range
of data densities to evaluate. We held out 30% of datapoints
for incidence and prevalence at random, ret the model,
and compared predictions to the held-out data. We
assessed model performance using two metrics: the rootmean squared error of the predictions compared with the
data held out, and the coverage of the data prediction with
95% uncertainty intervals. The appendix pp 73637
provides these metrics for the ten models tested. In all
cases, external validity was equal to or only slightly worse
than the internal validity.
As in GBD 2010, DisMod-MR was not used to model
estimates for a shortlist of causes; custom models were
created for many of these. For some of these causes,
important improvements in the modelling strategy were
implemented. Changes for HIV and malaria have been
described elsewhere.61 For dengue, the model was
modied to use the rst component of a principal
components analysis of Bhatt and colleagues dengue
transmission probability to improve estimation of case
rates.63 For lymphatic lariasis, precontrol levels were
estimated from data reported in the lymphatic lariasis
atlas.64 Last, based on crucial input from GBD
collaborators, we chose to model rheumatic heart disease
in low-income and middle-income countries separately
from high-income countries in view of potential
dierences in long-term cohort eects of treatment.
Estimation for cancer in GBD 2013 largely followed a
similar analytical strategy to GBD 2010, which used a
combination of incidence data, survival data, and
sequelae durations to estimate cancer prevalence and
YLDs.65,66 The analysis beneted from the inclusion of
both the latest edition of Cancer Incidence in Five
Continents and a larger number of other cancer registries
particularly in China. In GBD 2013, we also incorporated
new data from the US National Cancer Institutes
Surveillance, Epidemiology, and End Results Program
(SEER)67 and WHOs International Agency for Research
on Cancers Cancer Survival in Africa, Asia, the
Caribbean, and Central America to update best and worst
case survival, yearly survival trends, and sequelae
durations for all cancers.68 Based on evidence that
individuals with most cancers continue to have higher
mortality beyond 5 years than do the general population,
we estimated the burden of cancer for up to 10 years after
Before 1998
19982005
200613
Total

Larynx cancer
654%
681%
612%
755%
Tracheal, bronchus, and lung cancer
654%
691%
617%
766%
Breast cancer
660%
691%
617%
766%
Cervical cancer
654%
691%
612%
766%
Uterine cancer
654%
686%
617%
766%
Prostate cancer
654%
691%
617%
766%
Colon and rectum cancer
654%
691%
612%
761%
Lip and oral cavity cancer
601%
665%
601%
750%
Nasopharynx cancer
601%
660%
601%
745%
Other pharynx cancer
601%
660%
601%
745%
Gallbladder and biliary tract cancer
601%
660%
601%
745%
Pancreatic cancer
606%
676%
606%
750%
Malignant skin melanoma
622%
670%
606%
750%
Non-melanoma skin cancer
601%
681%
622%
750%
Ovarian cancer
606%
665%
612%
745%
Testicular cancer
606%
665%
601%
745%
Kidney cancer
606%
665%
601%
745%
Bladder cancer
606%
670%
606%
745%
Brain and nervous system cancer
606%
676%
612%
750%
Thyroid cancer
606%
660%
601%
745%
Mesothelioma
537%
644%
580%
739%
Hodgkins lymphoma
606%
665%
601%
745%
Non-Hodgkin lymphoma
606%
676%
606%
755%
Multiple myeloma
606%
670%
606%
750%
Leukaemia
660%
691%
622%
771%
Other neoplasms
660%
691%
628%
777%
713%
766%
691%
862%
Cardiovascular diseases
Rheumatic heart disease
154%
191%
186%
340%
Ischaemic heart disease
218%
426%
138%
500%
Cerebrovascular disease
638%
649%
633%
755%
Ischaemic stroke
590%
644%
628%
739%
Haemorrhagic stroke
596%
644%
622%
734%
Hypertensive heart disease
117%
101%
85%
186%
Cardiomyopathy and myocarditis
128%
229%
191%
309%
133%
Atrial brillation and utter
85%
106%
59%
Peripheral vascular disease
37%
90%
43%
117%
Endocarditis
59%
160%
144%
176%
Other cardiovascular and circulatory diseases

Chronic respiratory diseases
Chronic obstructive pulmonary disease
00%
05%
05%
05%
383%
649%
324%
686%
117%
170%
90%
223%
27%
133%
133%
154%
27%
133%
133%
154%
118%
176%
176%
235%
Coal workers pneumoconiosis
57%
200%
200%
229%
Other pneumoconiosis
16%
122%
117%
133%
346%
649%
250%
686%
80%
165%
138%
181%
154%
191%
181%
293%
Cirrhosis due to hepatitis B
106%
69%
43%
149%
Cirrhosis due to hepatitis C
128%
74%
43%
165%
Pneumoconiosis
Silicosis
Asbestosis
Asthma
Interstitial lung disease and pulmonary sarcoidosis
Other chronic respiratory diseases
Cirrhosis
Articles
Before 1998
19982005
200613
Total
Cirrhosis due to alcohol use
69%
53%
37%
96%
Cirrhosis due to other causes
53%
53%
43%
85%
303%
Digestive diseases
197%
250%
186%
Peptic ulcer disease
53%
144%
149%
170%
Gastritis and duodenitis
27%
138%
138%
154%
Injuries
Appendicitis
21%
133%
138%
149%
Paralytic ileus and intestinal obstruction
32%
154%
138%
170%
21%
133%
138%
149%
128%
144%
64%
191%
149%
We followed a similar strategy to GBD 2010 for estimating

the burden of injuries, except for an expanded list of
26 external cause-of-injury categories (from 15) and
47 nature-of-injury categories (from 23) for both shortterm outcomes and lasting disability (see appendix
pp 9096 for ICD codes). More detail was added to both
external causes and nature-of-injury categories to reduce
epidemiological heterogeneity within each combination
of cause and nature-of-injury category. The key analytical
steps are explained in greater detail in the appendix
pp 914. Here we provide a summary of the methods.
First, for each external cause, DisMod-MR 2.0 was used
to analyse incidence based on hospital, emergency
department, and survey data. Second, we estimated the
distribution of nature of injury for each external cause
using data that had both types of code available. When
individuals were coded with more than one nature-ofinjury code, we used the most severe. Third, we analysed
seven studies that provided at least 1 year of follow-up for
various natures of injury to estimate long-term disability.6975
Fourth, we estimated cohort prevalence of long-term
disability from the incident cases of injury for each
external cause and nature-of-injury combination while
accounting for excess mortality for the more severe postinjury sequelae. For some injuries, treatment modies the
disability weight. In these cases, we approximated the
fraction of injuries receiving treatment as a function of an
indicator of health system access.76
Short-term disability was estimated for all natures of
injury by cause-of-injury categories as the product of
prevalence (estimated by multiplying incidence by mean
duration) and the appropriate disability weight. The
duration for treated cases of injuries was determined by
information in the Dutch Injury Surveillance System
follow-up studies of 200104 and 200710.71,73 We used
expert opinion to estimate a multiplier for the duration of
short-term disability from untreated injuries and used
the estimates of access to care by country and year as we
have described for the long-term disability.
Inguinal, femoral, and abdominal hernia

Inammatory bowel disease
Vascular intestinal disorders
Gallbladder and biliary diseases
Pancreatitis
Other digestive diseases
Neurological disorders
21%
133%
138%
106%
165%
144%
223%
48%
149%
149%
160%
463%
372%
287%
553%
223%
Alzheimers disease and other dementias
186%
154%
122%
Parkinsons disease
181%
149%
74%
234%
Epilepsy
213%
160%
37%
282%
Multiple sclerosis
213%
160%
74%
261%
Migraine
160%
133%
117%
250%
90%
64%
106%
191%
Medication overuse headache
32%
48%
90%
112%
Other neurological disorders
85%
32%
00%
90%
378%
585%
356%
676%
191%
Tension-type headache
Mental and substance use disorders

Schizophrenia
170%
90%
37%
Alcohol use disorders
197%
287%
149%
314%
Drug use disorders
207%
473%
261%
516%
Opioid use disorders
128%
176%
27%
197%
Cocaine use disorders
69%
319%
59%
346%
Amphetamine use disorders

Cannabis use disorders
Other drug use disorders
Depressive disorders
Major depressive disorder
Dysthymia
Bipolar disorder
64%
239%
80%
277%
160%
420%
207%
468%
197%
239%
112%
330%
197%
239%
112%
330%
90%
138%
53%
186%
85%
160%
37%
186%
Anxiety disorders
128%
218%
53%
261%
Eating disorders
106%
122%
43%
149%
Anorexia nervosa
101%
122%
43%
144%
Bulimia nervosa
85%
117%
32%
149%
53%
59%
37%
96%
53%
53%
37%
96%
Autistic spectrum disorders

Autism
Aspergers syndrome
16%
48%
16%
53%
106%
101%
48%
191%
Conduct disorder
59%
64%
16%
112%
Idiopathic intellectual disability
64%
32%
11%
74%
YLDs from 29 residual causes
Other mental and substance use disorders
05%
05%
00%
11%
Diabetes, urogenital, blood, and endocrine

diseases
979%
984%
920%
984%
367%
351%
335%
585%
53%
181%
59%
191%
798%
824%
755%
894%
Despite expanding our list of causes and sequelae in

GBD 2013, many diseases remain for which we do not
explicitly model disease prevalence and YLDs. The GBD
cause list is collectively exhaustive such that all sequelae
with an ICD code are mapped to a cause group (appendix
pp 9096). Many less common sequelae are included in
29 of the residual categories. For 14 of these cause
groupings, epidemiological data for incidence or
Attention-decit or hyperactivity disorder
Diabetes mellitus
Acute glomerulonephritis
Chronic kidney disease
incidence. Estimates for cancer sequelae now represent

the burden for all cancer patients by contrast with
estimation of the burden just for cancer survivors (see
appendix pp 78 for more detail on aspects of estimating
non-fatal cancer outcomes that were dierent from the
methods used in GBD 2010).
Articles
prevalence are available so that they can be modelled as

other causes have been modelledthis set includes
meningitis, cirrhosis, liver cancer, pneumoconiosis, and
chronic kidney disease due to other causes, other
neoplasms, other cardiovascular and circulatory diseases,
other drug use disorders, other mental and substance
use disorders, other gynaecological diseases, other
musculoskeletal disorders, other skin and subcutaneous
diseases, age-related and other hearing loss, other vision
loss, other sense organ diseases, and other oral disorders.
For 12 residual categories (other intestinal infectious
diseases, other neglected tropical diseases, other maternal
disorders, other neonatal disorders, other nutritional
deciencies, other infectious diseases, other chronic
respiratory diseases, other digestive diseases, other
neurological disorders, other urinary diseases, other
haemoglobinopathies and haemolytic anaemias, and
other congenital anomalies), epidemiological data for
incidence and prevalence were not available for the entire
residual cause groupings but sucient cause of death
data allowed for cause of death estimates. For each
category, we identied causes within the larger cause
group that had both estimates of years of life lost (YLLs)
and YLDs, which we expected to have similar ratios of
mortality to morbidity. We then computed the ratio of
YLLs to YLDs for these specic causes (on a country
sexyear basis) and applied them to the residual
categorys YLLs to estimate its YLDs. This approach
makes the simplied assumption that on average within
a level 2 disease grouping the disability is proportionate
to mortality within a countrysexyear. For an additional
three residual categories (other sexually transmitted
diseases, other drug use disorders, and other mental and
substance use disorders), there were no overall
epidemiological data or sucient deaths to generate
cause of death estimates. For the last two, we used US
outpatient data or prevalence data from the Medical
Expenditure
Panel
Survey
(MEPS),
National
Epidemiologic Survey on Alcohol and Related Conditions
(NESARC), or the 1997 Australian mental health survey77
and applied a severity distribution from these surveys in
all countries and periods. These two causes for which US
and Australian data were applied worldwide account for
16% of global YLDs.
Before 1998
19982005
200613
Total

Chronic kidney disease due to diabetes mellitus
69%
85%
191%
271%
Chronic kidney disease due to hypertension
69%
117%
191%
287%
Chronic kidney disease due to

glomerulonephritis
59%
74%
191%
261%
32%
59%
191%
245%
154%
213%
176%
287%
Chronic kidney disease due to other causes

Urinary diseases and male infertility
Interstitial nephritis and urinary tract infections
21%
133%
138%
149%
Urolithiasis
85%
181%
160%
202%
Benign prostatic hyperplasia
69%
160%
144%
197%
Male infertility due to other causes
53%
32%
16%
80%
Gynaecological diseases
660%
952%
229%
952%
Uterine broids
21%
32%
48%
69%
Polycystic ovarian syndrome
21%
48%
32%
80%
Female infertility due to other causes
53%
32%
16%
80%
Endometriosis
37%
37%
48%
64%
Genital prolapse
32%
37%
05%
80%
644%
952%
69%
952%
Other urinary diseases
Premenstrual syndrome
Other gynaecological diseases
Haemoglobinopathies and haemolytic anaemias
Thalassaemias
16%
133%
138%
149%
979%
979%
601%
979%
872%
872%
872%
388%
Thalassaemia trait
11%
00%
00%
11%
Sickle cell disorders
963%
968%
521%
968%
Sickle cell trait
05%
00%
00%
05%
Glucose-6-phosphate dehydrogenase
deciency
399%
245%
53%
463%
Glucose-6-phosphate dehydrogenase
deciency trait
05%
05%
05%
16%
Other haemoglobinopathies and haemolytic

anaemias
Endocrine, metabolic, blood, and immune disorders
Musculoskeletal disorders
16%
133%
138%
149%
229%
441%
202%
511%
245%
Rheumatoid arthritis
165%
138%
96%
Osteoarthritis
106%
101%
74%
181%
128%
415%
133%
463%
128%
404%
122%
463%
64%
128%
32%
154%
112%
96%
48%
181%
Low back and neck pain

Low back pain
Neck pain
Gout
Other musculoskeletal disorders
64%
59%
21%
101%
Other non-communicable diseases
585%
612%
479%
750%
Congenital anomalies
266%
287%
213%
324%
Neural tube defects
144%
202%
207%
223%
Impairments
Congenital heart anomalies
207%
229%
207%
255%
As in GBD 2010, we estimated the countryagesexyear

prevalence of nine impairments: anaemia, epilepsy,
hearing loss, heart failure, intellectual disability,
infertility, vision loss, Guillain-Barr, and pelvic
inammatory disease. These impairments were selected
because they are sequelae of more than one disease and
data are available to estimate prevalence for the overall
impairment. Generally, overall impairment prevalence
was estimated using DisMod-MR 2.0. Cause-specic
estimates of impairments, such as the 19 causes of
blindness, are required to provide the total prevalence
Orofacial clefts
218%
245%
207%
255%
Downs syndrome
218%
239%
207%
255%
Turners syndrome
80%
101%
101%
106%
85%
106%
106%
112%
207%
234%
207%
255%
Klinefelters syndrome
Chromosomal unbalanced rearrangements
Other congenital anomalies
Skin and subcutaneous diseases
Dermatitis
Psoriasis
112%
96%
16%
165%
351%
468%
309%
511%
324%
399%
202%
436%
48%
90%
48%
138%
Articles
Before 1998
19982005
200613
Total

Cellulitis
16%
128%
133%
Bacterial skin diseases
37%
186%
154%
144%
218%
Scabies
85%
90%
59%
165%
Fungal skin diseases
27%
85%
59%
122%
Viral skin diseases
64%
74%
53%
128%
Acne vulgaris
59%
69%
59%
138%
Alopecia areata
21%
27%
21%
48%
Pruritus
21%
37%
32%
69%
Urticaria
32%
43%
32%
85%
Decubitus ulcer
21%
128%
133%
144%
Other skin and subcutaneous diseases

Sense organ diseases
05%
05%
05%
05%
223%
277%
144%
457%
Glaucoma
149%
106%
69%
234%
Cataract
170%
191%
117%
367%
Macular degeneration
122%
122%
69%
239%
00%
00%
32%
32%
122%
112%
21%
181%
160%
Uncorrected refractive error

Age-related and other hearing loss
Other vision loss
85%
74%
37%
Other sense organ diseases
05%
05%
05%
05%
394%
309%
250%
511%
Deciduous caries
287%
213%
176%
426%
Permanent caries
293%
213%
160%
410%
Periodontal diseases
186%
128%
53%
255%
96%
90%
90%
160%
Oral disorders
Edentulism and severe tooth loss

Other oral disorders
05%
05%
05%
05%
947%
947%
947%
963%
27%
340%
170%
426%
27%
340%
165%
420%
Pedestrian road injuries
11%
43%
80%
80%
Cyclist road injuries
11%
48%
74%
80%
Injuries
Transport injuries
Road injuries
Motorcyclist road injuries
11%
43%
74%
74%
Motor vehicle road injuries
11%
48%
74%
80%
Other road injuries
11%
43%
74%
74%
Other transport injuries
11%
43%
85%
85%
Unintentional injuries
32%
122%
138%
202%
Falls
21%
106%
133%
181%
Drowning
11%
74%
96%
117%
Fire, heat, and hot substances
27%
90%
122%
160%
Poisonings
16%
85%
112%
149%
Exposure to mechanical forces
16%
85%
96%
138%
Unintentional rearm injuries
11%
48%
85%
85%
Unintentional suocation
05%
48%
85%
85%
Other exposure to mechanical forces
11%
48%
85%
85%
Adverse eects of medical treatment
11%
48%
85%
85%
Animal contact
21%
85%
117%
154%
Venomous animal contact
11%
48%
85%
85%
Non-venomous animal contact
11%
48%
85%
85%
11%
48%
85%
85%
Foreign body in pulmonary aspiration and

foreign body in airway
11%
48%
85%
85%
Foreign body in eyes
11%
27%
48%
48%
Foreign body
estimated for that impairment. Anaemia, epilepsy,

hearing loss, heart failure, intellectual disability, and
pelvic inammatory disease are estimated for dierent
levels of severity. Separate estimates were made for
primary infertility (in couples who have not been able to
conceive) and secondary infertility (in couples having
trouble conceiving again) and, for each, if the impairment
is aecting men or women, or both. The severity
distribution of cause-specic prevalence of each
impairment was estimated as explained above or, in the
absence of severity-specic data, assumed to be
proportionate across all levels of severity. In the case of
epilepsy, severity levels were determined by mixed-eect
models for the proportions of primary, severe, and
treated epilepsy, and a meta-analysis for seizure-free
treated epilepsy, and thus had values that were specic
for country, age, sex, and year. DisMod-MR 2.0 models
produced country-specic, age-specic, sex-specic, and
year-specic levels of hearing loss and vision loss. Due to
little information about the severity levels of intellectual
disability, we assumed a similar distribution of severity
worldwide based on meta-analysis of intelligence
quotient (IQ)-specic data for the overall impairment.
This was supplemented with cause-specic distributions
for chromosomal causes and iodine deciency, whereas
the severity of intellectual disability included in the longterm sequelae of causes such as meningitis, neonatal
tetanus, and malaria was combined with several
impairments such as motor impairment, blindness, or
seizures. The severity of heart failure is derived from our
MEPS analysis and therefore is not specic for country,
year, age, or sex.
Our method for estimating overall anaemia was largely
the same as in GBD 2010 but with the addition of new
data sources, specically subnational data for the UK,
China, and Mexico.43 We adopted dierent thresholds for
dening anaemia during the neonatal period, because
the GBD 2010 thresholds did not account for
haematological realities of early life. The GBD 2013
thresholds match the WHO recommendations78 with the
exception of thresholds of less than 1 month because
there is no international cuto for diagnosis at that
age.43,79 To disaggregate marginal estimates of anaemia
severity and cause into a complete set of prevalence
estimates for cause and severity pairs, we developed a
new method for GBD 2013 that used techniques from
Bayesian contingency table modelling.80,81
In GBD 2010, hearing loss of more than or equal to
35 dB in DisMod-MR 1.0 was estimated and then broken
down into six severity levels based on a series of
regressions on the proportionate distribution across
categories. In GBD 2013, we rst estimated the
prevalence of normal hearing, hearing loss of 2034 dB
(mild), and greater than 35 dB (moderate and above);
these three categories were xed to add up to 100%. We
then ran separate DisMod-MR 2.0 models for ve severity
levels (ie, moderate 3549 dB, moderately severe
Articles
5064 dB, severe 6579 dB, profound 8094 dB, and

complete 95 dB), which were then proportionally
rescaled to t in the 35 dB or greater envelope. In GBD
2010, the same severity distribution was assumed for
each cause of hearing loss. In GBD 2013, we customised
the prevalence estimation for each cause. Hearing loss
due to otitis media and age-related hearing loss were
estimated by DisMod-MR 2.0 using prevalence data.
Hearing loss due to meningitis was estimated as a
proportion of meningitis cases from a meta-analysis.82
Congenital hearing loss was estimated using birth
prevalence data in DisMod-MR 2.0, assuming a constant
prevalence for all ages because there was no evidence of
an increased mortality risk. We assumed all hearing loss
from otitis media was mild or moderate on the basis of
reported distribution of hearing loss.83,84 To account for
hearing aids, we assumed that the use of a hearing aid
reduces the severity of hearing loss by one severity level.
The other causes were assumed to cover the full range of
severities. More details about impairments are provided
in the appendix pp 1532.
Severity distributions
For 213 causes, a range of sequelae are dened in terms of
severity. Important changes to the sequelae list with
regards to severity include low back pain, alcohol and drug
dependence categories, uterine prolapse, and epilepsy.
Milder states for low back pain and alcohol and drug
dependence categories were added because these
disorders had a large gap between asymptomatic cases
and the high value of the disability weight for the least
severe symptomatic categories, whereas the epidemiological data for severity indicates a sizeable
proportion of cases with milder disability. Stress
incontinence was added as a sequela of uterine prolapse
with a new disability weight that is distinct from full
incontinence. Also, epilepsy health states are now better
aligned with epidemiological data based on seizure
frequency. In cases in which severity is related to a
particular impairment, such as mild, moderate, and
severe anaemia due to malaria, the analysis is driven by
the impairment estimation described above. For some
outcomes such as COPD or asthma, data have been
gathered in dierent locations around the world and these
have been modelled using DisMod-MR 2.0 (see appendix
pp 694733 for details). In other cases, published metaanalyses have been used to estimate the allocation of cases
by severity. For the remaining causes, we used the same
approach for estimating the distribution of severity as in
the GBD 2010; empirical analysis of this model was
updated through the addition of 2 years from the US
MEPS. The appendix pp 68587 lists the GBD causes that
can be identied in MEPS and the corresponding
ICD-9 CM codes. In total, 203 960 observations, covering
119 676 individuals, were used. In the cases of dementia,
Parkinsons disease, multiple sclerosis, osteoarthritis,
schizophrenia, and bipolar disorder, data identied
Before 1998
19982005
200613
Total

Foreign body in other body part
Other unintentional injuries
Self-harm and interpersonal violence
11%
48%
85%
85%
27%
106%
117%
181%
165%
21%
90%
133%
Self-harm
11%
74%
117%
128%
Interpersonal violence
21%
85%
122%
160%
Assault by rearm
11%
48%
85%
85%
Assault by sharp object
11%
48%
85%
85%
Assault by other means
11%
21%
37%
37%
1000%
983%
989%
1000%
Exposure to forces of nature
1000%
988%
994%
1000%
Collective violence and legal intervention
1000%
991%
991%
1000%
Forces of nature, war, and legal intervention
GBD 2013=Global Burden of Diseases 2013 Study.
Table 1: GBD 2013 data representativeness index by cause
Before 1998
19982005 200613 Total
Anaemia
612%
569%
223%
745%
Epilepsy
356%
234%
117%
441%
Guillain-Barr
syndrome
122%
59%
00%
133%
234%
Hearing loss
101%
154%
59%
Heart failure
101%
176%
154%
213%
Infertility
495%
346%
271%
601%
Intellectual disability
122%
69%
32%
160%
Pelvic inammatory
disease
43%
122%
128%
149%
223%
468%
245%
601%
Vision loss
For more on DisMod-MR 2.0 see

http://ihmeuw.org/dismod-ode
For the Cancer Incidence in Five
Continents see http://ci5.iarc.fr/
Default.aspx
GBD 2013=Global Burden of Diseases 2013 Study.
Table 2: GBD 2013 data representativeness index by impairment, calculated

as fraction of countries with data for each impairment and period
through literature reviews were used to inform the severity

distribution. The introduction of a mild health state for
four drug dependence categories required identication
of epidemiological data to estimate the proportion of cases
with mild versus more severe disability. For cannabis
dependence, we used the NESARC survey in the USA and
the Australian National Survey of Mental Health and
Wellbeing. For the remaining three drug dependence
categories, we only had access to one study on polydrug
users in Australia, which led to about half of dependent
cases being assigned to the more severe and mild health
states. Although this information is derived from a nonrepresentative cohort of drug users, it was thought to be
more appropriate than deriving a severity distribution
from a household survey like NESARC in which only a
small proportion of individuals dependent on opioids,
cocaine, or amphetamines would be represented.
Revisions to disability weights

The GBD 2010 disability weights measurement study
introduced a new method of pairwise comparisons as a
means of eliciting weightings for health states in
Articles
<10%
10% to <15%
15% to <20%
20% to <25%
25% to <35%
35% to <45%
45% to <55%
55% to <65%
65% to <80%
>80%
ATG
VCT
Barbados
Comoros
West Africa
Dominica
Caribbean
LCA
Grenada
TTO
Maldives
TLS
Mauritius
Seychelles
Marshall Isl
Kiribati
Solomon Isl
FSM
Vanuatu
Samoa
Fiji
Tonga
Eastern
Mediterranean
Malta
Persian Gulf
Singapore
Balkan Peninsula
Figure 1: Percentage of causes with data available between 1990 and 2013 for 188 countries
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines. Isl=Islands.
population surveys.85,86 Data were gathered in ve countries

(Bangladesh, Indonesia, Peru, Tanzania, and the USA)
and supplemented with a web survey. In total, responses
were gathered from 30 230 people in 167 countries.
Respondents were presented with a series of randomly
selected pairwise comparisons of lay descriptions of
health states and asked to state which health state is
healthier than the other. Salomon and colleagues85
developed a statistical model that yields from these
pairwise comparisons disability weights on a scale from
0 (no health loss) to 1 (equivalent to death).
Based on important commentary and review of the GBD
2013 collaborators, we have revised the lay descriptions of
32 states and added 16 new states. The revised lay
descriptions were based on identifying inconsistency in
the way progression across levels of severity had been
handled for some outcomes and the addition of social
isolation to the descriptions for complete, profound, and
severe hearing loss. New states included ve milder health
states for alcohol and drug dependence; two health states
for the alignment of epilepsy with the epidemiological data
dening severe epilepsy in individuals who had on average
one or more ts per month and less severe epilepsy in
those with between one and 11 ts in the past year; two
milder health states for low back pain; and one each for
stress incontinence, concussion, hypothyroidism,
hyperthyroidism, thrombocytopenic purpura, vertigo, and
10
amputation of one arm without treatment. The appendix

pp 68893 provides a complete list of the lay descriptions
of all 235 GBD 2013 health states.
In 2013, we had the opportunity to collaborate with the
European Centre for Disease Prevention and Control to
gather new data for disability weights in four
population-based national surveys (Hungary, Italy,
Sweden, and the Netherlands) using the Salomon and
colleagues protocol.85,87 Because of funding and
questionnaire length, the surveys included 140 of 220 GBD
2010 health states for which the lay descriptions had not
been revised, 32 health states with revised lay descriptions,
and 42 new health states, 16 of which were included in
GBD 2013. These nationally representative samples were
comprised of 30 660 respondents. For GBD 2013, the data
of GBD 2010 disability weights measurement study and
the European disability weights measurement study88 were
pooled in a single analysis of individual responses, thus
doubling the number of respondents to 60 890 in both
studies. For states where the lay description was not
previously included, revised, or new, only the European
disability weights measurement study data were used.
This means that all disability weights in GBD 2013 dier
from the GBD 2010 disability weights. Most disability
weights changed slightly, but some dier more widely
(appendix pp 68893). Some of the more substantial
changes were due to the inclusion of incontinence in the
Articles
Cases in 1990
( 1000)
Cases in 2013
( 1000)
Percentage change Age-standardised

rate in 1990
(per 100 000)
Age-standardised
rate in 2013
(per 100 000)
Percentage change
Upper respiratory
infections
13 557 038
(13 317 034 to
13 806 346)
18 770 589
(18 479 508 to
19 048 703)
3826*
(3533 to 4160)
243 6212
(239 3836 to
248 0193)
259 4910
(255 5471 to
263 3184)
648*
(420 to 895)
Diarrhoeal disease
episodes
2 920 208
(2 866 614 to
2 968 429)
2 711 253
(2 666 452 to
2 761 161)
729*
(955 to 491)
46 2657
(45 4407 to
47 0035)
37 4676
(36 8582 to
38 1519)
1907*
(2098 to 1709)
Other exposure to
mechanical forces
349 533
(334 775 to
367 702)
381 968
(364 953 to
401 105)
928*
(686 to 1152)
60494
(57970 to
63696)
50928
(48669 to 53551)
1581*
(1757 to 1416)
Acute otitis media
339 485
(332 992 to
345 806)
324 720
(318 445 to
330 958)
444*
(703 to 188)
52922
(51949 to
53842)
44809
(43940 to 45667)
1534*
(1758 to 1309)
Tooth pain due to

permanent caries
164 255
(144 960 to
184 155)
222 966
(194 054 to
252 697)
3563*
(3263 to 3869)
30284
3 0706
(26769 to 33915) (26723 to 34790)
141
(094 to 358)
148 035
(123 990 to
172 137)
154 851
(132 130 to
180 387)
481
(486 to 1419)
26557
(22447 to
30759)
21943
(18705 to 25729)
1721*
(2261 to 1195)
Falls
107 951
(106 004 to
109 801)
154 533
(151 535 to
157 392)
4316*
(3953 to 4697)
20303
(19931 to
20639)
20175
(19880 to 20480)
062
(290 to 169)
Lower respiratory
infections
164 622
(162 190 to
167 306)
150 087
(146 724 to
152 859)
885*
(1207 to 667)
28914
(28497 to
29409)
22069
(21565 to 22462)
2358*
(2617 to 2186)
Clinical episodes of
malaria
172 741
(107 735 to
279 197)
146 761
(85 673 to
249 239)
1656
(3466 to 1248)
28537
(17411 to 47557)
20360
(11844 to 34656)
2981*
(4489 to 593)
Chlamydia infection
111 204
(108 362 to
114 280)
141 437
(137 606 to
144 793)
2725*
(2227 to 3131)
20018
(19520 to
20559)
18854
(18343 to 19297)
569*
(936 to 273)
Chickenpox and herpes

128 020
zoster
(126 377 to
129 582)
139 665
(138 706 to
140 700)
884*
(773 to 1073)
19927
19354
(19709 to 20150) (19208 to 19504)
299*
(400 to 154)
Hepatitis B
137 639
(133 533 to
143 049)
129 191
(124 907 to
132 890)
622*
(967 to 253)
26445
17792
(25621 to 27539) (17217 to 18302)
3274*
(3529 to 2995)
Gallbladder and biliary

diseases
78 635
(77 174 to 80 289)
104 111
(101 889 to
106 283)
3223*
(2862 to 3623)
20056
15942
(19711 to 20495) (15606 to 16278)
2056*
(2264 to 1822)
Hepatitis A
90 801
(86 969 to
94 635)
101 711
(97 926 to
105 499)
1187*
(1135 to 1246)
14817
(14325 to
15296)
Other unintentional
injuries
13969
(13454 to 14484)
576*
(610 to 533)
70 771
94 747
3388*
(69 804 to 71 730) (93 084 to 96 457) (3103 to 3683)
13521
13128
(13341 to 13702) (12923 to 13341)
290*
(493 to 083)
Interstitial nephritis
and urinary tract
infections
55 473
(54 702 to 56 225)
92 847
(91 652 to 93 940)
6710*
(6428 to 7038)
11568
13443
(11426 to 11709) (13270 to 13603)
1614*
(1425 to 1831)
Gastritis and
duodenitis
76 611
(75 707 to 77 550)
90 638
(89 750 to 91 660)
1815*
(1630 to 1994)
18091
13936
(17897 to 18314) (13801 to 1 4095)
2300*
(2412 to 2188)
56 316
(53 588 to 59 210)
78 197
(74 585 to 81 629)
3904*
(2892 to 4808)
9770
(9318 to 10245)
10385
(9904 to 10842)
653
(093 to 1310)
Dengue
8220
(3294 to 17 234)
58 435
61087*
1483
(23 615 to 121 951) (60625 to 61550) (594 to 3110)
8109
(3277 to 16923)
44731*
(44359 to 45091)
Non-venomous animal
65 300
57 822
contact
(63 282 to 67 643) (55 870 to 59 726)
1143*
(1555 to 721)
11901
8084
(11557 to 12285) (7829 to 8331)
3206*
(3484 to 2913)
Trichomonas infection
40 045
(37 105 to 43 115)
57 794
(53 923 to 63 336)
4345*
(3100 to 6193)
7370
(6851 to 7893)
7716
(7202 to 8453)
431
(466 to 1724)
Motor vehicle road

injuries
40 958
54 201
(39 248 to 42 998) (51 723 to 57 134)
3235*
(2852 to 3735)
7826
(7521 to 8213)
7633
(7293 to 8029)
246
(511 to 090)
11
Articles
Cases in 1990
( 1000)
Cases in 2013
( 1000)

rate in 1990
(per 100 000)
Age-standardised
rate in 2013
(per 100 000)
Percentage change
7384
(6365 to 8384)
147*
(266 to 025)

Tooth pain due to
deciduous caries
50 436
(43 544 to 57 157)
53 082
(45 756 to 60 269)
507*
(377 to 637)
7489
(6466 to 8484)
52 264
(51 134 to 53 504)
50 399
(48 835 to 52 173)
381
(737 to 075)
14570
8107
(14245 to 14911) (7861 to 8389)
4443*
(4654 to 4186)
Urolithiasis
33 330
(30 306 to 36 585)
48 615
4555*
(43 576 to 54 046) (4224 to 4934)
7449
(6794 to 8205)
6909
(6204 to 7678)
734*
(929 to 516)
Genital herpes
37 033
(35 871 to 38 277)
46 840
2627*
(45 386 to 48 578) (2276 to 3012)
6339
(6140 to 6555)
6226
(6034 to 6454)
185
(455 to 108)
Cellulitis
31 740
(28 667 to 34 738)
37 449
(33 421 to 41 180)
1785*
(1320 to 2204)
6743
(6071 to 7399)
5475
(4882 to 6040)
1880* (2135 to
1680)
Fire, heat, and hot

substances
36 843
(35 438 to 38 193)
33 433
(31 570 to 35 304)
924*
(1428 to 371)
6539
(6313 to 6770)
4506
(4265 to 4746)
3108*
(3468 to 2722)
Foreign body elsewhere

21 835
in body
(21 544 to 22 091)
31 155
(30 749 to 31 549)
4269*
(4010 to 4546)
4554
(4500 to 4608)
4610
(4553 to 4667)
123
(057 to 305)
Hepatitis E
28 446
(27 083 to 30 055)
1838*
(1133 to 2686)
4332
(4144 to 4511)
3868
(3684 to 4085)
1088*
(1618 to 462)
Collective violence and

60 427
21 567
legal intervention
(40 630 to 98 088) (11 959 to 48 571)
6408*
(7595 to 1739)
16285
3904
(10564 to 26516) (2293 to 8427)
7548*
(8387 to 4203)
Adverse eects of
medical treatment
13 489
(13 334 to 13 646)
19 946
(19 714 to 20 176)
4788*
(4568 to 5011)
2733
(2702 to 2764)
2691
(2663 to 2719)
152*
(293 to 016)
16 174
(15 804 to 16 557)
18 133
(17 708 to 18 553)
1212*
(914 to 1510)
2994
(2927 to 3063)
2492
(2436 to 2549)
1676*
(1883 to 1450)
Other transport
injuries
16 956
(16 240 to 18 001)
18 083
(17 246 to 19 205)
670*
(004 to 1362)
3157
(3028 to 3329)
2445
(2333 to 2598)
2250*
(2711 to 1766)
Pancreatitis
10 057
(9954 to 10 157)
17 163
(16 976 to 17 376)
7045*
(6814 to 7280)
2348
(2326 to 2371)
2510
(2483 to 2539)
684*
(545 to 828)
Motorcyclist road
injuries
14 619
(12 221 to 16 302)
16 692
(13 485 to 18 844)
1415*
(774 to 2146)
2735
(2279 to 3050)
2269
(1840 to 2562)
1708*
(2140 to 1190)
Appendicitis
14 105
(12 914 to 15 603)
16 423
(14 441 to 18 501)
1660*
(089 to 3682)
2636
(2419 to 2909)
2252
(1985 to 2531)
1458
(2548 to 015)
10 450
Pedestrian road
injuries by road vehicle (9702 to 11 340)
14 353
(13 302 to 15 545)
3738*
(3269 to 4365)
2098
(1943 to 2281)
2105
(1948 to 2275)
035
(312 to 453)
Meningitis cases due

to other causes
14 177
(13 756 to 14 595)
12 819
(12 410 to 13 260)
958*
(1365 to 573)
2246
(2179 to 2315)
1753
(1697 to 1812)
2189*
(2539 to 1863)
Typhoid fever
13 685
(11 708 to 17 982)
10 955
(9641 to 14 354)
1993*
(3068 to 653)
2273
(1955 to 2977)
1515
(1336 to 1985)
3330*
(4190 to 2236)
Hepatitis C
9367
(9188 to 9539)
10 840
(10 650 to 11 014)
1554*
(1257 to 1902)
2010
(1963 to 2056)
1577
(1547 to 1605)
2159*
(2394 to 1890)
9713
(8578 to 10 973)
10 711
(9478 to 12 157)
1030*
(521 to 1585)
1838
(1646 to 2059)
1529
(1359 to 1736)
1684*
(2005 to 1323)
Acute myocardial
infarction
4862
(4640 to 5074)
8557
(8199 to 8919)
7577*
(7424 to 7772)
1411
(1346 to 1476)
1393
(1332 to 1454)
129*
(209 to 034)
Assault by sharp object
6021
(5779 to 6234)
7983
(7641 to 8284)
3262*
(2692 to 3828)
1118
(1072 to 1156)
1076
(1031 to 1115)
375
(787 to 021)
Acute ischaemic
stroke
4309
(4118 to 4532)
6893
(6550 to 7352)
5961*
(4861 to 7286)
1284
(1227 to 1350)
1143
(1085 to 1223)
1113*
(1729 to 314)
Paratyphoid fever
8846
(7761 to 10 194)
6378
(5550 to 7253)
2788*
(4181 to 1283)
1445
(1275 to 1661)
880
(765 to 1000)
3909*
(5086 to 2648)
Maternal hypertensive
disorders
5582
(3681 to 7427)
5707
(3792 to 7519)
208
(125 to 748)
967
(639 to 1278)
752
(501 to 989)
2226*
(2437 to 1854)
Exposure to forces of
nature
7326
(4728 to 13 492)
5658
(3694 to 11 899)
2155
(4557 to 3137)
1957
(1149 to 3331)
973
(552 to 1875)
5075*
(7191 to 997)
Venomous animal
contact
5702
(5390 to 6040)
5548
(5278 to 5843)
268
(678 to 146)
1060
(1010 to 1114)
771
(737 to 808)
2728*
(2990 to 2443)
3959
(3692 to 4201)
5298
(4955 to 5607)
3381*
(3026 to 3776)
746
(696 to 791)
735
(686 to 777)
139
(397 to 145)
23 967
(22 840 to 24 969)
12
Articles
Cases in 1990
( 1000)
Cases in 2013
( 1000)

rate in 1990
(per 100 000)
Age-standardised
rate in 2013
(per 100 000)
Percentage change

Obstructed labour
5362
(4833 to 5947)
5122
(4491 to 5610)
423
(1990 to 1021)
937
(848 to 1036)
672
(590 to 736)
2799*
(3942 to 1741)
4429
(3994 to 5014)
4649
(4331 to 5015)
472
(762 to 1774)
776
(703 to 873)
611
(570 to 659)
2140*
(3027 to 1177)
Assault by rearm
2487
(2266 to 2671)
3609
(3313 to 3881)
4516*
(3956 to 5109)
482
(440 to 517)
500
(460 to 538)
377
(017 to 793)
Pulmonary aspiration
and foreign body in
airway
2777
(2639 to 2986)
3568
(3396 to 3832)
2850*
(2560 to 3145)
525
(499 to 563)
497
(474 to 534)
528*
(723 to 318)
Acute haemorrhagic
stroke
1886
(1817 to 1977)
3366
(3200 to 3543)
7850*
(6550 to 8981)
534
(515 to 559)
543
(514 to 573)
161
(568 to 855)
Poisonings
3409
(3347 to 3477)
3282
(3208 to 3352)
370*
(617 to 139)
614
(603 to 625)
446
(436 to 455)
2743*
(2923 to 2583)
Self-harm
3222
(3187 to 3257)
3270
(3240 to 3302)
151*
(020 to 279)
612
(606 to 618)
438
(433 to 442)
2848*
(2934 to 2761)
Unintentional rearm
injuries
2749
(2556 to 2925)
3126
(2902 to 3344)
1371*
(1007 to 1766)
494
(460 to 525)
427
(397 to 456)
1366*
(1630 to 1085)
Complications of
abortion
2366
(2235 to 2525)
2642
(2510 to 2784)
1154*
(179 to 2091)
419
(396 to 446)
349
(331 to 367)
1687*
(2401 to 1006)
Paralytic ileus and

intestinal obstruction
1501
(1481 to 1517)
2530
(2487 to 2572)
6838*
(6490 to 7176)
381
(375 to 385)
396
(389 to 403)
404*
(181 to 620)
Other sexually
transmitted diseases
1884
(1771 to 2008)
2393
(2259 to 2540)
2709*
(1735 to 3622)
361
(340 to 383)
323
(306 to 343)
1014*
(1670 to 389)
Drowning
1803
(1708 to 1921)
1664
(1571 to 1782)
770*
(1101 to 422)
325
(308 to 347)
236
(223 to 253)
2733*
(3005 to 2460)
Unintentional
suocation
1102
(1003 to 1205)
1593
(1443 to 1741)
4453*
(4031 to 4818)
194
(177 to 212)
218
(197 to 238)
1217*
(916 to 1493)
Acute myocarditis
961
(909 to 1031)
1481
(1377 to 1592)
5354*
(4158 to 6941)
228
(215 to 245)
220
(205 to 236)
356
(1138 to 597)
Maternal sepsis and

other maternal
infections
1881
(1684 to 2088)
1389
(1227 to 1522)
2648*
(3640 to 1531)
322
(289 to 356)
183
(162 to 200)
4342*
(5097 to 3494)
Causes are ordered by overall incidence. All data are shown with 95% uncertainty intervals. *Signicant percentage change.
Table 3: Global incidence of acute sequelae (for less than 3 months) by cause for incidence greater than 1 million cases per year
lay descriptions for spinal cord injury and the inclusion of

the psychological consequences of social isolation in
people with more severe hearing loss, leading to much
higher disability weights. The statistical analysis generates
uncertainty distributions for each disability weight that are
propagated into the uncertainty distributions of the
estimates of YLDs.
Comorbidity
Many individuals have more than one disease or injury
sequela at the same time. To accurately account for
comorbidity and its eect on disability for individuals, we
used the GBD 2010 microsimulation approach. In the
microsimulations, a set of individuals are exposed to the
probability of having all the dierent sequelae included
in the GBD to estimate a distribution of the combinations
that might be seen in each countryagesexyear. We
modelled the probabilities within each country
agesexyear of dierent sequelae as independent.
Although there are clear examples of the probability of
one sequela changing the probability of other sequelae,

such as diabetes and ischaemic heart disease, testing
reported by Vos and colleagues1 suggested that modelling
assuming independence was a reasonable approximation.
However, for less common sequelae the microsimulation
tends to increase the estimated uncertainty in the
number of YLDs substantially because, for example, a
sequela that is estimated to have a prevalence of less than
one in 10 000 will not appear randomly in many
microsimulations of 20 000. Two steps have been taken
to reduce the ination of uncertainty for uncommon
sequelae. First, the number of simulants in each
countryagesexyear was increased to 40 000; the main
limiting factor for the number of simulants is
computational resources needed to run each of the
62 880 countryagesexyear simulations 1000 times to
account for uncertainty in each of the input prevalence
rates. Second, we excluded sequelae in a
countryagesexyear with a prevalence of less than one
in 20 000 from the microsimulation. The combined
13
Articles
A
Number of sequelae
0
1
2
4
5
1990
10
2013
Female population
Age (years)
Male population
Female population
Male population
80
7579
7074
6569
6064
5559
5054
4549
4044
3539
3034
2529
2024
1519
1014
59
04
50
40
30
20
10
00
10
20
30
40
50
50
40
30
20
10
00
10
20
30
40
50
250
200
150
100
50
00
50
100
150
200
250
250
200
150
100
50
00
50
100
150
200
250
Age (years)
B
80
7579
7074
6569
6064
5559
5054
4549
4044
3539
3034
2529
2024
1519
1014
59
04
Age (years)
C
80
7579
7074
6569
6064
5559
5054
4549
4044
3539
3034
2529
2024
1519
1014
59
04
80 70 60 50 40 30 20 10 0 0 10 20 30 40 50 60 70 80
Population (millions)
80 70 60 50 40 30 20 10 0 0
10 20 30 40 50 60 70 80
Population (millions)
Figure 2: Population pyramids for developed countries (A), developing countries (excluding sub-Saharan Africa) (B), and sub-Saharan African countries (C)
with individuals grouped by number of sequelae, 1990 and 2013
disability weight for individuals with several sequelae

was computed as in the GBD 2010 using a multiplicative
model; namely, the individuals disability weight is equal
14
to one minus the cross product of one minus the

disability weight for each sequela that the individual has.
An output from the comorbidity microsimulation is
Articles
Percentage
change
Age-standardised
rate in 1990
(per 100 000)
Age-standardised
rate in 2013
(per 100 000)
Percentage
change
2 389 517
(2 349 584 to
2 428 957)
3708*
(3548 to 3931)
33 6174
(33 0566 to
34 1304)
33 1524
(32 6089 to
33 6998)
147
(257 to
014)
1 072 423
Individuals with
recurrent tension-type (1 050 263 to
1 095 165)
headaches
1 561 447
(1 537 571 to
1 585 766)
4549*
(4186 to 4939)
21 7518
(21 3208 to
22 2025)
21 7518
(21 4281 to
22 0928)
000
(238 to
258)
Iron-deciency
anaemia
1 209 665
(1 205 539 to
1 213 899)
1 208 216
(1 205 927 to
1 210 478)
023
(061 to 013)
21 4211
(21 3521 to
21 4881)
16 7232
(16 6903 to
16 7560)
2194*
(2222 to
2167)
Glucose-6-phosphate
dehydrogenase
deciency trait
851 395
(846 058 to 855 869)
1 181 972
(1 174 352 to
1 188 844)
3865*
(3764 to 3987)
16 0221
(15 9233 to
16 1056)
16 5052
(16 3998 to
16 6009)
297*
(223 to 388)
Age-related and other

hearing loss
724 592
(676 905 to 767 910)
1 128 939
(1 055 658 to
1 200 476)
5566*
(5274 to 5837)
18 5208
(17 4462 to
19 5272)
17 3182
(16 2918 to
18 3219)
650*
(793 to
515)
Asymptomatic genital
herpes
760 731
(733 076 to 783 174)
1 124 670
(1 087 191 to
1 157 170)
4766*
(4473 to 5063)
16 8021
(16 1997 to
17 2930)
15 9147
(15 3830 to
16 3775)
532*
(708 to
350)
Individuals with
recurrent migraine
581 025
(569 050 to 594 688)
848 366
(831 035 to 864 852)
4606*
(4144 to 5008)
11 6908
(11 4606 to
11 9578)
11 7144
(11 4800 to
11 9392)
033
(280 to
299)
Ascariasis
1 078 935
(952 859 to 1 239 751)
804 370
(713 418 to 922 212)
2552*
(3777 to 1042)
20 2188
(17 6651 to
23 5054)
11 1548
(98861 to 12 7937)
4481*
(5424 to
3309)
473 167
(410 058 to 543 736)
683 714
4421*
(597 898 to 780 963) (4120 to 4795)
93249
96041
301*
(81946 to 10 6088) (84247 to 10 9140) (195 to 382)
Acne vulgaris
537 177
(507 605 to 567 912)
661 635
(622 842 to 700 242)
89483
(84576 to 94504)
89073
(83764 to 94250)
035
(781 to
729)
Uncorrected refractive
error
433 575
(425 242 to 442 348)
659 847
5197*
(648 299 to 671 447) (4903 to 5496)
10 4786
(10 2741 to
10 6839)
99317
(97559 to 10 1066)
524*
(701 to
343)
Low back pain
414 049
(408 102 to 420 024)
651 009
5676*
(641 143 to 662 885) (5355 to 6145)
94667
(93309 to 95943)
94425
(93027 to 96204)
043
(240 to
247)
301 876
(298 122 to 305 412)
503 967
6669*
(496 870 to 511 448) (6368 to 7009)
72187
(71322 to 73046)
73232
(72212 to 74296)
138
(042 to
339)
Other skin and

314 509
subcutaneous diseases (207 790 to 470 452)
495 328
(319 462 to 761 256)
5707*
(4847 to 6442)
72859
(45447 to 11 5638)
72875
(45591 to 11 5275)
003
(091 to
090)
Trichuriasis
543 402
(465 656 to 645 140)
477 374
(441 257 to 518 365)
1163
(2872 to 495)
10 1450
(85765 to 12 2013)
66181
(61175 to 71892)
3436*
(4783 to
2104)
Asymptomatic
deciduous caries
454 348
(450 942 to 457 847)
474 970
(471 627 to 478 341)
438*
(356 to 512)
67440
(66939 to 67953)
66045
(65578 to 66511)
213*
(288 to
144)
Hookworm disease
498 224
(436 949 to 577 353)
471 816
(437 050 to 511 319)
510
(2016 to 975)
93883
65375
(81529 to 10 9823) (60538 to 70844)
3006*
(4159
to 1842)
Diabetes mellitus
175 851
(159 924 to 187 156)
409 967
13291*
(381 806 to 432 038) (12369 to
14235)
41373
(37130 to 44428)
59910
(55609 to 63408)
4478*
(3850 to
5133)
Neck pain
226 306
(221 678 to 230 966)
349 305
(341 160 to 359 767)
5406*
(4911 to 5988)
50380
(49387 to 51419)
49689
(48544 to 51149)
146
(458 to
217)
Genital prolapse
218 569
(214 601 to 222 616)
343 708
(336 959 to 350 327)
5702*
(5302 to 6148)
48270
(47449 to 49115)
47853
(46937 to 48743)
091
(330 to
174)
Cases in 1990 ( 1000) Cases in 2013

( 1000)
Asymptomatic
permanent caries
1 740 088
(1 710 605 to
1 766 930)
2317*
(1386 to 3263)
15
Articles

( 1000)
Percentage
change
Age-standardised
rate in 1990
(per 100 000)
Age-standardised
rate in 2013
(per 100 000)
Percentage
change

Malaria parisitaemia,
anaemia, or chronic
sequelae
258 173
(249 606 to 265 369)
342 598
(332 249 to 351 506)
3256*
(2998 to 3515)
45171
(43673 to 46431)
47026
(45600 to 48248)
412*
(212 to 609)
Glucose-6-phosphate
dehydrogenase
deciency
229 334
(223 528 to 234 741)
337 629
(329 361 to 345 754)
4707*
(4212 to 5195)
42041
(40987 to 43029)
46817
(45675 to 47941)
1136*
(761 to
1507)
Dermatitis
240 442
(208 170 to 274 870)
333 785
(289 927 to 381 312)
3867*
(3619 to 4113)
47033 (40716 to
53608)
46248
(40275 to 52669)
169*
(238 to
091)
Chronic obstructive
pulmonary disease
198 729
(192 134 to 205 570)
328 504
(317 289 to 339 461)
6513*
(6380 to 6627)
48777
(47179 to 50485)
49038
(47417 to 50669)
051
(022 to
120)
Chronic hepatitis B
infection
333 998
(328 310 to 339 584)
316 130
(310 691 to 321 470)
542*
(786 to 334)
64934
(63795 to 66083)
44115
(43366 to 44843)
3206*
(3373 to
3055)
196 514
Individuals with
recurrent premenstrual (185 656 to 207 309)
syndrome
302 732
(284 373 to 321 830)
5381*
(4029 to 6791)
36814
(34725 to 38870)
40258
(37795 to 42776)
919
(011 to
1941)
Schistosomiasis
219 167
(196 779 to 240 733)
290 628
(252 099 to 337 576)
3091*
(2286 to 5191)
41029
(36817 to 45057)
39987
(34688 to 46448)
369
(969 to
1181)
Anxiety disorders
186 837
(148 567 to 228 275)
265 610
(213 015 to 318 817)
4241*
(3664 to 4675)
37063
(30016 to 44515)
36892
(29943 to 44158)
046
(175 to
080)
Sickle cell trait
166 448
(158 185 to 174 094)
261 741
(249 515 to 272 736)
5701*
(5422 to 5966)
30370
(28863 to 31759)
36241
(34547 to 37765)
1926*
(1714 to
2131)
Major depressive
disorder
164 643
(136 031 to 195 432)
253 314
5343*
(208 457 to 299 691) (4905 to 5891)
34092
(28129 to 40217)
35547
(29225 to 41882)
424*
(237 to 617)
Edentulism and severe

171 998
tooth loss
(169 934 to 174 085)
250 684
(247 512 to 253 463)
4560*
(4336 to 4794)
48455
(47880 to 49034)
40495
(40007 to 40938)
1644*
(1770 to
1510)
Other musculoskeletal
disorders
138 898
(121 127 to 157 325)
248 188
(216 691 to 281 934)
7835 *
(7499 to 8254)
34390
(29960 to 38885)
36695
(32210 to 41409)
663*
(496 to
888)
Osteoarthritis
140 495
(139 147 to 141 802)
241 825
7194*
(239 656 to 243 897) (6979 to 7429)
39391
(39013 to 39748)
38379
(38021 to 38710)
258*
(381 to
122)
Asthma
182 776
(180 098 to 185 615)
241 695
(238 151 to 245 465)
3210*
(2946 to 3491)
36269
(35767 to 36786)
34297
(33810 to 34811)
548*
(724 to
346)
Falls
141 364
(140 330 to 142 427)
232 033
(230 024 to 233 795)
6414*
(6246 to 6566)
23165
(23000 to 23337)
23531
(23321 to 23722)
158*
(045 to 255)
Thalassaemia trait
151 187
(138 147 to 169 166)
207 562
(192 411 to 228 438)
3733*
(3466 to 3959)
28203
(25690 to 31635)
28918
(26792 to 31844)
265*
(049 to 454)
Peripheral vascular
disease
104 476
(99 440 to 109 950)
185 137
(172 556 to 196 597)
7798*
(5995 to 9118)
29722
(28347 to 31173)
29587
(27652 to 31282)
012
(993 to
669)

112 461
due to other causes
(89 218 to 141 835)
173 091
(142 396 to 213 010)
5386*
(4354 to 6360)
25079
(20230 to 31030)
25746
(21359 to 31498)
312
(589 to
1011)
Uterine broids
105 090
(97 076 to 112 367)
171 005
(158 156 to 182 513)
6246*
(6124 to 6378)
23597
(21882 to 25132)
23203
(21458 to 24759)
177*
(233 to
118)
Chronic hepatitis C
infection
126 203
(124 380 to 128 156)
146 576
(144 285 to 148 813)
1604*
(1361 to 1852)
27418
(27056 to 27817)
21031
(20707 to 21344)
2331*
(2484 to
2167)
16
Articles

( 1000)
Percentage
change
Age-standardised
rate in 1990
(per 100 000)
Age-standardised
rate in 2013
(per 100 000)
Percentage
change

Other sense organ
diseases
108 541
(101 217 to 114 894)
145 834
(135 459 to 154 591)
3419*
(3251 to 3615)
20936
(19524 to 22164)
20907
(19420 to 22167)
017
(135 to
119)
Viral skin diseases
105 924
(87 145 to 124 492)
127 924
(105 593 to 151 636)
2052*
(1790 to 2428)
18052
(14873 to 21326)
17721
(14733 to 20859)
184*
(315 to
031)
Other mental and

substance use
disorders
81 356
(76 311 to 86 284)
124 043
(116 741 to 131 002)
5234*
(5095 to 5376)
17170
(16174 to 18128)
17204
(16204 to 18168)
019*
(010 to 030)
Polycystic ovarian
syndrome
80 815
(79 286 to 82 412)
122 311
(119 573 to 124 929)
5111*
(4663 to 5558)
15998
(15698 to 16297)
16378
(16015 to 16729)
231
(060 to
522)
Iodine deciency
130 223
(124 180 to 136 611)
115 602
(110 007 to 120 997)
1139*
(1677 to 538)
25119
(23893 to 26439)
15861
(15089 to 16603)
3695*
(4087 to
3255)
82 920
(65 067 to 102 663)
due to
glomerulonephritis
108 861
(88 330 to 135 482)
3270*
(1731 to 4129)
18661
(14872 to 23599)
15902
(12958 to 19667)
1354*
(2556 to
659)
Dysthymia
102 410
(91 246 to 113 441)
5462*
(5239 to 5720)
14573
(13090 to 16116)
14538
(13014 to 16096)
027
(125 to
066)

79 945
due to hypertension
(61 412 to 104 029)
101 253
(81 410 to 129 993)
2677*
(1834 to 3491)
16343
(12830 to 20382)
14538
(11814 to 18443)
1074*
(1759 to
528)
Benign prostatic
hyperplasia
55 230
(54 318 to 56 058)
99 148
(97 356 to 100 912)
7929*
(7537 to 8371)
16027
(15764 to 16271)
16520
(16223 to 16818)
301*
(076 to 559)
Other cardiovascular
and circulatory
diseases
41 600
(29 939 to 54 543)
95 225
(67 433 to 121 734)
13023*
(5389 to 23475)
10681
(7631 to 14026)
14461
(10244 to 18456)
3640
(860 to
9875)
Idiopathic intellectual
disability
76 996
(59 712 to 95 120)
94 673
(75 907 to 116 665)
2262*
(1275 to 3578)
13831
(10701 to 17141)
13051
(10449 to 16100)
577
(1346 to
442)
56 161
(54 049 to 58 489)
(post-myocardial
infarction, angina, or
heart failure)
92 521
(89 680 to 95 453)
6471*
(5694 to 7215)
16031
(15451 to 16661)
15187
(14725 to 15665)
524*
(961 to
095)
49 339
(38 328 to 65 278)
due to diabetes
mellitus
88 711
(71 150 to 111 417)
8245*
(5865 to 9683)
12302
(9513 to 16621)
13549
(10955 to 16848)
1185
(359 to
2119)
Food-borne
trematodiases
52 958
(41 937 to 64 062)
80 195
(64 648 to 96 212)
5108*
(4423 to 5968)
11309
(8924 to 13707)
11312
(9069 to 13560)
014
(477 to
556)
Urticaria
49 676
(47 217 to 52 480)
79 583
(72 812 to 86 296)
6053*
(4416 to 7498)
10611
(10076 to 11193)
11332
(10415 to 12254)
733
(379 to
1659)
Endocrine, metabolic,
blood, and immune
disorders
72 090
(70 251 to 73 866)
79 556
(77 363 to 81 282)
1027*
(692 to 1383)
13514
(13178 to 13861)
11320
(11013 to 11560)
1624*
(1876 to
1365)
Urolithiasis
38 598
(30 507 to 47 160)
78 780
(59 732 to 101 143)
10376*
(9118 to 11517)
10173
(8109 to 12456)
12268
(9311 to 15577)
2080*
(1350 to
2690)
Alcohol dependence
57 161
(54 423 to 60 107)
76 897
(73 454 to 80 492)
3438*
(3230 to 3642)
11324
(10859 to 11868)
10468
(10016 to 10948)
757*
(878 to
650)
Other exposure to
mechanical forces
62 216
(61 710 to 62 739)
76 514
(75 819 to 77 259)
2298*
(2163
to 2451)
10770
(10689 to 10858)
8887
(8806 to 8976)
1749*
(1838 to
1647)
66 141
(58 829 to 73 600)
Causes are ordered by overall prevalence. All data are shown with 95% uncertainty intervals. *Signicant percentage change.
Table 4: Global prevalence of chronic sequelae (for longer than 3 months) by cause for prevalence greater than 1%
17
Articles
Total prevalence ( 1000)
Total YLDs ( 1000)
1990
2013
1990
2013
1 211 3699 (6623%)
1 208 3601 (6257%)
40 0355 (6455%)
36 6123 (5951%)
Thalassaemia trait
75 1801 (411%)
104 2326 (540%)
27996 (451%)
Malaria
57 9691 (317%)
80 6024 (417%)
21961 (354%)
Gastritis and
duodenitis
56 8368 (311%)
63 2229 (327%)
Other neglected
tropical diseases
62 8771 (344%)
Other
haemoglobinopathies
and haemolytic
anaemias
Iron-deciency
anaemia
Prevalence by severity in 2013 ( 1000)

Mild
Moderate
Severe
607 8907 (3148%)
554 2646 (2870%)
46 2048 (239%)
37696 (613%)
39 7771 (206%)
59 9378 (310%)
45177 (023%)
29350 (477%)
32 3470 (167%)
43 8722 (227%)
43832 (023%)
20924 (337%)
22044 (358%)
24 7682 (128%)
35 6230 (184%)
28317 (015%)
59 7283 (309%)
22449 (362%)
20485 (333%)
25 9962 (135%)
31 0163 (161%)
27158 (014%)
57 2422 (313%)
55 8040 (289%)
15667 (253%)
13255 (215%)
34 6205 (179%)
19 5948 (101%)
15887 (008%)
Other infectious
diseases
52 3243 (286%)
49 7714 (258%)
17425 (281%)
15424 (251%)
24 5004 (127%)
23 3275 (121%)
19434 (010%)
blood, and immune
disorders
49 9284 (273%)
49 3278 (255%)
15498 (250%)
13760 (224%)
27 2031 (141%)
20 2801 (105%)
18447 (010%)
17485 (009%)
Sickle cell trait
29 8623 (163%)
43 3539 (224%)
10035 (162%)
13966 (227%)
20 0414 (104%)
21 5640 (112%)
Uterine broids
28 0432 (153%)
36 8337 (191%)
11066 (178%)
13049 (212%)
21 3282 (110%)
14 5407 (075%)
9648 (005%)
Hookworm disease
32 0398 (175%)
34 5796 (179%)
10218 (165%)
10040 (163%)
18 0376 (093%)
15 3080 (079%)
12339 (006%)
34 6716 (190%)
32 7267 (169%)
9806 (158%)
9746 (158%)
14 9956 (078%)
16 7170 (087%)
10141 (005%)

due to other causes
16 4591 (090%)
26 0072 (135%)
8572 (138%)
13306 (216%)
13 1548 (068%)
12 1403 (063%)
7121 (004%)
Schistosomiasis
14 4881 (079%)
20 6351 (107%)
4853 (078%)
6710 (109%)
95466 (049%)
10 1510 (053%)
9375 (005%)
Other gynaecological
diseases
15 5769 (085%)
17 3832 (090%)
4628 (075%)
4486 (073%)
98420 (051%)
71088 (037%)
4324 (002%)

due to hypertension
10 8503 (059%)
14 1426 (073%)
5876 (095%)
7338 (119%)
79860 (041%)
57382 (030%)
4185 (002%)

due to
glomerulonephritis
11 1809 (061%)
14 0599 (073%)
6133 (099%)
7459 (121%)
69244 (036%)
65572 (034%)
5783 (003%)

due to diabetes
mellitus
65696 (036%)
12 1163 (063%)
3480 (056%)
6066 (099%)
80242 (042%)
35458 (018%)
5463 (003%)
18015 (010%)
31850 (016%)
1825 (029%)
3214 (052%)
4342 (002%)
21765 (011%)
5743 (003%)
Glucose-6-phosphate
dehydrogenase
deciency trait
12537 (007%)
19838 (010%)
395 (006%)
488 (008%)
11964 (006%)
7329 (004%)
545 (000%)
13880 (008%)
18585 (010%)
394 (006%)
451 (007%)
10998 (006%)
7244 (004%)
344 (000%)
5193 (003%)
7435 (004%)
249 (004%)
338 (005%)
3897 (002%)
2053 (001%)
1485 (001%)
5442 (003%)
432 (007%)
462 (008%)
Glucose-6-phosphate
dehydrogenase
deciency
Thalassaemias
Total prevalence
Total YLDs
5098 (003%)
1 828 9422 (10000%)
1 931 2026 (10000%)
62 0238 (10000%)
61 5256 (10000%)
312 (000%)
3754 (002%)
1375 (001%)
950 1352 (4920%)
905 5018 (4689%)
75 5656 (391%)
42986 (699%)
46 2879 (7523%)
10 9391 (1778%)
Data are number (%). YLDs=years lived with disability.
Table 5: Prevalence and YLDs, with percentage of total, for anaemia by cause in 1990 and 2013, and prevalence by severity in 2013
counts of the number of sequelae for each simulant in

the population. The numbers of simulants with dierent
comorbidities in a countryagesexyear was adjusted
from 40 000 to equal the estimated population in each
countryagesexyear to produce the estimated
distribution of individuals in each country with comorbidities. Sequelae with a prevalence of less than one
in 20 000 that were not included in the microsimulation,
are also not included in the population pyramids showing
18
individuals by numbers of sequelae (gure 2AC). A

technical description of the comorbidity simulation is
given in the appendix p 2.
We have reported 95% uncertainty intervals for each
quantity in this analysis. For disease or sequelae
incidence or prevalence rates, age-standardised rates or
counts, the models such as DisMod-MR 2.0 provide
posterior distributions for each quantity from which 95%
uncertainty intervals are computed. For YLDs, we
Articles
Total YLDs ( 1000)
1990
2013
1990
Age-related and other

hearing loss
726 1183
(8996%)
1 130 1923
(9215%)
21 6326 (8618%) 32 5797 (8937%)
Otitis media
56 3916
(699%)
67 3169
(549%)
12439 (496%)
Other congenital
anomalies
21 0131
(260%)
25 8518
(211%)
Pneumococcal
meningitis
15046
(019%)
Mild
Moderate to severe
738 0055 (6018%)
383 9644 (3131%)
14609 (401%)
53 2014 (434%)
14 1155 (115%)
20655 (823%)
22996 (631%)
76541 (062%)
152785 (125%)
12325 (010%)
16867 (014%)
14 341
(012%)
644 (026%)
515 (014%)
8714 (007%)
5401 (004%)
143 (000%)
84 (000%)
8969
Haemophilus influenzae
(011%)
type B meningitis
6861
(006%)
414 (016%)
270 (007%)
4032 (003%)
2687 (002%)
90 (000%)
51 (000%)
Other meningitis
8341
(010%)
6225
(005%)
365 (015%)
228 (006%)
3765 (003%)
2359 (002%)
54 (000%)
46 (000%)
Meningococcal
meningitis
3992
(005%)
3158
(003%)
171 (007%)
117 (003%)
1981 (002%)
1110 (001%)
48 (000%)
19 (000%)
Total prevalence
807 1578
(10000%)
1 226 4196
(10000%)
Total YLDs
2013
25 1014
(10000%)
36 4531
(10000%)
Profound
19427 (016%)
Complete
62798 (051%)
-
800 7103 (6529%)
414 5141 (3380%)
32087 (026%)
79865 (065%)
93314 (2560%)
24 3902 (6691%)
7739 (212%)
19576 (537%)
Table 6: Prevalence and YLDs, with percentage of total, for hearing impairment by cause in 1990 and 2013, and prevalence by severity in 2013
incorporated uncertainty in prevalence and uncertainty

in the disability weight into the posterior distribution of
YLDs. In practice, we estimated the posterior distribution
of YLDs by taking 1000 samples from the posterior
distribution of prevalence and 1000 samples of the
disability weight to generate 1000 samples of the YLD
distribution. We estimated the 95% uncertainty interval
by reporting the 25th and 975th values of the distribution.
Uncertainty intervals for YLDs at dierent timepoints
(1990, 1995, 2000, 2005, 2010, and 2013) for a particular
disease or sequela are correlated because of the shared
uncertainty in the disability weight.
Role of the funding source

The funder of the study had no role in study design, data
collection, data analysis, data interpretation, or writing of
the report. The corresponding author had full access to
all the data in the study and had nal responsibility for
the decision to submit for publication.
Results
Figure 2AC shows the population pyramid for developed
countries, developing countries excluding sub-Saharan
Africa, and sub-Saharan Africa in 1990 and 2013 broken
down by the number of sequelae, ranging from none to
more than ten sequelae. Most of the worlds population
had at least one of the GBD sequelae and most people
had several. As expected, in view of the strong relation
between age and disease prevalence for most noncommunicable diseases and injuries, the number of
individuals with several morbidities rapidly increased
with age. In developed countries in 2013, 359% of the
age group 04 years had no sequelae with only 003%
older than 80 years with no sequelae (gure 2A). In the
age group older than 80 years, 103% had one to four

sequelae, 646% had ve to nine sequelae and 251%
had ten or more sequelae in 2013. The percentage of each
age group with several morbidities rose progressively
with age irrespective of the cuto used to dene several
morbidities. Due to this relation and the demographic
shifts towards older ages in developed countries, the
number of individuals with more than ten sequelae
increased by 516% from 1990 to 2013. In the oldest age
group, 236% of women and 278% of men had more
than ten sequelae, but the large population imbalance at
older age favouring women meant that there were
14 times more women than men with ten or more
sequelae.
Figure 2B shows the pyramids for developing countries
outside of sub-Saharan Africa, showing that the birth
cohorts in 2013 were smaller than in 1990. The major
demographic change was the large expansion of adults in
the age groups 2054 years for men and women from
1990 to 2013. Comparison of 1990 and 2013 showed little
change in the distribution of the population in each age
group by the number of sequelae. Rising numbers with
several morbidities were attributable to ageing. 203% of
the age group 04 years and 005% older than 80 years
had no sequelae. In the oldest age group, 125% had one
to four sequelae, 639% had ve to nine sequelae, and
235% had ten or more sequelae.
As shown in gure 2C, the main result was the massive
growth in population in sub-Saharan African countries
from 1990 to 2013 and continued pattern of a low
percentage of the population at older ages driven by high
fertility and high mortality. Due to several very common
sequelae that start early in life such as anaemia,
soil-transmitted helminths, and schistosomiasis, only
19
Articles
Total YLDs ( 1000)
1990
1990
2013

2013
Mild
Moderate
Severe
10 2989 (3279%)
20 3726 (3304%)
11143 (2551%)
22161 (2589%)
50553 (820%)
41313 (670%)
11 1861 (1814%)
Hypertensive heart
disease
51284 (1633%)
10 9069 (1769%)
5591 (1280%)
11939 (1395%)
27073 (439%)
22158 (359%)
59838 (970%)
Other cardiovascular
and circulatory diseases
41176 (1311%)
95421 (1548%)
4489 (1028%)
10426 (1218%)
23561 (382%)
19458 (316%)
52403 (850%)
Cardiomyopathy and
myocarditis
40776 (1298%)
76299 (1237%)
4519 (1035%)
8479 (991%)
18801 (305%)
15538 (252%)
41961 (681%)
Chronic obstructive
pulmonary disease
30365 (967%)
58464 (948%)
12220 (2798%)
23664 (2765%)
14382 (233%)
12015 (195%)
32068 (520%)
Rheumatic heart
disease
28378 (904%)
42740 (693%)
3162 (724%)
4732 (553%)
10555 (171%)
8731 (142%)
23455 (380%)
blood, and immune
disorders
3382 (108%)
8524 (138%)
392 (090%)
973 (114%)
2081 (034%)
1742 (028%)
4701 (076%)
Congenital heart
anomalies
4959 (158%)
6217 (101%)
600 (137%)
748 (087%)
1522 (025%)
1268 (021%)
3427 (056%)
Iron-deciency
anaemia
3732 (119%)
4466 (072%)
431 (099%)
512 (060%)
1101 (018%)
908 (015%)
2457 (040%)
Chagas disease
2801 (089%)
3839 (062%)
314 (072%)
429 (050%)
953 (015%)
783 (013%)
2103 (034%)
Endocarditis
1362 (043%)
2502 (041%)
157 (036%)
291 (034%)
616 (010%)
509 (008%)
1376 (022%)
Other
haemoglobinopathies
and haemolytic
anaemias
930 (030%)
2166 (035%)
110 (025%)
252 (029%)
529 (009%)
443 (007%)
1194 (019%)
Thalassaemias
964 (031%)
1178 (019%)
119 (027%)
145 (017%)
293 (005%)
238 (004%)
647 (010%)
Interstitial lung disease

and pulmonary
sarcoidosis
513 (016%)
1021 (017%)
243 (056%)
481 (056%)
252 (004%)
208 (003%)
562 (009%)
162 (005%)
377 (006%)
78 (018%)
180 (021%)
93 (002%)
77 (001%)
207 (003%)
81 (003%)
204 (003%)
10 (002%)
25 (003%)
50 (001%)
41 (001%)
113 (002%)
Glucose-6-phosphate
dehydrogenase
deciency
Silicosis
108 (003%)
162 (003%)
52 (012%)
78 (009%)
40 (001%)
33 (001%)
89 (001%)
Coal workers
pneumoconiosis
58 (002%)
90 (001%)
28 (006%)
43 (005%)
22 (000%)
18 (000%)
50 (001%)
Iodine deciency
43 (001%)
69 (001%)
06 (001%)
09 (001%)
17 (000%)
14 (000%)
38 (001%)
Asbestosis
24 (001%)
41 (001%)
11 (003%)
20 (002%)
10 (000%)
08 (000%)
22 (000%)
Total prevalence
Total YLDs
31 4085 (10000%)
61 6576 (10000%)
43674 (10000%)
85587 (10000%)
15 2502 (2473%)
12 5503 (2035%)
33 8571 (5491%)
10693 (1249%)
12111 (1415%)
62782 (7335%)
Table 7: Prevalence and YLDs, with percentage of total, for heart failure by cause in 1990 and 2013, and prevalence by severity in 2013
78% of the age group 04 years and 0002% at age

80 years and older in sub-Saharan Africa had no sequelae
in 2013. Although there were few individuals reaching
the oldest age groups, in the population aged 80 years
and older, 19% had one to four sequelae, 426% had
ve to nine, and 555% had ten or more sequelae, which
were higher than in developed countries. Multiple
morbidities were also common in all regions in working
age adults (2064 years): 317% with ve or more
sequelae in developed countries, 379% in developing
countries outside of sub-Saharan Africa, and 616% in
sub-Saharan Africa. Of the 23 billion individuals in
2013 with more than ve sequelae, 814% were younger
than 65 years.
20
The comprehensive and systematic nature of GBD

provides an opportunity to assess the most common
acute disorders aecting people around the world and
the trends from 1990 to 2013. Table 3 shows the 65 causes
of acute disease (<3 months duration) and injury
incidence with more than 1 million cases per year in
2013. For the causes with more than one acute sequela,
such as typhoid fever (acute infection, intestinal
perforation, and intestinal bleeding), maternal sepsis
(puerperal sepsis and other maternal infections), or
hypertension in pregnancy (eclampsia, pre-eclampsia,
and other hypertensive disorders in pregnancy), we
aggregated all the acute sequelae for a cause for
presentation in table 3. Of note, there are two disorders
Articles
Total YLDs ( 1000)
1990
2013
1990
2013
Borderline
Idiopathic intellectual
disability
77 1025
(6524%)
94 6800
(6147%)
38223
(3830%)
46667
(3146%)
Preterm birth
complications
59130
(500%)
13 5763
(881%)
5581
(559%)
14504
(978%)
Chromosomal
unbalanced
rearrangements
63982
(541%)
11 1717
(725%)
8591
(861%)
15904
(1072%)
Neonatal
encephalopathy due to
birth asphyxia and
trauma
95203
(806%)
89474
(581%)
8925
(894%)
12283
(828%)
Downs syndrome
45464
(385%)
81844
(531%)
6056
(607%)
11579
(781%)
Ischaemic stroke
26864
(227%)
48871
(317%)
9679
(970%)
17642
(1189%)
Pneumococcal
meningitis
31326
(265%)
28032
(182%)
3822
(383%)
3448
(232%)
Haemorrhagic stroke
10408
(088%)
19668
(128%)
3866
(387%)
7288
(491%)
Haemolytic disease and

7683
other neonatal jaundice (065%)
14005
(091%)
4255
(426%)
7818
(527%)
10008
(085%)
13822
(090%)
623
(062%)
858
(058%)
3831 (025%)
16544
Haemophilus inuenzae
(140%)
type B meningitis
13096
(085%)
2445
(245%)
2067
(139%)
Other meningitis
14069
(119%)
10502
(068%)
2209
(221%)
Encephalitis
8734
(074%)
8866
(058%)
Neural tube defects
2937
(025%)
Meningococcal
meningitis
Mild
Moderate
Profound
59462 (386%)
21185 (138%)
11 4807 (745%)
12776 (083%)
5352 (035%)
2828 (018%)
37331 (242%)
30387 (197%)
19538 (127%)
10345 (067%)
71284 (463%)
8331 (054%)
6452 (042%)
3408 (022%)
27351 (178%)
22262 (145%)
14313 (093%)
7578 (049%)
29782 (193%)
12485 (081%)
6603 (043%)
4208 (027%)
2729 (018%)
1442 (009%)
11973 (078%)
5034 (033%)
2661 (017%)
6418 (042%)
4964 (032%)
2622 (017%)
7912 (051%)
1266 (008%)
813 (005%)
4434 (029%)
3290 (021%)
2705 (018%)
1745 (011%)
922 (006%)
1723
(116%)
3407 (022%)
2651 (017%)
2225 (014%)
1452 (009%)
767 (005%)
1207
(121%)
1313
(088%)
3377 (022%)
2237 (015%)
1627 (011%)
1063 (007%)
561 (004%)
4779
(031%)
1518
(152%)
2461
(166%)
3126 (020%)
1653 (011%)
5387
(046%)
4292
(028%)
904
(091%)
753
(051%)
633 (004%)
335 (002%)
Syphilis
3102
(026%)
3152
(020%)
575
(058%)
584
(039%)
3152 (020%)
963
(008%)
1970
(013%)
394
(039%)
799
(054%)
1970 (013%)
Maternal hypertensive
1409
disorders
(012%)
1289
(008%)
95
(010%)
88
(006%)
1289 (008%)
Tetanus
5802
(049%)
716
(005%)
307
(031%)
59
(004%)
649 (004%)
31 (000%)
24 (000%)
12 (000%)
Malaria
455
(004%)
667
(004%)
254
(025%)
377
(025%)
306 (002%)
236 (002%)
125 (001%)
313
(003%)
445
(003%)
05
(001%)
07
(000%)
Iodine deciency
600
(005%)
383
(002%)
100
(010%)
64
(004%)
African
trypanosomiasis
338
(003%)
94
(001%)
165
(017%)
47
(003%)
Total prevalence
118 1746
(10000%)
154 0247
(10000%)
Total YLDs
99797
(10000%)
14 8334
(10000%)
38 8731 (2524%)
Severe
14 8043 (961%)
32 9379 (2138%)
14116 (092%)
10340 (067%)
7516 (049%)
1282 (008%)
410 (003%)
12136 (079%)
1077 (007%)
965 (006%)
35 (000%)
285 (002%)
98 (001%)
61 (000%)
32 (000%)
139770 (907%)
63179 (410%)
37 8093 (2455%)
7224 (487%)
67 0779 (4355%)
28 8426 (1873%)
32093 (2164%)
49251 (3320%)
39633 (2672%)
20133 (1357%)
Table 8: Prevalence and YLDs, with percentage of total, for intellectual disability by cause in 1990 and 2013, and prevalence by severity in 2013
with an incidence of greater than 2 billion in 2013: upper

respiratory infections (188 billion) and diarrhoeal
diseases (27 billion). Another 12 diseases and injuries
accounted for between 100 million to 1 billion incident

cases per year in 2013: injuries due to other exposure to
mechanical force, acute otitis media, tooth pain due to
21
Articles
dengue, gonorrhoea, the initial episodes of genital

herpes, trichomoniasis, and several disorders aecting
the digestive system, including gastritis and duodenitis,
peptic ulcer disease, pancreatitis, and appendicitis.
Among the most common causes of acute disease
incidence, 47 increased in absolute numbers of incident
cases from 1990 to 2013 but only 13 had rising agestandardised rates of which six had signicant increases
(upper respiratory infections, interstitial nephritis,
urinary tract infections, dengue, pancreatitis, paralytic
ileus, intestinal obstruction, and unintentional
suocation; table 3). Numbers declined for 18 of
caries of permanent teeth, bacterial skin diseases

(including impetigo and abscess), falls; lower respiratory
infections, clinical episodes of malaria, chlamydia
infection, varicella (including chickenpox and herpes
zoster episodes), acute hepatitis B, gallbladder and biliary
tract disease, and acute hepatitis A. There were
28 diseases and injuries with incident cases between
10 million and 100 million per year including several
injuries, such as non-venomous animal contact, motor
vehicle road injuries, re, heat, and hot substances,
motorcycle and pedestrian injuries, and infections such
as urinary tract infections, typhoid, hepatitis C and E,
Total prevalence (1000)
Total YLDs ( 1000)

1990
Prevalence by severity in 2013 (1000)
1990
2013
Uncorrected refractive
error
434 2226
(8374%)
660 1188
(8528%)
78311 (5660%)
11 2572 (5600%)
80 4518 (1039%)
99431 (128%)
94820 (122%)
Cataract
29 9150
(577%)
44 2231
(571%)
18606 (1345%)
29167 (1451%)
31 6365 (409%)
48578 (063%)
77288 (100%)
Other vision loss
22 3581
(431%)
26 8130
(346%)
14504 (1048%)
17935 (892%)
19 5385 (252%)
21787 (028%)
50958 (066%)
78485
(151%)
13 8838
(179%)
4129 (298%)
7256 (361%)
11 3705 (147%)
14984 (019%)
10149 (013%)
Glaucoma
66920
(129%)
10 9001
(141%)
4957 (358%)
8075 (402%)
72761 (094%)
9844 (013%)
26396 (034%)
Preterm birth
complications*
18444
(036%)
44120
(057%)
4349 (314%)
11354 (565%)
10221 (013%)
5634 (007%)
23599 (030%)
Diabetes mellitus
26314
(051%)
38169
(049%)
3258 (235%)
4770 (237%)
10988 (014%)
1637 (002%)
25545 (033%)
Vitamin A deciency
41815
(081%)
33722
(044%)
1993 (144%)
1537 (076%)
30145 (039%)
2035 (003%)
1542 (002%)
Trachoma
39834
(077%)
24282
(031%)
2716 (196%)
1712 (085%)
16594 (021%)
3298 (004%)
4390 (006%)
Onchocerciasis
19075
(037%)
11838
(015%)
1273 (092%)
784 (039%)
8565 (011%)
1425 (002%)
1848 (002%)
Pneumococcal
meningitis*
9503
(018%)
8639
(011%)
425 (031%)
355 (018%)
1369 (002%)
2936
Neonatal encephalopathy
(006%)
due to birth asphyxia
and trauma
4783
(006%)
1585 (115%)
2586 (129%)
4783 (006%)
Other meningitis*
5227
(010%)
3761
(005%)
442 (032%)
307 (015%)
1575 (002%)
Haemolytic disease and

other neonatal jaundice
1966
(004%)
3739
(005%)
1056 (076%)
2016 (100%)
3739 (005%)
Haemophilus inuenzae
type B meningitis*
3958
(008%)
2982
(004%)
97 (007%)
68 (003%)
119 (000%)
Meningococcal
meningitis*
3582
(007%)
2700
(003%)
460 (033%)
344 (017%)
1913 (002%)
Encephalitis*
2475
(005%)
2364
(003%)
93 (007%)
81 (004%)
255 (000%)
Malaria
117
(000%)
173
(000%)
62 (004%)
92 (005%)
173 (000%)
19
34 (002%)
10 (000%)
19 (000%)
Tetanus
Total prevalence
Total YLDs
63
(000%)
(000%)
518 5671
(10000%)
774 0678
(10000%)
2013
Moderate
13 8350 (10000%) 20 1022 (10000%)
Severe
Blind
157 9246 (2040%)
20 8652 (270%)
45657 (2271%)
34257 (1704%)
Presbyopia
33 0481 (427%)
64344 (3201%)
560 2419 (7238%)
560 2419 (7238%)

56506 (2811%)
Data are number (%). YLDs=years lived with disability. *Mild and monocular vision impairment not listed, but estimates are included in totals.
Table 9: Prevalence and YLDs, with percentage of total, for vision impairment by cause in 1990 and 2013, and prevalence by severity in 2013
22
Articles
Mean YLDs
1000
Mean rank
(95% UI)
1990 leading causes
2013 leading causes
Mean rank
(95% UI)
Mean YLDs
(1000)
Median percentage
change
46 068
13 (12)
1 Low back pain
1 Low back pain
10 (11)
72 318
57% (53 to 61)
40 079
20 (13)
2 Iron-deciency anaemia
2 Major depression
21 (24)
51 784
53% (49 to 59)
33 711
28 (14)
3 Major depression
3 Iron-deciency anaemia
36 (26)
36 663
9% (10 to 7)
22 294
47 (46)
4 Neck pain
4 Neck pain
43 (36)
34 348
54% (49 to 60)
21 633
51 (37)
5 Other hearing loss
5 Other hearing loss
53 (39)
32 580
51% (45 to 55)
19 805
58 (48)
6 Migraine
6 Migraine
66 (310)
28 898
46% (41 to 50)

136% (127 to 144)
17 180
69 (49)
7 Anxiety disorders
7 Diabetes
67 (59)
29 518
15 151
79 (610)
8 COPD
8 COPD
78 (410)
26 131
72% (67 to 79)
12 672
95 (712)
9 Other musculoskeletal
9 Anxiety disorders
85 (510)
24 356
42% (36 to 47)
12 533
95 (811)
10 Diabetes
10 Other musculoskeletal
92 (710)
22 644
79% (75 to 83)
10 337
116 (1013)
11 Falls
11 Schizophrenia
115 (1115)
15 204
52% (50 to 54)

23% (14 to 35)
9995
120 (916)
12 Schizophrenia
12 Falls
127 (1214)
12 818
8048
147 (1219)
13 Asthma
13 Osteoarthritis
128 (1115)
12 811
75% (73 to 78)
7831
155 (1023)
14 Refraction and accommodation
14 Refraction and accommodation
155 (1122)
11 257
44% (40 to 47)
7362
162 (1320) 15 Diarrhoeal diseases
15 Asthma
161 (1221)
10 596
32% (29 to 35)
7307
164 (1419) 16 Osteoarthritis
16 Dysthymia
174 (1421)
9849
55% (52 to 57)
6780
185 (1424) 17 Dermatitis
17 Bipolar disorder
175 (1225)
9911
49% (46 to 53)
7491
188 (836)
18 Medication overuse headache
178 (1227)
9846
120% (109 to 134)
18 War and legal intervention
6643
188 (1326) 19 Bipolar disorder
19 Other mental and substance
185 (1424)
9257
52% (50 to 54)
6368
197 (1524)
20 Dermatitis
188 (1525)
9278
37% (35 to 39)
20 Dysthymia
6076
206 (1525) 21 Other mental and substance
21 Alzheimers disease
222 (1826)
7774
92% (85 to 99)
5699
221 (1726)
22 Alcohol use disorders
230 (1828)
7654
34% (32 to 37)
5827
229 (1238) 23 Acne vulgaris
23 Epilepsy
232 (1830)
7544
41% (28 to 57)
5365
235 (1829) 24 Epilepsy
24 Edentulism
259 (2131)
6856
46% (43 to 48)
5288
239 (1731)
25 Conduct disorder
25 Diarrhoeal diseases
261 (2330)
6854
7% (9 to 5)
26 Edentulism
26 Acne vulgaris
27 Medication overuse headache
29 Conduct disorder
28 Alzheimers disease
52 War and legal intervention
22 Alcohol use disorders
Communicable, maternal, neonatal,

and nutritional disorders
Injuries
Figure 3: Top 25 causes of global YLDs in 1990 and 2013

YLD=years lived with disability. UI=uncertainty interval. COPD=chronic obstructive pulmonary disease.
65 causes in table 3, seven of which were infectious

diseases that predominantly aected children. Two were
maternal disorders and for one, peptic ulcer disease, the
decline was not signicant. Some injuries such as nonvenomous animal contact, re, heat, and hot substances,
collective violence and legal intervention, exposure to
forces of nature, venomous animal contact, poisoning,
and drowning decreased in absolute incidence numbers.
For 52 of 65 causes, age-standardised rates declinedfor
34 causes, numbers increased due to demographic
change even though age-standardised rates declined. In
the set of causes of more than 1 million cases per year,
dengue had the most striking increase in the agestandardised rates (4473%; table 3).
Table 4 summarises the prevalence of chronic disease
and injury sequelae (>3 months) aggregated to the cause
level. This table provides a high-level view of the leading
causes of chronic disorders worldwide for the 59 causes
with a global prevalence of greater than 1% in 2013.
Leading causes were a mixture of oral disorders,
neurological disorders, skin diseases, musculoskeletal
disorders, neglected tropical diseases, gynaecological
disorders, chronic kidney disease, some causes of
anaemia, age-related hearing, other vision loss, and
injuries. Eight causes aected more than 10% of the

world population in 2013: permanent caries without
pain, tension-type headaches, iron-deciency anaemia,
glucose-6-phosphate dehydrogenase deciency trait, agerelated and other hearing loss, genital herpes without
symptoms, migraine, and ascariasis. Another 51 causes
aicted between 1% and 10% of the worlds population.
In this set of disorders were those that were not
prominent causes of YLDs because the average disability
weight was low, but they might have been important in
terms of health system resources or health service
planning. These disorders included glucose-6-phosphate
dehydrogenase deciency, genital prolapse, premenstrual
syndrome, edentulism, polycystic ovary syndrome,
uterine broids, and several skin diseases.
Rates for only six causes of chronic disease
(micronutrient deciencies, worm infestations, and
chronic hepatitis B; table 4) declined fast enough to lead
to declines in the absolute numbers for each worldwide.
As noted in table 3, several acute infectious diseases and
other acute disorders also declined in absolute numbers.
The numbers of cases increased for 17 other chronic
disorders but there were signicant reductions in agestandardised rates: age-related and other hearing loss,
23
Articles
genital herpes, uncorrected refractive error, deciduous

caries without pain, dermatitis, edentulism and severe
tooth loss, osteoarthritis, uterine broids, chronic
hepatitis C, viral skin diseases, chronic kidney disease
due to hypertension, ischaemic heart disease (angina,
post-myocardial infarction, and heart failure), alcohol
use disorders, asthma, chronic kidney disease due to
glomerulonephritis, injury due to other exposure to
mechanical forces, and endocrine, metabolic, blood, and
immune disorders. Five chronic disease and injury states
showed signicant increases in age-standardised rates of
greater than 5% from 1990 to 2013: glucose-6-phosphate
dehydrogenase deciency, diabetes mellitus, sickle cell
trait, other musculoskeletal disorders, and urolithiasis.
Table 5 show the estimated prevalence and the
distribution of prevalence by cause and severity of ve
major impairments in 1990 and 2013 (the remaining four
impairments are reported in the appendix pp 1532).
Table 5 also provides overall YLDs due to each
impairment to provide context for the total burden
related to each impairment.
We estimated that 183 billion individuals had anaemia
in 1990, rising to 193 billion in 2013 (table 5). Taking
into account the distribution of anaemia across mild,
moderate, and severe, total anaemia YLDs equalled
620 million in 1990, dropping slightly to 615 million in
2013. This number of YLDs made anaemia from all
causes larger than the second leading disease
contributing to YLDs, major depressive disorder
(table 10). In addition to the reduction in overall
prevalence, there was a small but notable shift towards
more cases of mild anaemia and less severe and moderate
anaemia from 1990 to 2013. By 2013, 492% of individuals
had mild anaemia, 469% had moderate anaemia, and
39% had severe anaemia (table 5). Iron-deciency
anaemia accounted for 626% of all cases and 315% of
mild, 287% of moderate, and 24% of severe anaemia.
The next ve most common causes of anaemia overall
were thalassaemia trait, malaria, gastritis, and duodenitis,
other neglected tropical diseases, and other haemoglobinopathies and haemolytic anaemias. Hookworm
and schistosomiasis together accounted for 552 million
cases and malaria accounted for a further 806 million
cases. From 1990 to 2013, the number of anaemia cases
due to malaria increased by 389%. Causes with an
increase in cases of more than 50% included chronic
kidney disease due to diabetes mellitus, chronic kidney
disease due to other causes, and sickle cell disorders.
Table 5 shows that the estimated number of individuals
with some form of hearing impairment (20 dB or more)
rose from 8072 million in 1990 to 123 billion in 2013.
Globally, hearing loss accounted for 251 million YLDs in
1990, increasing 453% to 365 million YLDs in 2013. In
2013, 8007 million people had mild hearing loss (less
than 35 dB), whereas 4145 million had moderate or
moderate to severe hearing loss. The number with
complete hearing loss (80 million) was somewhat
24
higher than in 1990 (67 million). Just over 90% of

hearing loss was classied as age-related and other
hearing loss in 2013. Otitis media was the next most
important cause of overall hearing loss but only caused
mild or moderate hearing loss. In 2013, congenital
anomalies accounted for 21% of all hearing loss but
211% of complete hearing loss.
Table 5 provides a detailed breakdown at the global
level of the 617 million cases of heart failure (left-sided
and right-sided) in the world, more than half of which
were classed as severe. Worldwide, the number of
individuals who had heart failure increased 964% from
1990 to 2013. A third of heart failure was due to ischaemic
heart disease (table 5). Five other causes accounted for
620% of heart failure: hypertensive heart disease, other
cardiovascular and circulatory diseases, cardiomyopathy
and myocarditis, COPD, and rheumatic heart disease
(table 5). All other causes each accounted for about 5% of
heart failure. Notably, in 2013, Chagas disease accounted
for 06% of heart failure globally but 114% in Brazil. All
causes of heart failure accounted for 86 million YLDs in
2013 (table 5).
Table 5 shows that the number of individuals with
intellectual impairment increased from 1182 million in
1990 to 1540 million in 2013. In 2013, we estimated that
borderline (IQ 7084) and mild intellectual impairment (IQ
5069) accounted for 1049 million cases and moderate,
severe, and profound intellectual impairment around
491 million cases. The most important causes of intellectual
impairment in 2013 were idiopathic intellectual disability
(615%) followed by neonatal causes (mainly preterm birth
complications and neonatal encephalopathy), congenital
causes (mainly Downs syndrome and chromosomal
unbalanced rearrangements), cerebrovascular disease, and
infectious causes (mainly meningitis; tables 59).
Comparison of the levels by cause in 1990 and 2013 showed
that idiopathic intellectual disability increased 227%,
intellectual disability from preterm birth complications
increased 1296%, and intellectual disability from neonatal
encephalopathy decreased 58%.
Table 5 shows the distribution of visual impairment
including presbyopia in 1990 and 2013. The numbers of
individuals with visual impairment, taking into account
the availability of visual aids, increased from 5186 million
in 1990 to 7741 million in 2013. 724% of this total in
2013 was uncorrected presbyopia. Excluding presbyopia,
in 1990 there were 1370 million individuals with
moderate or severe vision loss increasing to 1788 million
in 2013 (table 5). Over the same period there was an
increase in blindness from 231 million to 330 million.
The increase in age-standardised rates per 100 000 for
visual impairment overall was from 12 7022 to 11 7409
and for blindness from 6025 to 5213. The most
important cause of visual impairment in terms of
prevalence and YLDs was uncorrected refractive error
accounting for just over 85% of all cases and 56% of
YLDs due to vision impairment. In terms of YLDs, the
Articles
Prevalent cases in 2013 Percentage change

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)
Percentage change in Percentage change in

age-standardised YLDs
YLDs from
from 1990 to 2013
1990 to 2013
All causes
764 8044
(572 3796 to
990 4670)
423*
(402 to 443)
39*
(51 to 30)
Communicable, maternal, neonatal,

and nutritional diseases
101 4951
(71 5331 to
138 4580)
76*
(40 to 118)
152*
(180 to 122)
77333
(54944 to
10 0779)
1254*
(1137 to 1410)
471*
(395 to 574)
36697
(25197 to 48891)
519*
(486 to 552)
13
(34 to 07)
40637
(29189 to 53274)
3017*
(2594 to 3543)
1715*
(1420 to 2087)
HIV/AIDS and tuberculosis
Tuberculosis
HIV/AIDS
12 1118
(11 7916 to 12 4520)
516*
(493 to 540)
19*
(33 to 03)
HIV/AIDS resulting in mycobacterial

infection
7247
(4960 to 9225)
2757*
(2212 to 3350)
1440*
(1073 to 1841)
2683
(1625 to 3886)
2755*
(2181 to 3351)
1446*
(1049 to 1854)
HIV/AIDS resulting in other diseases
28 5066
(27 4151 to 30 9704)
2341*
(2178 to 2628)
1345*
(1228 to 1548)
37953
(27267 to 49746)
3041*
(2572 to 3610)
1740*
(1409 to 2143)
14 3397
(10 1084 to
19 5419)
02
(28 to 46)
165*
(185 to 136)
68542
(47019 to 94153)
69*
(92 to 47)
180*
(199 to 160)
2037
(1385 to 2814)
233*
(322 to 129)
357*
(431 to 273)
Diarrhoea, lower respiratory, and

other common infectious diseases
Diarrhoeal diseases
Intestinal infectious diseases
42 4096
(41 7695 to 43 1702)
69*
(89 to 47)
183*
(201 to 164)
Typhoid fever
11983
(11033 to 13006)
199*
(307 to 65)
333*
(419 to 224)
1586
(1090 to 2233)
190*
(305 to 42)
323*
(418 to 205)
Paratyphoid fever
7359
(6404 to 8369)
279*
(418 to 128)
391*
(509 to 265)
383
(240 to 576)
271*
(416 to 97)
384*
(503 to 239)
68
(32 to 134)
610*
(676 to 518)
674*
(729 to 597)
Other intestinal infectious diseases
Lower respiratory infections
44733
(43747 to 45542)
128*
(157 to 107)
255*
(279 to 238)
4609
(3105 to 6427)
141*
(174 to 117)
261*
(289 to 242)
Upper respiratory infections
244 3275
(240 7896 to
247 6292)
384*
(357 to 415)
63*
(42 to 86)
28631
(15979 to 47635)
384*
(354 to 416)
66*
(44 to 90)
Otitis media
85 2280
(82 1903 to 88 6674)
144*
(119 to 169)
111*
(129 to 91)
16964
(10176 to 26979)
144*
(114 to 176)
101*
(122 to 77)
Meningitis
16791
(11658 to 22596)
117*
(155 to 79)
314*
(344 to 278)
Pneumococcal
78056
(49299 to 11 6055)
55
(113 to 18)
307*
(347 to 256)
6981
(4941 to 9178)
52
(115 to 34)
276*
(321 to 209)
Haemophilus inuenzae type B
32462
(13734 to 59622)
191*
(264 to 120)
385*
(436 to 322)
3755
(2588 to 5103)
137*
(205 to 33)
310*
(363 to 223)
Meningococcal
13212
(4906 to 28476)
199*
(285 to 120)
409*
(466 to 345)
1673
(1063 to 2516)
171*
(250 to 80)
372*
(425 to 293)
Other meningitis
35952
(19017 to 63058)
202*
(279 to 129)
396*
(449 to 332)
4383
(2992 to 6042)
174*
(233 to 119)
352*
(397 to 307)
Encephalitis
17398
(7957 to 40037)
31
(165 to 126)
275*
(411 to 211)
2291
(1599 to 3057)
108*
(47 to 179)
206*
(250 to 154)
Diphtheria
11
(07 to 20)
621*
(834 to 154)
657*
(846 to 250)
01
(00 to 02)
621*
(835 to 148)
658*
(846 to 250)
Whooping cough
25325
(19657 to 32392)
300*
(306 to 294)
325*
(331 to 318)
1255
(730 to 2007)
300*
(319 to 277)
324*
(343 to 302)
Tetanus
1771
(1175 to 2657)
871*
(925 to 779)
901*
(942 to 829)
132
(85 to 213)
782*
(854 to 645)
822*
(882 to 710)
Measles
1924
(1504 to 2429)
771*
(792 to 749)
780*
(801 to 759)
173
(102 to 267)
771*
(800 to 738)
780*
(808 to 748)
25
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013
57158
(55876 to 58353)
24
(49 to 03)
1972
(1221 to 2992)
476*
(411 to 545)
18
(57 to 27)
20 1007
(13 2024 to
28 9461)
33
(102 to 67)
287*
(331 to 230)

Varicella and herpes zoster
Neglected tropical diseases and
malaria
284*
(255 to 317)
Malaria
351 0511
(344 7721 to
358 0136)
308*
(284 to 332)
30*
(11 to 49)
31705
(21323 to 45919)
301*
(252 to 350)
78*
(37 to 119)
Chagas disease
94339
(92411 to 96284)
224*
(195 to 257)
163*
(183 to 140)
975
(649 to 1370)
336*
(288 to 391)
174*
(202 to 142)
497
(255 to 904)
1347*
(1078 to 1650)
758*
(580 to 973)
Leishmaniasis
Visceral
1137
(941 to 1409)
351*
(171 to 549)
144
(04 to 305)
80
(52 to 123)
358*
(146 to 618)
152
(25 to 367)
Cutaneous and mucocutaneous
39148
(33004 to 46696)
1742*
(1445 to 2092)
953*
(752 to 1199)
417
(190 to 801)
1751*
(1460 to 2109)
971*
(766 to 1224)
African trypanosomiasis
197
(106 to 343)
711*
(753 to 659)
795*
(824 to 758)
54
(26 to 95)
707*
(753 to 645)
791*
(823 to 747)
Schistosomiasis
290 6279
309*
(252 0987 to 337 5761) (229 to 519)
37
(97 to 118)
28617
(14836 to 54672)
341*
(264 to 554)
03
(56 to 163)
Cysticercosis
10308
(9014 to 11856)
263*
(373 to 100)
502*
(575 to 390)
3104
(2122 to 4095)
209*
(339 to 30)
465*
(551 to 344)
Cystic echinococcosis
8492
(8225 to 8932)
154*
(170 to 129)
424*
(435 to 408)
792
(549 to 1103)
153*
(189 to 110)
420*
(443 to 392)
Lymphatic lariasis
43 8500
(36 9408 to 52 9058)
321*
(391 to 247)
533*
(580 to 484)
20221
(10963 to 32944)
59
(157 to 264)
323*
(460 to 193)
Onchocerciasis
16 9564
(11 4775 to 26 7894)
312*
(398 to 219)
515*
(576 to 453)
11798
(5566 to 19927)
254*
(370 to 109)
489*
(577 to 384)
Trachoma
24288
(19242 to 29812)
392*
(463 to 301)
654*
(695 to 603)
1712
(1153 to 2417)
372*
(430 to 304)
642*
(675 to 605)
Dengue
34855
(12837 to 78186)
6109*
(6063 to 6155)
4473*
(4436 to 4509)
5659
(1864 to 14146)
6072*
(5584 to 6595)
4468*
(4113 to 4868)
Yellow fever
21
(07 to 49)
598*
(637 to 543)
683*
(714 to 640)
01
(00 to 02)
598*
(637 to 543)
683*
(714 to 640)
Rabies
09
(07 to 11)
398*
(543 to 273)
552*
(651 to 461)
01
(01 to 02)
398*
(543 to 272)
552*
(651 to 461)
36916
(21858 to 58017)
460*
(506 to 414)
588*
(623 to 553)
448*
(542 to 331)
9339
(5166 to 15761)
742*
(774 to 706)
801*
(825 to 773)
Intestinal nematode infections
Ascariasis
804 3701
255*
(713 4175 to 922 2121) (378 to 104)
Trichuriasis
477 3744
(441 2568 to
518 3651)
116
(287 to 49)
344*
(478 to 210)
5760
(3101 to 9726)
276*
(394 to 104)
459*
(550 to 328)
Hookworm disease
471 8162
(437 0496 to
511 3188)
51
(202 to 97)
301*
(416 to 184)
21817
(13386 to 33545)
109*
(173 to 44)
329*
(380 to 277)
Food-borne trematodiases
80 1945
(64 6481 to 96 2124)
511*
(442 to 597)
01
(48 to 56)
36348
(11602 to 76924)
501*
(406 to 600)
18
(81 to 49)
Other neglected tropical diseases
59 7059
(58 7035 to 61 0201)
50
(110 to 16)
183*
(233 to 128)
22607
(14736 to 33586)
89*
(134 to 01)
206*
(250 to 128)
13418
(9245 to 18243)
184*
(82 to 274)
150*
(219 to 84)
Maternal disorders
20274
(19324 to 21198)
305*
(222 to 392)
21
(81 to 44)
695
(474 to 975)
112
(07 to 225)
164*
(252 to 81)
Maternal sepsis and other maternal

infections
17814
(12354 to 25159)
135*
(235 to 50)
416*
(477 to 356)
214
(116 to 363)
224*
(353 to 97)
432*
(518 to 345)
26
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013
Maternal hypertensive disorders
12776
(7563 to 19788)
35
(04 to 102)
213*
(238 to 172)
647
(315 to 1128)
29
(28 to 97)
218*
(256 to 173)
Obstructed labour
29021
(26001 to 32221)
204*
(129 to 275)
148*
(198 to 102)
9515
(6415 to 13040)
209*
(123 to 303)
143*
(201 to 80)
Complications of abortion
218
(146 to 297)
115*
(18 to 209)
169*
(240 to 101)
25
(14 to 40)
120*
(20 to 223)
166*
(238 to 91)
Other maternal disorders

Neonatal disorders
2322
(1558 to 3437)
221
(143 to 622)
105
(373 to 185)
12 6488
(92 914 to
16 2626)
1309*
(1085 to 1587)
805*
(631 to 1017)
Preterm birth complications
56 2720
(49 5046 to 64 2044)
1654*
(1430 to 1925)
989*
(819 to 1184)
66897
(49141 to 86436)
1876*
(1669 to 2103)
1194*
(1042 to 1369)
Neonatal encephalopathy due to

birth asphyxia and trauma
22 8586
(11 8314 to 38 6187)
34
(187 to 534)
205
(376 to 192)
23881
(17836 to 31530)
571*
(324 to 840)
256*
(54 to 481)
Neonatal sepsis and other neonatal

infections
503
(165 to 1066)
1100*
(1000 to 1275)
1077*
(978 to 1250)
66
(20 to 150)
1103*
(974 to 1281)
1081*
(953 to 1257)
Haemolytic disease and other

neonatal jaundice
49993
(38930 to 67923)
1329*
(668 to 2767)
842*
(336 to 1978)
16068
(11223 to 22346)
1124*
(611 to 2209)
667*
(282 to 1519)
Other neonatal disorders

Nutritional deciencies
19576
(13344 to 26985)
1288*
(822 to 1891)
803*
(438 to 1266)
41 7653
(27 6786 to
60 3517)
94*
(120 to 70)
261*
(278 to 245)
167
(370 to 116)
25743
(15883 to 39203)
130
(349 to 169)
163
(370 to 123)
Protein-energy malnutrition
20 7569
(16 9853 to 25 7594)
Iodine deciency
115 6024
114*
(110 0072 to 120 9971) (168 to 54)
370*
(409 to 325)
20750
(12946 to 32919)
114*
(171 to 54)
367*
(408 to 323)
Vitamin A deciency
33724
(27324 to 39263)
194*
(244 to 146)
349*
(393 to 311)
1537
(990 to 2249)
229*
(287 to 169)
391*
(441 to 335)
1 208 2164
(1 205 9272 to
1 210 4778)
02
(06 to 01)
219*
(222 to 217)
36 6635
(24 3710 to
53 0847)
86*
(98 to 71)
258*
(267 to 249)
Other nutritional deciencies

Other communicable, maternal,
neonatal, and nutritional diseases
Sexually transmitted diseases
excluding HIV
132
(347 to 161)
2988
(1579 to 5354)
438*
(639 to 100)
457*
(652 to 131)
35654
(22823 to 54600)
97*
(56 to 158)
134*
(158 to 99)
13838
(8301 to 24046)
380*
(331 to 425)
26
(56 to 05)
371*
(395 to 343)
584
(396 to 818)
15
(53 to 99)
369*
(408 to 320)
Syphilis
3152
(3065 to 3245)
Chlamydial infection
1478465
295*
(144 1697 to 151 0275) (248 to 334)
55*
(88 to 28)
6465
(4110 to 10194)
371*
(310 to 433)
04
(42 to 48)
32 7261
(31 1627 to 34 3167)
388*
(296 to 476)
48
(20 to 114)
2254
(1448 to 3441)
434*
(291 to 610)
79
(26 to 209)
Trichomoniasis
67 0759
(62 7626 to 72 7646)
456*
(333 to 623)
40
(44 to 156)
1139
(451 to 2429)
455*
(323 to 641)
42
(49 to 169)
Genital herpes
1 176 4945
(1 160 2774 to
1 194 5172)
476*
(447 to 506)
53*
(71 to 35)
3116
(983 to 7485)
457*
(408 to 496)
48*
(68 to 26)
Other sexually transmitted diseases
12482
(9717 to 16124)
19
(41 to 102)
319*
(358 to 265)
279
(190 to 402)
200*
(92 to 324)
169*
(243 to 81)
4441
(2905 to 6411)
149*
(121 to 175)
173*
(194 to 153)
1980
(1283 to 2878)
259*
(229 to 291)
09
(35 to 20)
Hepatitis
Hepatitis A
78239
(75328 to 81153)
15
(25 to 64)
119*
(113 to 125)
58*
(61 to 53)
27
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013

Hepatitis B
331 0370
(325 3596 to
336 6384)
55*
(79 to 34)
321*
(337 to 306)
1726
(1120 to 2474)
22
(23 to 67)
318*
(350 to 286)
Hepatitis C
147 8263
(145 5207 to
150 0802)
160*
(136 to 185)
233*
(248 to 217)
169
(110 to 243)
155*
(100 to 214)
212*
(251 to 171)
Hepatitis E
21882
(20833 to 23119)
184*
(113 to 269)
109*
(162 to 46)
566
(363 to 821)
229*
(121 to 344)
86*
(164 to 00)
Leprosy
6588
(6136 to 7075)
613*
(540 to 696)
15
(60 to 35)
397
(266 to 560)
734*
(610 to 866)
57
(15 to 134)
Other infectious diseases
49 7596
(48 6255 to 51 0290)
49*
(78 to 20)
206*
(229 to 182)
16979
(11300 to 24698)
75*
(117 to 11)
198*
(234 to 146)
626 4777
(465 2877 to
806 5738)
542*
(530 to 558)
14*
(07 to 22)
67639
(49892 to 87159)
825*
(754 to 908)
85*
(44 to 135)
Neoplasms
Oesophageal cancer
8405
(7063 to 10152)
562*
(308 to 900)
95
(242 to 99)
1257
(889 to 1672)
496*
(302 to 728)
136*
(244 to 03)
Stomach cancer
25321
(23477 to 27365)
361*
(258 to 474)
210*
(269 to 147)
2904
(2094 to 3681)
282*
(191 to 383)
257*
(309 to 200)
1906
(1333 to 2532)
769*
(556 to 1020)
45
(76 to 190)
Liver cancer
Liver cancer due to hepatitis B
4509
(3733 to 5388)
912*
(487 to 1507)
142
(108 to 485)
670
(463 to 899)
707*
(445 to 1020)
20
(136 to 205)
Liver cancer due to hepatitis C
5126
(4386 to 5998)
3676*
(2847 to 4782)
1687*
(1207 to 2300)
746
(526 to 999)
3105*
(2565 to 3785)
1357*
(1068 to 1743)
Liver cancer due to alcohol use
1972
(1687 to 2268)
102
(88 to 344)
358*
(465 to 222)
299
(207 to 401)
20
(103 to 163)
404*
(476 to 321)
Liver cancer due to other causes
1215
(1021 to 1430)
10
(231 to 223)
407*
(541 to 270)
191
(131 to 256)
98
(240 to 44)
458*
(542 to 375)
Larynx cancer
8998
(7497 to 10698)
416*
(302 to 581)
166*
(230 to 71)
860
(600 to 1152)
328*
(220 to 496)
220*
(283 to 124)
Tracheal, bronchus, and lung cancer
32274
(30397 to 34268)
722*
(619 to 821)
08
(54 to 65)
4674
(3385 to 5932)
646*
(549 to 729)
37
(93 to 12)
Breast cancer
18 4190
(17 7406 to 19 1414)
1269*
(1155 to 1394)
297*
(235 to 365)
10682
(7608 to 14281)
1007*
(866 to 1143)
157*
(78 to 232)
Cervical cancer
31808
(26231 to 35990)
72
(54 to 219)
352*
(426 to 268)
2438
(1698 to 3330)
83
(35 to 223)
346*
(417 to 266)
Uterine cancer
29608
(23079 to 35164)
665*
(390 to 978)
38
(190 to 133)
1937
(1237 to 2736)
629*
(364 to 921)
60
(206 to 98)
Prostate cancer
11 1359
(10 0025 to 13 1234)
1788*
(1581 to 2127)
560*
(446 to 750)
8937
(6567 to 11925)
1642*
(1420 to 2083)
482*
(358 to 729)
Colon and rectum cancer
85916
(82527 to 89170)
1072*
(978 to 1156)
184*
(131 to 232)
7019
(5127 to 8991)
955*
(865 to 1041)
115*
(63 to 165)
Lip and oral cavity cancer
24165
(20444 to 27821)
768*
(563 to 1034)
29
(90 to 182)
2069
(1452 to 2783)
723*
(529 to 982)
00
(111 to 146)
Nasopharynx cancer
5011
(4223 to 5962)
297*
(58 to 585)
211*
(357 to 40)
479
(331 to 643)
259*
(56 to 496)
235*
(360 to 94)
Other pharynx cancer
7525
(6449 to 8571)
812*
(539 to 1094)
47
(109 to 206)
660
(455 to 885)
755*
(513 to 1015)
14
(126 to 163)
Gallbladder and biliary tract cancer
1583
(1359 to 1776)
467*
(293 to 627)
171*
(272 to 80)
391
(270 to 521)
398*
(227 to 549)
205*
(306 to 115)
Pancreatic cancer
3843
(3559 to 4129)
1005*
(842 to 1178)
143*
(52 to 245)
736
(521 to 962)
921*
(806 to 1037)
99*
(31 to 168)
28
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013
Malignant skin melanoma
23415
(18084 to 31513)
879*
(659 to 1071)
139*
(05 to 249)
1379
(917 to 2050)
808*
(595 to 997)
91
(38 to 202)
Non-melanoma skin cancer
55296
(49621 to 62049)
1088*
(788 to 1417)
182*
(03 to 369)
1262
(825 to 1881)
1528*
(1165 to 2002)
425*
(213 to 703)
Ovarian cancer
10538
(9757 to 11450)
683*
(561 to 823)
09
(81 to 70)
1349
(970 to 1746)
651*
(520 to 797)
29
(107 to 48)
Testicular cancer
5560
(4236 to 6810)
608*
(321 to 849)
94
(97 to 256)
343
(222 to 490)
576*
(308 to 805)
66
(108 to 219)
Kidney cancer
19606
(18298 to 20994)
1173*
(1045 to 1316)
318*
(239 to 404)
1392
(992 to 1858)
1097*
(970 to 1235)
261*
(182 to 343)
Bladder cancer
23596
(20772 to 25632)
585*
(498 to 691)
88*
(142 to 28)
1798
(1321 to 2355)
525*
(441 to 625)
128*
(178 to 69)
Brain and nervous system cancer
11932
(10106 to 13733)
522*
(286 to 709)
72
(72 to 189)
1219
(871 to 1651)
554*
(343 to 718)
56
(67 to 159)
Thyroid cancer
21794
(18153 to 25092)
1002*
(748 to 1299)
244*
(96 to 413)
1276
(857 to 1809)
949*
(713 to 1224)
197*
(66 to 356)
Mesothelioma
504
(442 to 576)
947*
(659 to 1109)
129
(43 to 220)
108
(74 to 144)
966*
(665 to 1130)
141
(44 to 235)
Hodgkins lymphoma
7253
(6250 to 9972)
127
(309 to 590)
347
(467 to 167)
575
(387 to 821)
120
(268 to 564)
362
(457 to 110)
Non-Hodgkin lymphoma
29564
(24480 to 32531)
1217*
(827 to 1420)
384*
(123 to 507)
2162
(1516 to 2926)
1122*
(757 to 1311)
314*
(64 to 433)
Multiple myeloma
4274
(3493 to 5288)
1078*
(781 to 1371)
190*
(13 to 369)
863
(597 to 1149)
986*
(689 to 1241)
134
(45 to 286)
Leukaemia
21173
(19787 to 22482)
443*
(248 to 586)
67
(46 to 156)
2496
(1827 to 3202)
521*
(384 to 638)
41
(40 to 114)
Other neoplasms
67850
(59381 to 74175)
1855*
(1045 to 2154)
932*
(470 to 1130)
4468
(3125 to 5964)
1723*
(1023 to 1990)
783*
(396 to 970)
21 1770
(14 9478 to
28 4367)
892*
(691 to 1087)
103
(10 to 213)
Cardiovascular diseases
Rheumatic heart disease
32 9039
(31 6085 to 34 0237)
628*
(513 to 720)
135*
(60 to 197)
18213
(12113 to 25308)
608*
(475 to 737)
95
(03 to 181)
92 9367
(90 0919 to 95 8608)
647*
(570 to 722)
52*
(96 to 10)
58041
(40552 to 79023)
675*
(588 to 766)
40
(88 to 12)
Cerebrovascular disease
37436
(26699 to 48439)
835*
(759 to 935)
50*
(05 to 112)
Ischaemic stroke
18 3055
(17 7674 to 18 9207)
815*
(726 to 927)
24
(28 to 91)
26501
(18751 to 34923)
818*
(726 to 933)
30
(22 to 99)
Haemorrhagic stroke
73635
(71397 to 76161)
889*
(806 to 986)
102*
(54 to 161)
10935
(7590 to 14381)
885*
(797 to 990)
106*
(56 to 171)
Hypertensive heart disease
10 8937
(10 5267 to 112464)
1128*
(1016 to 1239)
191*
(127 to 254)
11939
(8449 to 16339)
1138*
(1028 to 1249)
200*
(137 to 263)
Cardiomyopathy and myocarditis
79930
(77383 to 82693)
850*
(779 to 930)
85*
(43 to 134)
8657
(5915 to 11596)
868*
(790 to 951)
98*
(52 to 148)
Atrial brillation and utter
11 1786
(10 6551 to 11 6837)
636*
(539 to 714)
103*
(156 to 58)
8578
(6037 to 11774)
642*
(543 to 719)
97*
(151 to 52)
Peripheral vascular disease
185 1372
780*
(172 5557 to 196 5972) (599 to 912)
01
(99 to 67)
1277
(624 to 2238)
496*
(312 to 643)
197*
(295 to 120)
Endocarditis
3103
(2521 to 3610)
717*
(559 to 862)
46
(51 to 136)
325
(212 to 467)
774*
(597 to 962)
70
(39 to 184)
Other cardiovascular and circulatory

diseases
95 2252
(67 4332 to 121 7338)
1302*
(539 to 2347)
364
(86 to 987)
67304
1312*
(39261 to 10 0979) (537 to 2365)
371
(84 to 997)
29
Articles

( 1000)
in prevalence
from 1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013
38 6187
(26 8647 to
51 4583)
551*
(503 to 606)
00
(25 to 28)
05
(02 to 12)
26 1313
(17 7853 to
35 7869)
723*
(674 to 786)
55*
(27 to 93)
508
(360 to 690)
969*
(892 to 1033)
173*
(125 to 213)
Percentage change
in age-standardised
prevalence from
1990 to 2013

Chronic respiratory diseases
Chronic obstructive pulmonary

disease
Pneumoconiosis
328 5036
(317 2891 to
339 4610)
651*
(638 to 663)
Silicosis
562
(526 to 596)
498*
(473 to 523)
118*
(133 to 105)
107
(69 to 151)
499*
(472 to 523)
118*
(133 to 105)
Asbestosis
148
(140 to 155)
675*
(640 to 714)
07
(28 to 17)
28
(18 to 39)
681*
(646 to 721)
04
(25 to 20)
Coal workers pneumoconiosis
364
(346 to 381)
551*
(531 to 568)
69*
(80 to 59)
68
(46 to 98)
551*
(530 to 569)
69*
(81 to 59)
1649
(1540 to 1743)
1442*
(1379 to 1503)
474*
(440 to 511)
305
(199 to 439)
1418*
(1360 to 1482)
457*
(423 to 497)
Asthma
241 6947
(238 1511 to
245 4646)
321*
(295 to 349)
55*
(72 to 35)
10 5958
316*
(69246 to 15 1020) (289 to 346)
53*
(72 to 32)
Interstitial lung disease and

pulmonary sarcoidosis
5950
(5691 to 6225)
698*
(589 to 789)
51
(15 to 106)
807
(507 to 1179)
709*
(595 to 802)
54
(15 to 112)
Other chronic respiratory diseases

Cirrhosis
17600
(11500 to 26179)
84
(46 to 264)
328*
(407 to 218)
5446
(3811 to 7504)
292*
(255 to 332)
149*
(172 to 126)
Cirrhosis due to hepatitis B
8690
(8132 to 9230)
216*
(114 to 302)
208*
(272 to 153)
1432
(988 to 1977)
209*
(91 to 316)
210*
(281 to 139)
Cirrhosis due to hepatitis C
8849
(8372 to 9477)
605*
(520 to 744)
16
(36 to 105)
1449
(1008 to 2013)
599*
(498 to 753)
16
(42 to 114)
Cirrhosis due to alcohol use
8015
(7466 to 8643)
100*
(11 to 214)
334*
(386 to 271)
1312
(893 to 1801)
103
(02 to 227)
331*
(392 to 260)
Cirrhosis due to other causes
7420
(6939 7895)
336*
(244 to 463)
36
(35 to 132)
1253
(856 to 1751)
333*
(207 to 505)
35
(63 to 164)
84579
(60665 to
11 2839)
244*
(199 to 288)
219*
(247 to 192)
Digestive diseases
35 5152
(33 9625 to 36 9071)
54*
(79 to 25)
458*
(471 to 441)
12686
(8732 to 17745)
14
(59 to 37)
432*
(455 to 403)
Gastritis and duodenitis
64 7999
(63 3175 to 66 2126)
114*
(78 to 149)
267*
(287 to 247)
23842
(16170 to 33887)
63*
(17 to 103)
276*
(304 to 252)
Appendicitis
6217
(5464 to 6996)
170*
(10 to 372)
146
(254 to 00)
1902
(1269 to 2631)
174
(10 to 392)
136
(267 to 18)
Paralytic ileus and intestinal

obstruction
1146
(1114 to 1176)
504*
(447 to 563)
46*
(12 to 80)
351
(238 to 475)
492*
(412 to 574)
47
(06 to 106)
Inguinal, femoral, and abdominal

hernia
25 3934
(24 0845 to 26 3610)
457*
(360 to 531)
105*
(161 to 59)
2623
(1294 to 4908)
457*
(358 to 531)
99*
(156 to 53)
Inammatory bowel disease
10 5759
(10 4101 to 10 7376)
757*
(727 to 786)
96*
(77 to 114)
22232
(15441 to 30282)
756*
(715 to 795)
101*
(76 to 125)
Vascular intestinal disorders
353
(332 to 386)
699*
(587 to 816)
07
(76 to 65)
108
(72 to 146)
688*
(541 to 837)
02
(97 to 98)
Gallbladder and biliary diseases
58938
(57377 to 61190)
370*
(326 to 439)
182*
(208 to 143)
6149
(4288 to 8268)
369*
(315 to 436)
179*
(210 to 143)
Pancreatitis
19728
(19517 to 19974)
708*
(684 to 733)
69*
(55 to 84)
5798
(3989 to 7716)
705*
(651 to 758)
73*
(41 to 105)
8888
(6127 to 12284)
59
(85 to 171)
342*
(433 to 272)
Other digestive diseases
30
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013
59 3601
(41 0360 to
80 8718)
596*
(548 to 645)
50*
(24 to 79)

Neurological disorders
Alzheimers disease and other

dementias
53 0505
(51 6637 to 54 3598)
885*
(821 to 950)
07
(40 to 28)
77736
(57031 to 98673)
918*
(853 to 985)
00
(35 to 38)
Parkinsons disease
58663
(47772 to 69500)
809*
(777 to 836)
21*
(04 to 35)
6948
(4685 to 9641)
812*
(773 to 852)
27*
(06 to 46)
Epilepsy
21 7120
(20 1603 to 23 1084)
316*
(202 to 438)
25
(108 to 67)
75442
(51641 to 99259)
405*
(285 to 565)
44
(45 to 159)
Multiple sclerosis
22936
(22389 to 23456)
1172*
(1100 to 1240)
354*
(307 to 395)
7546
(5476 to 9510)
1161*
(1063 to 1257)
351*
(290 to 411)
Migraine
848 3665
(831 0346 to
864 8521)
461*
(414 to 501)
03
(28 to 30)
28 8981
(17 5858 to
42 4201)
461*
(414 to 505)
08
(24 to 37)
Tension-type headache
1 561 4465
(1 537 5714 to
1 585 7658)
455*
(419 to 494)
00
(24 to 26)
23632
(11519 to 41550)
455*
(417 to 495)
03
(21 to 29)
Medication overuse headache
62 8993
(43 1430 to 80 6560)
1202*
(1095 to 1338)
428*
(359 to 519)
98457
(57779 to 15 1003)
1202*
(1093 to 1337)
433*
(362 to 524)
Other neurological disorders
116
(100 to 133)
459*
(360 to 563)
09
(56 to 79)
14858
(10566 to 19186)
314*
(127 to 404)
296*
(392 to 248)
161 8119
(116 0578 to
210 2560)
450*
(429 to 472)
10*
(03 to 19)
521*
(503 to 541)
11
(22 to 01)
Mental and substance use disorders
Schizophrenia
23 6006
(22 1706 to 25 0387)
521*
(503 to 536)
15*
(24 to 06)
15 2044
(11 1693 to
18 1886)
76 8966
(73 4540 to 80 4919)
344*
(323 to 364)
76*
(88 to 65)
76536
343*
(51507 to 10 9523) (320 to 366)
75*
(88 to 61)
12 2224
(85131 to 16 1728)
413*
(363 to 463)
06
(24 to 38)
Drug use disorders
Opioid use disorders
14 0718
(11 1030 to 181 392)
589*
(544 to 628)
64*
(30 to 95)
58495
(39079 to 81840)
591*
(540 to 636)
67*
(32 to 102)
Cocaine use disorders
73846
(72163 to 75493)
321*
(284 to 358)
59*
(85 to 33)
10129
(6669 to 14302)
321*
(272 to 371)
57*
(92 to 23)
Amphetamine use disorders
14 9229
(14 4906 to 15 3707)
264*
(212 to 313)
41*
(80 to 06)
19610
(12330 to 28329)
266*
(208 to 322)
38
(81 to 03)
Cannabis use disorders
13 6250
(12 4292 to 14 9380)
224*
(206 to 240)
65*
(76 to 55)
3956
(2612 to 5762)
224*
(190 to 261)
64*
(89 to 37)
Other drug use disorders

Depressive disorders
30033
(19989 to 41645)
285*
(215 to 365)
44
(97 to 14)
61 6328
(41 3538 to
85 6214)
536*
(496 to 584)
40*
(22 to 56)
253 3142
(208 4572 to
299 6913)
534*
(490 to 589)
42*
(24 to 62)
51 7839
(33 8882 to
73 6658)
534*
(488 to 592)
47*
(27 to 67)
Dysthymia
102 4096
(91 2462 to 113 4412)
546*
(524 to 572)
03
(12 to 07)
98489
(65866 to
14 1660)
546*
(521 to 572)
01
(10 to 12)
Bipolar disorder
48 7784
(43 4989 to 54 3712)
491*
(467 to 522)
09
(04 to 24)
99111
(62606 to
14 7910)
492*
(464 to 525)
13
(04 to 29)
Anxiety disorders
265 6101
424*
(213 0151 to 318 8170) (366 to 468)
05
(17 to 08)
24 3558
(16 1486 to
35 1390)
421*
(364 to 465)
02
(16 to 13)
31
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013
18200
(11545 to 27203)
276*
(237 to 321)
12
(42 to 17)

Eating disorders
Anorexia nervosa
20636
(16835 to 25350)
354*
(311 to 407)
55*
(22 to 92)
4404
(2855 to 6483)
359*
(302 to 418)
60*
(17 to 103)
Bulimia nervosa
65379
(49172 to 88576)
248*
(204 to 292)
37*
(69 to 08)
13797
(8507 to 21366)
251*
(202 to 302)
34
(71 to 01)
84490
338*
(58881 to 11 4587) (327 to 349)
07
(00 to 15)
Autistic spectrum disorders
Autism
21 7167
(20 7318 to 22 7135)
341*
(335 to 348)
03*
(01 to 06)
53450
(35836 to 73099)
339*
(324 to 355)
07
(03 to 18)
Aspergers syndrome
31 1001
(29 2517 to 32 9051)
337*
(329 to 345)
04*
(03 to 05)
31040
(21696 to 43250)
336*
(323 to 350)
07
(01 to 15)
Attention-decit or hyperactivity
disorder
39 3435
(36 5742 to 42 0936)
138*
(128 to 149)
05
(13 to 05)
4799
(2874 to 7458)
139*
(121 to 160)
03
(19 to 15)
Conduct disorder
51 1097
(48 0069 to 54 5570)
163*
(154 to 172)
22*
(14 to 31)
61590
(38682 to 89116)
165*
(150 to 180)
24*
(11 to 38)
Idiopathic intellectual disability
94 6728
(75 9065 to 116 6647)
226*
(127 to 358)
58
(135 to 44)
46667
(30848 to 66400)
220*
(121 to 350)
61
(139 to 38)
Other mental and substance use

disorders
124 0429
523*
(116 7414 to 131 0018) (509 to 538)
02*
(01 to 03)
92572
(62779 to 124115)
523*
(505 to 541)
06
(01 to 13)
65 5614
(46 2015 to
87 8345)
727*
(692 to 766)
141*
(119 to 164)
Diabetes, urogenital, blood, and

endocrine diseases
Diabetes mellitus
409 9670
(381 8063 to
432 0384)
1329*
(1237 to 1424)
448*
(385 to 513)
29 5181
(20 4191 to
40 1693)
1357*
(1272 to 1437)
434*
(379 to 485)
Acute glomerulonephritis
377
(351 to 405)
34*
(60 to 12)
222*
(242 to 206)
19
(12 to 28)
33*
(60 to 11)
222*
(242 to 206)
12 3473
495*
(91016 to 15 8149) (434 to 539)
28*
(64 to 04)

diabetes mellitus
88 7109
(71 1501 to 111 4172)
824*
(586 to 968)
119
(36 to 212)
24918
(18029 to 32207)
805*
(657 to 926)
106*
(20 to 177)

hypertension
101 2534
(81 4104 to 129 9930)
268*
(183 to 349)
107*
(176 to 53)
26353
(19153 to 34155)
231*
(163 to 332)
224*
(269 to 163)

glomerulonephritis
108 8609
(88 3303 to 135 4819)
327*
(173 to 413)
135*
(256 to 66)
24959
(18090 to 32520)
339*
(256 to 433)
69*
(119 to 05)
Chronic kidney disease due to other

causes
173 0907
(142 3959 to
213 0104)
539*
(435 to 636)
31
(59 to 101)
47243
(35030 to 60632)
634*
(559 to 719)
69*
(09 to 127)
48803
(32129 to 70171)
838*
(778 to 911)
85*
(51 to 124)
Urinary diseases and male infertility
Interstitial nephritis and urinary tract

17537
infections
(17302 to 17753)
675*
(646 to 709)
162*
(143 to 184)
581
(364 to 856)
668*
(599 to 747)
164*
(118 to 213)
Urolithiasis
80 6225
(61 5627 to 103 0699)
1019*
(896 to 1133)
200*
(129 to 261)
6618
(4114 to 9840)
958*
(830 to 1093)
204*
(130 to 276)
Benign prostatic hyperplasia
99 1484
(97 3561 to 100 9116)
793*
(754 to 837)
30*
(08 to 56)
35529
(23165 to 49937)
800*
(759 to 845)
36*
(13 to 63)
Male infertility due to other causes
39 2762
(36 9506 to 41 6187)
440*
(333 to 553)
29
(48 to 110)
2586
(1118 to 5314)
436*
(323 to 566)
30
(51 to 120)
1957*
(942 to 2415)
860*
(234 to 1147)
Other urinary diseases
3489
(1758 to 5440)
Gynaecological diseases
91314
445*
(59825 to 13 5958) (403 to 493)
35*
(61 to 05)
Uterine broids
171 0054
625*
(158 1559 to 182 5135) (612 to 638)
18*
(23 to 12)
21647
(12423 to 36779)
366*
(294 to 436)
143*
(183 to 106)
Polycystic ovarian syndrome
122 3106
511*
(119 5727 to 124 9293) (466 to 556)
23
(06 to 52)
11912
(5623 to 22274)
517*
(471 to 564)
30*
(01 to 61)
32
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013
Female infertility due to other causes
34 6786
(31 1039 to 38 0093)
583*
(448 to 724)
107*
(17 to 203)
1919
(752 to 3991)
569*
(424 to 716)
110*
(10 to 210)
Endometriosis
14 6612
(14 2308 to 15 0944)
479*
(419 to 535)
16
(56 to 21)
13596
(9064 to 18615)
481*
(421 to 543)
13
(53 to 28)
Genital prolapse
343 7078
(336 9588 to
350 3274)
570*
(530 to 615)
09
(33 to 17)
10942
(5345 to 20410)
571*
(529 to 617)
07
(33 to 21)
Premenstrual syndrome
302 7317
(284 3731 to
321 8296)
538*
(403 to 679)
92
(01 to 194)
25486
(15813 to 37770)
540*
(407 to 679)
95*
(01 to 195)
Other gynaecological diseases
20 7580
(19 6994 to 21 7928)
157*
(69 to 264)
193*
(256 to 118)
5813
(3957 to 8266)
42
(46 to 213)
272*
(335 to 147)
70719
(47308 to 101070)
232*
(207 to 265)
23
(42 to 03)
Haemoglobinopathies and
haemolytic anaemias
Thalassaemias
7667
(6918 to 8498)
116*
(85 to 191)
25
(51 to 38)
619
(421 to 880)
102*
(18 to 221)
42
(113 to 58)
Thalassaemia trait
207 5618
(192 4113 to
228 4376)
373*
(347 to 396)
27*
(05 to 45)
37696
(25089 to 54422)
346*
(310 to 388)
59*
(31 to 93)
32504
(30917 to 34005)
776*
(699 to 861)
523*
(458 to 596)
3421
(2462 to 4559)
794*
(681 to 909)
497*
(401 to 590)
Sickle cell trait
261 7407
(249 5154 to
272 7359)
570*
(542 to 597)
193*
(171 to 213)
13966
(9294 to 20049)
390*
(320 to 490)
138*
(80 to 236)
Glucose-6-phosphate
dehydrogenase deciency
337 6288
(329 3606 to
345 7537)
471*
(421 to 519)
114*
(76 to 151)
363
(248 to 504)
405*
(317 to 495)
114*
(48 to 181)
Glucose-6-phosphate
dehydrogenase deciency trait
1 181 9725
(1 174 3521 to
1 188 8440)
386*
(376 to 399)
30*
(22 to 39)
488
(301 to 733)
236
(10 to 509)
07
(206 to 204)
Other haemoglobinopathies and

haemolytic anaemias
56 0101
(54 4702 to 57 2586)
23
(55 to 13)
266*
(290 to 240)
14165
(9365 to 20517)
127*
(175 to 64)
314*
(351 to 264)
79 5560
(77 3632 to 81 2823)
103*
(69 to 138)
162*
(188 to 137)
26106
(17979 to 36290)
69*
(22 to 128)
167*
(202 to 123)
146 2313
(103 7631 to
194 3046)
607*
(586 to 636)
06
(05 to 23)
568*
(539 to 594)
46*
(63 to 31)
Endocrine, metabolic, blood, and

immune disorders
Musculoskeletal disorders
Rheumatoid arthritis
16 8632
(16 7144 to 17 0358)
570*
(547 to 591)
51*
(65 to 38)
39256
(28186 to 51785)
Osteoarthritis
241 8250
(239 6558 to
243 8967)
719*
(698 to 743)
26*
(38 to 12)
12 8111
754*
(90300 to 17 2812) (729 to 778)
02
(16 to 12)
106 6655
(74 1169 to
142 9597)
558*
(533 to 596)
04
(19 to 19)
Low back and neck pain
Low back pain
651 0088
(641 1434 to
662 8851)
568*
(536 to 614)
04
(24 to 25)
72 3176
(49 0510 to
99 7385)
567*
(535 to 615)
00
(20 to 29)
Neck pain
349 3052
(341 1603 to
359 7674)
541*
(491 to 599)
15
(46 to 22)
34 3479
(23 7920 to
47 4185)
540*
(490 to 599)
12
(43 to 26)
Gout
58256
(57500 to 59048)
675*
(646 to 708)
23*
(40 to 03)
1855
(1290 to 2492)
677*
(626 to 733)
18
(47 to 14)
248 1882
(216 6911 to
281 9336)
784*
(750 to 825)
66*
(50 to 89)
22 6436
(15 2538 to
31 6846)
786*
(750 to 829)
70*
(53 to 93)
33
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013

Other non-communicable diseases
Congenital anomalies
117 9510
(78 4733 to
170 9056)
448*
(428 to 467)
41*
(54 to 30)
80225
614*
(59226 to 10 1684) (525 to 728)
197*
(132 to 282)
Neural tube defects
14702
(14346 to 15082)
592*
(538 to 644)
254*
(212 to 296)
4612
(3254 to 5996)
616*
(537 to 707)
279*
(214 to 351)
Congenital heart anomalies
34 3159
(33 1780 to 35 6912)
880*
(803 to 985)
400*
(345 to 478)
12304
(5408 to 20795)
868*
(773 to 976)
407*
(345 to 485)
Orofacial clefts
58076
(56219 to 59881)
944*
(861 to 1059)
479*
(412 to 566)
688
(456 to 988)
763*
(652 to 895)
371*
(284 to 473)
Downs syndrome
85385
(81857 to 88978)
795*
(701 to 882)
328*
(260 to 392)
11671
(8948 to 14597)
913*
(805 to 1014)
364*
(293 to 429)
Turners syndrome
2575
(2466 to 2712)
512*
(426 to 623)
148*
(84 to 233)
43
(22 to 69)
521*
(429 to 648)
145*
(75 to 238)
2163
(2071 to 2267)
420*
(332 to 527)
65*
(00 to 145)
13
(06 to 24)
472*
(370 to 588)
55
(18 to 139)
Chromosomal unbalanced
rearrangements
11 6493
(11 1541 to 12 2351)
740*
(660 to 830)
275*
(217 to 340)
16029
(12036 to 20384)
851*
(756 to 950)
306*
(248 to 371)
Other congenital anomalies
25 8400
(22 1705 to 29 2831)
229*
(172 to 287)
106*
(147 to 65)
34864
(24366 to 46412)
387*
(265 to 564)
43
(46 to 174)
39 0510
(25 0445 to
60 1258)
373*
(338 to 403)
03
(20 to 23)
Skin and subcutaneous diseases
Dermatitis
333 7854
(289 9273 to
381 3124)
387*
(362 to 411)
17*
(24 to 09)
92784
368*
(60290 to 13 3267) (347 to 392)
06
(14 to 03)
Psoriasis
58 2641
(51 7202 to 64 6094)
460*
(440 to 488)
22*
(30 to 16)
47267
(32547 to 66219)
459*
(432 to 488)
19*
(30 to 06)
Cellulitis
17059
(14297 to 20403)
191*
(132 to 251)
182*
(212 to 159)
1202
(786 to 1702)
186*
(113 to 266)
180*
(219 to 138)
57597
(46935 to 72782)
67
(162 to 37)
238*
(299 to 176)
326
(124 to 721)
71
(163 to 29)
240*
(298 to 177)
Scabies
66 1075
(62 4301 to 70 6359)
248*
(150 to 401)
40
(113 to 73)
17054
(9672 to 27116)
248*
(148 to 403)
37
(112 to 78)
683 7138
(597 8982 to
780 9634)
442*
(412 to 479)
30*
(19 to 38)
38472
(15745 to 81398)
441*
(411 to 479)
33
(22 to 41)
Viral skin diseases
127 9236
(105 5934 to
151 6359)
205*
(179 to 243)
18*
(31 to 03)
39550
(23984 to 61509)
204*
(178 to 241)
17
(30 to 00)
Acne vulgaris
661 6349
(622 8425 to
700 2417)
232*
(139 to 326)
04
(78 to 73)
71808
(34516 to 13 2141)
232*
(137 to 327)
03
(77 to 74)
Alopecia areata
87755
(86144 to 89379)
461*
(425 to 494)
11
(34 to 12)
2924
(1868 to 4352)
456*
(412 to 500)
09
(36 to 18)
Pruritus
10246
(9881 to 10741)
553*
(463 to 631)
02
(59 to 53)
108
(51 to 200)
548*
(449 to 649)
00
(64 to 65)
Urticaria
79 5828
(72 8123 to 86 2963)
605*
(442 to 750)
73
(38 to 166)
47207
(30365 to 67372)
607*
(434 to 755)
77
(35 to 176)
Decubitus ulcer
19214
(18530 to 20012)
595*
(518 to 671)
81*
(131 to 33)
2775
(1960 to 3712)
581*
(498 to 668)
77*
(129 to 25)
Other skin and subcutaneous

diseases
495 3276
(319 4623 to
761 2555)
571*
(485 to 644)
00
(09 to 09)
29031
(12741 to 61236)
570*
(485 to 645)
04
(06 to 13)
34
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013
54 4281
(36 4584 to
76 0754)
474*
(441 to 501)
82*
(97 to 67)

Sense organ diseases
Glaucoma
10 8999
(98532 to 12 0028)
630*
(502 to 747)
35
(106 to 29)
8075
(5716 to 11028)
631*
(548 to 709)
46*
(97 to 02)
Cataract
44 2216
(39 3260 to 48 6031)
475*
(413 to 564)
176*
(208 to 130)
29167
(20551 to 39622)
567*
(506 to 639)
125*
(157 to 86)
13 8738
(12 1765 to 15 5626)
763*
(694 to 893)
16
(56 to 51)
7256
(5094 to 9851)
750*
(690 to 878)
44
(86 to 14)
Uncorrected refractive error
659 8472
(648 2987 to
671 4467)
520*
(490 to 550)
52*
(70 to 34)
11 2572
435*
(71498 to 17 4523) (404 to 472)
89*
(106 to 70)
1 128 9391
(1 055 6575 to
1 200 4764)
557*
(527 to 584)
65*
(79 to 52)
32 5797
(22 0837 to
45 8461)
507*
(454 to 548)
79*
(102 to 54)
Other vision loss
26 8060
(24 1160 to 29 6969)
199*
(160 to 238)
222*
(250 to 199)
17935
(12604 to 24520)
237*
(194 to 276)
211*
(235 to 190)
Other sense organ diseases
164 6122
(163 1169 to
166 3899)
342*
(325 to 362)
02
(14 to 12)
43480
(27043 to 64351)
337*
(317 to 358)
01
(13 to 16)
16 4495
(10 0223 to
25 5063)
476*
(458 to 497)
77*
(97 to 55)
Oral disorders
Deciduous caries
492 9205
(490 6571 to
495 3852)
44*
(36 to 52)
21*
(28 to 14)
1811
(790 to 3509)
57*
(41 to 75)
09
(23 to 08)
Permanent caries
2 633 3288
(2 607 9319 to
2 658 7495)
374*
(358 to 396)
12
(23 to 04)
24110
(11026 to 46645)
405*
(383 to 430)
18*
(01 to 37)
503 9672
(496 8704 to
511 4484)
667*
(637 to 701)
14
(04 to 34)
32860
(13183 to 67503)
668*
(638 to 703)
17
(02 to 37)
Edentulism and severe tooth loss
250 6836
(247 5123 to
253 4630)
456*
(434 to 479)
164*
(177 to 151)
68556
(46472 to 94204)
456*
(433 to 479)
162*
(176 to 149)
Other oral disorders
126 9455
(125 4523 to
128 5682)
447*
(425 to 469)
05
(20 to 09)
37157
(23475 to 55586)
446*
(422 to 469)
03
(19 to 12)
Injuries
Transport injuries
Road injuries
36 8315
(26 8957 to
48 7480)
03
(137 to 113)
370*
(454 to 300)
10 1949
(74779 to
13 4378)
62
(10 to 145)
317*
(362 to 268)
85934
(63059 to 11 3137)
69
(07 to 158)
310*
(358 to 258)
Pedestrian road injuries
37 8441
(37 4571 to 38 2167)
537*
(517 to 556)
06
(07 to 19)
22718
(16571 to 29935)
172*
(89 to 270)
236*
(285 to 178)
13 6786
(13 4392 to 13 9251)
241*
(221 to 262)
149*
(163 to 134)
8124
(5946 to 10742)
28
(35 to 99)
339*
(379 to 295)
Motorcyclist road injuries
32 4836
(31 9646 to 33 0197)
280*
(255 to 300)
172*
(189 to 159)
16492
(12017 to 22045)
42
(122 to 51)
382*
(431 to 325)
Motor vehicle road injuries
60 7337
(59 8485 to 61 5931)
408*
(393 to 424)
27*
(37 to 15)
37778
(28110 to 49469)
81*
(03 to 167)
309*
(356 to 258)
Other road injuries
13715
(13511 to 13936)
179*
(159 to 198)
228*
(242 to 215)
823
(610 to 1073)
57
(114 to 10)
401*
(434 to 361)
26 2930
(25 8996 to 26 7090)
229*
(203 to 252)
217*
(235 to 201)
16015
(11732 to 21185)
22
(31 to 85)
351*
(385 to 312)
Other transport injuries
35
Articles

( 1000)
in prevalence
from 1990 to 2013
Percentage change
in age-standardised
prevalence from
1990 to 2013
YLDs in 2013
( 1000)

YLDs from
from 1990 to 2013
1990 to 2013
21 6494
(16 0360 to
28 7269)
179*
(105 to 258)
280*
(328 to 227)

Unintentional injuries
Falls
250 0444
613*
(247 4382 to 252 5489) (597 to 628)
09
(02 to 18)
12 8181
235*
(93569 to 16 9968) (136 to 350)
283*
(345 to 211)
Drowning
61491
(60223 to 62754)
137*
(106 to 167)
239*
(259 to 219)
3736
(2734 to 4851)
86*
(135 to 24)
379*
(409 to 341)
Fire, heat, and hot substances
35 3262
(34 0973 to 36 5758)
74*
(34 to 118)
287*
(314 to 255)
11722
(8671 to 15514)
47
(100 to 06)
368*
(398 to 338)
Poisonings
9252
(9103 to 9395)
51*
(28 to 70)
292*
(307 to 279)
787
(562 to 1045)
63*
(98 to 27)
367*
(390 to 344)
37580
(27486 to 49854)
52*
(03 to 104)
301*
(330 to 269)
Exposure to mechanical forces
Unintentional rearm injuries
37290
(36393 to 38209)
299*
(267 to 333)
133*
(154 to 111)
1466
(1090 to 1943)
64
(03 to 142)
298*
(340 to 251)
Unintentional suocation
9496
(9234 to 9798)
665*
(632 to 694)
134*
(116 to 150)
542
(402 to 716)
422*
(347 to 501)
33
(81 to 16)
Other exposure to mechanical forces
113 1115
157*
(105 8597 to 120 5144) (129 to 180)
180*
(197 to 165)
35572
(25977 to 47264)
47
(00 to 98)
304*
(333 to 273)
10
(24 to 04)
2010
(1271 to 2952)
484*
(461 to 507)
57*
(72 to 40)
4035
(2995 to 5276)
63*
(106 to 14)
364*
(390 to 335)
Adverse eects of medical treatment

Animal contact
15261
(12267 to 18202)
462*
(440 to 485)
Venomous
22741
(22049 to 23466)
26
(21 to 68)
311*
(342 to 283)
1531
(1105 to 2011)
75*
(126 to 22)
371*
(405 to 336)
Non-venomous
12 0898
(10 5229 to 13 7755)
56
(109 to 00)
328*
(359 to 296)
2505
(1839 to 3378)
54
(109 to 06)
360*
(389 to 328)
2548
(1868 to 3250)
221*
(162 to 290)
194*
(233 to 150)
Foreign body
Pulmonary aspiration and foreign

body in airway
8878
(8734 to 9027)
425*
(397 to 455)
46*
(63 to 28)
502
(384 to 646)
27
(105 to 74)
337*
(386 to 272)
11648
(7375 to 15861)
415*
(377 to 467)
04
(15 to 23)
603
(350 to 917)
306*
(260 to 349)
104*
(154 to 69)
Foreign body in other body part
39123
(34656 to 43836)
420*
(340 to 496)
40*
(83 to 02)
1443
(1080 to 1865)
301*
(239 to 369)
165*
(201 to 127)
51 1320
(49 3590 to 52 9460)
452*
(431 to 477)
39*
(52 to 25)
25895
(19051 to 34453)
342*
(297 to 391)
160*
(185 to 133)
10535
(7780 to 13880)
18
(50 to 105)
344*
(385 to 292)
2316
(1670 to 3073)
17
(69 to 54)
390*
(422 to 348)
8219
(6104 to 10777)
28
(45 to 120)
330*
(374 to 273)
Other unintentional injuries

Self-harm and interpersonal violence
Self-harm
Interpersonal violence
59408
(58452 to 60512)
215*
(185 to 242)
247*
(263 to 232)
Assault with rearm
38702
(37652 to 39742)
467*
(426 to 505)
32*
(59 to 07)
1631
(1200 to 2166)
219*
(148 to 298)
211*
(254 to 165)
Assault with sharp object
60786
(58689 to 63111)
419*
(364 to 472)
70*
(103 to 37)
1723
(1249 to 2332)
185*
(108 to 280)
229*
(276 to 172)
10 1334
(98358 to 10 4483)
214*
(188 to 237)
179*
(193 to 166)
4865
(3642 to 6357)
64
(129 to 24)
388*
(429 to 334)
39337
(18607 to 78210)
507*
(577 to 402)
679*
(726 to 610)
Forces of nature, war, and legal

intervention
Exposure to forces of nature
14 3355
(71333 to 28 6801)
82
(46 to 290)
374*
(456 to 245)
5568
(2806 to 11170)
07
(151 to 223)
367*
(458 to 220)
Collective violence and legal

intervention
43 4781
(23 5802 to 77 3046)
270*
(322 to 173)
467*
(512 to 408)
33769
(15473 to 67846)
546*
(602 to 461)
703*
(742 to 645)
All data are reported with 95% uncertainty intervals. YLDs=years lived with disability. *Signicant percentage change.
Table 10: Prevalent cases and YLDs for 2013, percentage change, and percentage change of age-standardised rates between 1990 and 2013 for all causes
36
Articles
next most important cause was cataract followed by other

vision loss, preterm birth complications, glaucoma,
macular degeneration, and diabetes.
Figure 3 shows the comparison of the leading causes of
global YLDs in 1990 and 2013, which provides detailed
cause breakdowns that were most relevant to prioritising
specic programmes or interventions. The top cause in
1990 and 2013 was low back pain. The second leading
cause changed due to the decline in iron-deciency
anaemia and the rise in major depressive disorder. Two
more top ten causes were musculoskeletal disorders:
neck pain and the large category of other musculoskeletal
disorders. Other top ten causes included migraine, agerelated and other hearing loss, COPD, anxiety, and
diabetes. Causes that increased more than two ranks
from 1990 to 2013 included diabetes mellitus, osteoarthritis, dysthymia, medication overuse headache, and
Alzheimers disease and other dementias. Declines of
more than two ranks were noted for dermatitis,
diarrhoeal diseases, acne vulgaris, conduct disorder, and
war and legal intervention.
Table 10 provides the global estimates of prevalence and
YLDs for 2013 and change from 1990 to 2013 for each
cause (the full details at the levels of the sequelae;
prevalence, YLD, and change between 1990 and 2013 by
cause and age group; and prevalence, YLD, and change
between 1990 and 2013 by cause and country are shown
in the appendix pp 738811). In the GBD framework,
individuals should be assigned to a unique sequela such
that the sum of the YLDs or prevalence by sequela should
equal the total prevalence and YLDs for a disease or
injury. Since specic sequelae are of substantive interest
to help target interventions or needs for new interventions,
and to enhance the transparency of computation, we have
provided the full list of causes and sequelae. Comparison
of the percentage change in absolute number of YLDs
from 1990 to 2013 and the percentage change in the
age-standardised YLD rate shows where demographic
change, both population increase and rising mean age,
had a major eect. Age-standardised YLDs and prevalence
for several infectious diseases showed signicant declines
of greater than 10% including diarrhoeal diseases,
typhoid, paratyphoid, lower respiratory infections,
meningitis, encephalitis, diphtheria, whooping cough,
tetanus, measles, Chagas, African trypanosomiasis,
cysticercosis, cystic echinococcosis, lymphatic lariasis,
onchocerciasis, trachoma, rabies, ascariasis, trichuriasis,
and hookworm. By contrast, signicant increases in agestandardised rates of greater than 10% were noted for
HIV (from 1990 to 2013, but declines since 2005),61
cutaneous and mucocutaneous leishmaniasis, and
dengue. Some other disorders such as malaria,
tuberculosis, upper respiratory infections, varicella, and
schistosomiasis did not show signicant changes in
either direction of greater than 10%.
Age-standardised YLD rates for all maternal causes and
sequelae combined declined signicantly. Overall age-
standardised YLDs for neonatal disorders increased

805% from 1990 to 2013 (table 10). Large increases in
age-standardised rates were noted for all neonatal causes.
Age-standardised YLDs and prevalence of nutritional
deciencies decreased as did the absolute numbers of
cases. Although there was a decline in the agestandardised rates for syphilis, they were either nonsignicant or small for chlamydia and gonorrhoea (table
10). The decline was signicant for hepatitis B and C, but
non-signicant for hepatitis A and E. Of note, the number
of individuals with hepatitis C infection increased.
Age-standardised YLD rates from all non-communicable
diseases changed by only 14% from 1990 to 2013, but
YLD numbers increased by 542% (table 10). Stagnant
overall rates masked highly diverse trends for specic
causes. Overall, neoplasm YLDs increased 825% and
age-standardised rates increased signicantly by 85%.
However, within the category of neoplasms, signicant
declines were noted for stomach cancer, liver cancer due
to alcohol use, liver cancer due to other causes, larynx
cancer, cervical cancer, nasopharynx cancer, gallbladder
and biliary tract cancer, and bladder cancer. Signicant
increases were noted for liver cancer due to hepatitis C,
breast cancer, prostate cancer, colon and rectum cancer,
pancreatic cancer, non-melanoma skin cancer, kidney
cancer, thyroid cancer, non-Hodgkin lymphoma, and
other neoplasms. Of note, there was no signicant change
in the trachea, bronchus, and lung cancer agestandardised rates. YLDs for cardiovascular diseases
overall increased 892%, but age-standardised rates did
not change signicantly. Among cardiovascular causes,
age-standardised YLD rates declined signicantly for
atrial brillation and utter and peripheral vascular
diseases. By contrast, age-standardised rates increased
signicantly by more than 5% for hypertensive heart
disease and cardiomyopathy and myocarditis.
Numbers of YLDs from chronic respiratory diseases
increased from 1990 to 2013 by 551% but age-standardised
rates remained stagnant (table 10). Overall cirrhosis agestandardised prevalence and YLD rates declined, although
for cirrhosis caused by hepatitis C the change was not
signicant. Among the digestive diseases, gastritis and
duodenitis, appendicitis, inguinal, femoral, and
abdominal hernia, gallbladder and biliary diseases, and
other digestive diseases increased in absolute terms but
declined in age-standardised rates. By contrast,
inammatory bowel diseases, paralytic ileus and intestinal
obstruction, and pancreatitis increased in numbers and
rates. YLDs from neurological disorders, as a group,
increased 596%, but age-standardised rates increased by
only 50%. There was no change in age-standardised rates
for Alzheimers and other dementias but YLD numbers
increased by 918%. The age-standardised rates of
Parkinsons disease and primary epilepsy increased but
not signicantly, consistent with the consideration that
they are largely genetically determined. YLDs from
multiple sclerosis increased in age-standardised rates and
37
Articles
10
Global
Back pain
MDD
Iron
Neck pain
Hearing
Migraine
Diabetes
COPD
Anxiety
Other MSK
Developed countries
Back pain
MDD
Neck pain
Other MSK
Hearing
Diabetes
Migraine
Falls
Anxiety
COPD
Developing countries
Back pain
MDD
Iron
Neck pain
Hearing
Migraine
Diabetes
COPD
Anxiety
Other MSK
High-income countries
Back pain
Neck pain
MDD
Other MSK
Diabetes
Hearing
Anxiety
Falls
Migraine
COPD
Australasia
Back pain
MDD
Other MSK
Neck pain
Migraine
Anxiety
Asthma
COPD
Hearing
Diabetes
Diabetes
Australia
Back pain
MDD
Other MSK
Neck pain
Migraine
Anxiety
COPD
Asthma
Hearing
New Zealand
Back pain
MDD
Neck pain
Anxiety
Other MSK
Asthma
COPD
Hearing
Diabetes
Migraine
High-income Asia Pacific
Back pain
Other MSK
Neck pain
Diabetes
MDD
Hearing
Iron
Migraine
Falls
Osteoarthritis
Brunei
Back pain
Neck pain
MDD
Iron
Other MSK
Migraine
Anxiety
Diabetes
Schizophrenia
Dermatitis
Japan
Back pain
Other MSK
Diabetes
Neck pain
MDD
Hearing
Falls
Iron
Alzheimer
Osteoarthritis
Singapore
MDD
Diabetes
Other MSK
Neck pain
Back pain
Iron
Hearing
Falls
Anxiety
Schizophrenia
Falls
South Korea
Back pain
Neck pain
Other MSK
Migraine
Diabetes
Iron
MDD
Hearing
Anxiety
High-income North America
Back pain
Other MSK
MDD
Anxiety
COPD
Diabetes
Neck pain
Hearing
Falls
Migraine
Canada
Back pain
Other MSK
Neck pain
MDD
Hearing
Diabetes
Migraine
Anxiety
Asthma
Falls
USA
Back pain
MDD
Other MSK
Anxiety
COPD
Diabetes
Neck pain
Hearing
Falls
Migraine
Southern Latin America
Back pain
MDD
Neck pain
Anxiety
Other MSK
COPD
Hearing
Asthma
Diabetes
Iron
Argentina
Back pain
MDD
Neck pain
Anxiety
Other MSK
COPD
Hearing
Iron
Diabetes
Asthma
Chile
Back pain
MDD
Neck pain
Anxiety
Other MSK
COPD
Epilepsy
Migraine
Hearing
Asthma
Uruguay
Back pain
MDD
Neck pain
Anxiety
Other MSK
COPD
Hearing
Asthma
Iron
Diabetes
Western Europe
Back pain
Neck pain
Falls
MDD
Hearing
Diabetes
Migraine
Anxiety
Other MSK
Alzheimer
Andorra
Back pain
Neck pain
MDD
Falls
Hearing
Migraine
Anxiety
Other MSK
COPD
Alzheimer
Austria
Neck pain
Back pain
Migraine
Falls
MDD
Hearing
Diabetes
Anxiety
Other MSK
COPD
Belgium
Back pain
Neck pain
Falls
MDD
Diabetes
Migraine
COPD
Hearing
Alzheimer
Anxiety
Cyprus
Back pain
Neck pain
MDD
Diabetes
Migraine
Anxiety
Falls
Hearing
Other MSK
COPD
Denmark
Back pain
Neck pain
MDD
Falls
COPD
Other MSK
Anxiety
Alzheimer
Hearing
Migraine
Finland
Back pain
Falls
Neck pain
MDD
Diabetes
Hearing
Migraine
Oth unint
Alzheimer
Asthma
France
Back pain
MDD
Neck pain
Falls
Anxiety
Hearing
Migraine
Other MSK
Diabetes
Alzheimer
Germany
Back pain
Hearing
Neck pain
Falls
Diabetes
MDD
Anxiety
Other MSK
Migraine
Alzheimer
Greece
Back pain
Neck pain
Falls
MDD
Hearing
Diabetes
Other MSK
Anxiety
COPD
Alzheimer
Iceland
Back pain
Neck pain
Diabetes
MDD
Falls
Migraine
COPD
Anxiety
Hearing
Other MSK
Other MSK
Ireland
MDD
Neck pain
Back pain
Anxiety
Migraine
Falls
Asthma
Diabetes
Hearing
Israel
Back pain
MDD
Neck pain
Migraine
Falls
Hearing
Other MSK
Diabetes
Iron
COPD
Italy
Back pain
Neck pain
Migraine
Falls
Hearing
MDD
Other MSK
Alzheimer
Anxiety
COPD
Luxembourg
Back pain
Neck pain
Migraine
MDD
Falls
Diabetes
Hearing
Anxiety
Other MSK
COPD
Malta
Back pain
Neck pain
Diabetes
MDD
Falls
Migraine
Hearing
Anxiety
Other MSK
COPD
Netherlands
Back pain
Neck pain
Anxiety
Migraine
MDD
Diabetes
Hearing
Other MSK
Dermatitis
COPD
Norway
Back pain
Neck pain
Anxiety
MDD
Falls
Diabetes
Hearing
Other MSK
Migraine
Alzheimer
Portugal
Back pain
MDD
Neck pain
Diabetes
Hearing
Migraine
Anxiety
Other MSK
Asthma
Falls
Spain
Diabetes
Back pain
Neck pain
MDD
Falls
Hearing
Migraine
Other MSK
COPD
Anxiety
Sweden
Back pain
Falls
MDD
Neck pain
Hearing
COPD
Anxiety
Migraine
Other MSK
Asthma
Switzerland
Back pain
Falls
Neck pain
COPD
MDD
Hearing
Migraine
Anxiety
Diabetes
Alzheimer
UK
Back pain
Neck pain
Falls
MDD
Diabetes
Hearing
Migraine
Anxiety
Other MSK
COPD
England
Back pain
Neck pain
Falls
MDD
Diabetes
Hearing
Migraine
Anxiety
Other MSK
COPD
Northern Ireland
Back pain
MDD
Neck pain
Falls
Diabetes
Migraine
Hearing
Anxiety
Other MSK
COPD
Scotland
Back pain
Neck pain
Diabetes
Falls
Hearing
Migraine
Asthma
Other MSK
MDD
Anxiety
Wales
Back pain
MDD
Neck pain
Falls
Hearing
Diabetes
Migraine
Anxiety
Other MSK
COPD
Central Europe, eastern Europe, and central Asia
Back pain
MDD
Hearing
Migraine
Neck pain
Diabetes
Falls
Osteoarthritis
Other MSK
Med Head
Central Asia
Back pain
MDD
Diabetes
Migraine
Iron
Neck pain
Hearing
Falls
Anxiety
Osteoarthritis
Armenia
Back pain
MDD
Diabetes
Hearing
Migraine
Falls
Neck pain
Iron
Osteoarthritis
Anxiety
Azerbaijan
Back pain
MDD
Diabetes
Migraine
Iron
Falls
Neck pain
Hearing
Anxiety
Osteoarthritis
Other MSK
Georgia
Diabetes
MDD
Hearing
Back pain
Falls
Migraine
Neck pain
Osteoarthritis
COPD
Kazakhstan
Back pain
MDD
Diabetes
Migraine
Hearing
Neck pain
Iron
Falls
Anxiety
Osteoarthritis
Kyrgyzstan
MDD
Back pain
Migraine
Diabetes
Iron
Neck pain
Hearing
Falls
Anxiety
Osteoarthritis
Mongolia
MDD
Back pain
Migraine
Diabetes
Neck pain
Hearing
Iron
Falls
Anxiety
Alcohol
Tajikistan
MDD
Back pain
Iron
Migraine
Diabetes
Falls
Neck pain
Hearing
Anxiety
Schizophrenia
Turkmenistan
MDD
Back pain
Migraine
Diabetes
Iron
Neck pain
Hearing
Falls
Anxiety
Schizophrenia
Schizophrenia
Uzbekistan
MDD
Back pain
Migraine
Diabetes
Iron
Neck pain
Hearing
Falls
Anxiety
Central Europe
Back pain
Falls
MDD
Hearing
Diabetes
Neck pain
Migraine
Osteoarthritis
COPD
Iron
Albania
Back pain
Falls
MDD
Iron
Migraine
Hearing
Diabetes
Neck pain
Anxiety
Osteoarthritis
COPD
Bosnia and Herzegovina
Back pain
Falls
MDD
Hearing
Diabetes
Neck pain
Migraine
Osteoarthritis
War
Bulgaria
Back pain
Falls
Diabetes
Hearing
MDD
Neck pain
Osteoarthritis
Migraine
COPD
Anxiety
Croatia
Back pain
Hearing
MDD
Diabetes
Falls
Neck pain
Migraine
Osteoarthritis
COPD
Anxiety
Czech Republic
Back pain
Falls
MDD
Hearing
Diabetes
Neck pain
Migraine
Osteoarthritis
COPD
Anxiety
Hungary
Back pain
Falls
MDD
Hearing
Diabetes
Neck pain
Migraine
Osteoarthritis
COPD
Anxiety
Macedonia
Back pain
Falls
MDD
Hearing
Diabetes
Neck pain
Migraine
Osteoarthritis
Iron
COPD
Montenegro
Back pain
Falls
MDD
Hearing
Diabetes
Neck pain
Migraine
Osteoarthritis
Iron
COPD
Poland
Back pain
Falls
MDD
Hearing
Diabetes
Neck pain
Migraine
Osteoarthritis
COPD
Anxiety
Romania
Back pain
Falls
MDD
Hearing
Diabetes
Neck pain
Migraine
Osteoarthritis
Iron
COPD
Serbia
Back pain
MDD
Hearing
Diabetes
Falls
Neck pain
Migraine
Osteoarthritis
COPD
Iron
(Figure 4 continues on next page)

38
Articles
Slovakia
Back pain
Falls
MDD
Hearing
Diabetes
Neck pain
Migraine
Osteoarthritis COPD
10
Anxiety
Slovenia
Back pain
Falls
Hearing
MDD
Diabetes
Neck pain
Migraine
Osteoarthritis COPD
Anxiety
Eastern Europe
Back pain
MDD
Hearing
Migraine
Neck pain
Med head
Other MSK
Diabetes
Osteoarthritis
Alcohol
Belarus
Back pain
MDD
Hearing
Migraine
Neck pain
Osteoarthritis
Med head
Other MSK
Diabetes
Alcohol
Estonia
MDD
Back pain
Hearing
Migraine
Neck pain
Diabetes
Osteoarthritis
Other MSK
Med Head
Alcohol
COPD
Latvia
Back pain
Hearing
MDD
Migraine
Neck pain
Osteoarthritis
Diabetes
Other MSK
Med Head
Lithuania
Back pain
MDD
Hearing
Migraine
Neck pain
Osteoarthritis
Diabetes
Other MSK
Med Head
Moldova
Back pain
MDD
Hearing
Migraine
Neck pain
Iron
Diabetes
Osteoarthritis Med Head
Russia
Back pain
MDD
Hearing
Migraine
Neck pain
Med head
Other MSK
Diabetes
Osteoarthritis
Alcohol
Ukraine
Back pain
MDD
Hearing
Migraine
Neck pain
Osteoarthritis
Diabetes
Other MSK
Med head
COPD
Latin America and Caribbean
Back pain
MDD
Anxiety
Diabetes
Hearing
Other MSK
Iron
Migraine
Neck pain
Asthma
Andean Latin America
MDD
Back pain
Anxiety
Iron
Migraine
Hearing
Neck pain
COPD
Asthma
Other MSK
Asthma
COPD
Other MSK
Bolivia
MDD
Iron
Back pain
Anxiety
Migraine
Hearing
Neck pain
Other MSK
COPD
Ecuador
MDD
Back pain
Iron
Anxiety
Hearing
Migraine
Neck pain
COPD
Other MSK
Asthma
Peru
MDD
Back pain
Anxiety
Migraine
Iron
Hearing
Asthma
War
Neck pain
COPD
Caribbean
MDD
Iron
Diabetes
Anxiety
Back pain
Hearing
Neck pain
Migraine
COPD
Other MSK
Antigua and Barbuda
MDD
Anxiety
Diabetes
Iron
Back pain
Hearing
Migraine
Neck pain
COPD
Other MSK
Barbados
MDD
Diabetes
Back pain
Hearing
Anxiety
Asthma
Iron
COPD
Other MSK
Neck pain
Belize
MDD
Iron
Anxiety
Diabetes
Back pain
Migraine
Hearing
Neck pain
COPD
Other MSK
Cuba
Diabetes
MDD
Hearing
Anxiety
Back pain
Asthma
COPD
Iron
Neck pain
Other MSK
Dominica
MDD
Diabetes
Anxiety
Back pain
Hearing
Iron
Migraine
Neck pain
COPD
Other MSK
Dominican Republic
MDD
Back pain
Iron
Anxiety
Diabetes
Hearing
Migraine
Neck pain
COPD
Other MSK
Grenada
MDD
Iron
Anxiety
Back pain
Diabetes
Hearing
Migraine
Neck pain
COPD
Other MSK
Guyana
Iron
MDD
Anxiety
Back pain
Diabetes
Migraine
Hearing
Neck pain
COPD
Other MSK
Haiti
Iron
MDD
Anxiety
Disaster
Back pain
Hearing
Migraine
Neck pain
Diabetes
COPD
Other MSK
Jamaica
MDD
Iron
Anxiety
Back pain
Diabetes
Hearing
Migraine
Neck pain
COPD
Saint Lucia
MDD
Diabetes
Anxiety
Back pain
Hearing
Iron
Neck pain
COPD
Migraine
Other MSK
Saint Vincent and the Grenadines
MDD
Diabetes
Anxiety
Back pain
Iron
Hearing
Migraine
Neck pain
COPD
Other MSK
Suriname
MDD
Iron
Anxiety
Diabetes
Back pain
Hearing
Migraine
Neck pain
COPD
Other MSK
The Bahamas
MDD
Diabetes
Anxiety
Back pain
Hearing
Iron
Migraine
COPD
Neck pain
Other MSK
Trinidad and Tobago
MDD
Diabetes
Anxiety
Back pain
Hearing
Iron
Other MSK
COPD
Migraine
Neck pain
Central Latin America
MDD
Back pain
Diabetes
Anxiety
Hearing
Iron
Other MSK
Migraine
Neck pain
COPD
Colombia
MDD
Back pain
Anxiety
Hearing
Diabetes
Other MSK
Asthma
Migraine
COPD
Iron
Costa Rica
MDD
Back pain
Asthma
Hearing
Anxiety
Other MSK
Diabetes
Neck pain
COPD
Migraine
War
El Salvador
Back pain
MDD
Iron
Hearing
Anxiety
Asthma
Diabetes
Other MSK
Neck pain
Guatemala
Iron
Back pain
MDD
Anxiety
War
Hearing
Diabetes
Migraine
Neck pain
COPD
Honduras
MDD
Back pain
Iron
Anxiety
Hearing
Diabetes
Asthma
Neck pain
Migraine
COPD
Mexico
MDD
Back pain
Diabetes
Hearing
Other MSK
Anxiety
Iron
Neck pain
Migraine
COPD
Nicaragua
War
MDD
Back pain
Iron
Diabetes
Anxiety
Hearing
Asthma
Migraine
Neck pain
Panama
Back pain
MDD
Diabetes
Hearing
Anxiety
Asthma
Iron
Other MSK
Neck pain
Migraine
Venezuela
Back pain
MDD
Diabetes
Hearing
Anxiety
Other MSK
Migraine
Neck pain
COPD
Asthma
Tropical Latin America
Back pain
MDD
Anxiety
Diabetes
Hearing
Other MSK
Asthma
Neck pain
Migraine
COPD
Brazil
Back pain
MDD
Anxiety
Diabetes
Hearing
Other MSK
Asthma
Neck pain
Migraine
COPD
Paraguay
Back pain
Anxiety
MDD
Hearing
Other MSK
Migraine
Diabetes
Neck pain
Asthma
Iron
Southeast Asia, east Asia, and Oceania
Back pain
Neck pain
MDD
Hearing
Diabetes
Iron
Schizophrenia
Other MSK
COPD
Migraine
Anxiety
East Asia
Back pain
Neck pain
MDD
Diabetes
Hearing
Other MSK
Schizophrenia
Iron
COPD
China
Back pain
Neck pain
MDD
Diabetes
Hearing
Other MSK
Schizophrenia
Iron
COPD
Anxiety
North Korea
Back pain
Neck pain
Iron
Hearing
MDD
Schizophrenia
Diabetes
Other MSK
COPD
Anxiety
Taiwan
Back pain
Neck pain
Hearing
Diabetes
Anxiety
Other MSK
COPD
Migraine
Schizophrenia
MDD
Oceania
Back pain
Iron
MDD
Diabetes
Hookworm
Neck pain
Hearing
Migraine
Anxiety
COPD
Dermatitis
Federated States of Micronesia
Back pain
Iron
Diabetes
MDD
Hearing
Neck pain
Anxiety
Migraine
COPD
Fiji
Back pain
Diabetes
MDD
Hearing
Neck pain
Iron
COPD
Other MSK
Migraine
Anxiety
Kiribati
Trichuria
Back pain
Iron
MDD
Neck pain
Hearing
Diabetes
Migraine
RHD
Anxiety
Marshall Islands
Back pain
Iron
Trichuria
MDD
Hearing
Neck pain
Diabetes
Anxiety
COPD
Migraine
Papua New Guinea
Iron
Back pain
Hookworm
MDD
Diabetes
Neck pain
Hearing
Migraine
Anxiety
Dermatitis
Samoa
Back pain
Iron
Hearing
MDD
Diabetes
Neck pain
COPD
Dermatitis
Anxiety
Migraine
Dermatitis
Solomon Islands
Back pain
Iron
MDD
Hearing
Neck pain
Diabetes
RHD
Anxiety
Migraine
Tonga
Back pain
Iron
Hearing
MDD
Diabetes
Neck pain
COPD
Anxiety
Migraine
Other MSK
Vanuatu
Back pain
MDD
Hearing
Neck pain
Iron
Diabetes
Migraine
Anxiety
Thalass trait
COPD
Southeast Asia
Back pain
Iron
Hearing
MDD
Migraine
Diabetes
COPD
Neck pain
Schizophrenia
Anxiety
Cambodia
War
Iron
Back pain
Hearing
Migraine
MDD
COPD
Neck pain
Anxiety
Schizophrenia
Indonesia
Back pain
Iron
Migraine
MDD
Hearing
COPD
Diabetes
Neck pain
Schizophrenia
Anxiety
Laos
Iron
Back pain
FB trema
Migraine
Hearing
MDD
COPD
Neck pain
Diabetes
Anxiety
Malaysia
Back pain
Diabetes
Anxiety
MDD
COPD
Migraine
Hearing
Neck pain
Trichuria
Iron
Maldives
Back pain
Diabetes
Iron
MDD
Migraine
Hearing
COPD
Thalass trait
Neck pain
Anxiety
Myanmar
Hearing
Back pain
Migraine
MDD
Iron
COPD
Diabetes
Neck pain
Schizophrenia
Anxiety
Philippines
Back pain
Iron
Hearing
MDD
Diabetes
Migraine
COPD
Neck pain
Anxiety
Schizophrenia
Sri Lanka
Back pain
Hearing
Iron
Diabetes
MDD
Migraine
COPD
Neck pain
Asthma
Schizophrenia

39
Articles
10
Thailand
Migraine
Hearing
Diabetes
MDD
Other MSK
Back pain
COPD
Neck pain
Schizophrenia
Asthma
Timor-Leste
Iron
Back pain
Migraine
Hearing
MDD
COPD
Refraction
Neck pain
Anxiety
Diarrhoea
Vietnam
Back pain
War
MDD
Hearing
Iron
Migraine
COPD
Neck pain
Schizophrenia
Diabetes
South Asia
Back pain
MDD
Iron
Migraine
COPD
Hearing
Neck pain
Diabetes
Anxiety
Refraction
Afghanistan
Iron
Back pain
MDD
War
Anxiety
Migraine
Opioids
Neck pain
Diarrhoea
Diabetes
Bangladesh
Back pain
Iron
MDD
Migraine
COPD
Anxiety
Hearing
Other MSK
Neck pain
Diabetes
Bhutan
Back pain
MDD
Migraine
COPD
Hearing
Iron
Anxiety
Neck pain
Diabetes
Other MSK
India
MDD
Back pain
Iron
Migraine
COPD
Hearing
Neck pain
Diabetes
Anxiety
Refraction
Nepal
Back pain
Iron
Migraine
COPD
MDD
Hearing
Anxiety
Neck pain
Other MSK
Diabetes
Pakistan
MDD
Iron
Back pain
Migraine
COPD
Diabetes
Hearing
Anxiety
Neck pain
Diarrhoea
North Africa and Middle East
Back pain
MDD
Iron
Diabetes
Migraine
Neck pain
Anxiety
Opioids
COPD
Hearing
Algeria
Back pain
MDD
Iron
Diabetes
Neck pain
Migraine
Anxiety
Opioids
Other MSK
COPD
Bahrain
Back pain
Diabetes
MDD
Opioids
Iron
Neck pain
Migraine
Anxiety
COPD
Other MSK
Egypt
Back pain
Iron
Diabetes
MDD
Neck pain
Migraine
Anxiety
COPD
Refraction
Other MSK
Iran
Back pain
MDD
Neck pain
Diabetes
Anxiety
Migraine
Iron
Opioids
COPD
Med head
Iraq
Iron
Back pain
Anxiety
MDD
Diabetes
War
Migraine
Neck pain
COPD
Dermatitis
Jordan
MDD
Diabetes
Back pain
Iron
Opioids
Anxiety
Migraine
Neck pain
COPD
NN preterm
Kuwait
Diabetes
MDD
Opioids
Iron
Neck pain
Migraine
Anxiety
Back pain
COPD
Asthma
Lebanon
Diabetes
MDD
War
Anxiety
Iron
Opioids
Neck pain
Back pain
Migraine
COPD
Libya
Back pain
Diabetes
MDD
Iron
Neck pain
Anxiety
Migraine
Opioids
COPD
Hearing
Morocco
Back pain
MDD
Iron
Diabetes
Neck pain
Migraine
Anxiety
COPD
Opioids
Other MSK
Oman
Back pain
MDD
Diabetes
Opioids
Iron
Migraine
Anxiety
Neck pain
COPD
Asthma
Palestine
MDD
Back pain
Iron
Diabetes
Anxiety
Migraine
Neck pain
COPD
Other MSK
Opioids
Qatar
Opioids
Back pain
MDD
Diabetes
Neck pain
Migraine
Anxiety
COPD
Schizophrenia
Iron
Saudi Arabia
Diabetes
Back pain
MDD
Opioids
Iron
Migraine
Neck pain
Anxiety
Asthma
COPD
Sudan
Iron
Back pain
MDD
Anxiety
Neck pain
Migraine
Diabetes
Schisto
Refraction
Diarrhoea
Syria
MDD
Back pain
War
Migraine
Diabetes
Iron
Anxiety
Neck pain
Opioids
COPD
Tunisia
MDD
Back pain
Diabetes
Neck pain
Iron
Anxiety
Opioids
COPD
Hearing
Other MSK
Turkey
Back pain
MDD
Migraine
Diabetes
Iron
Neck pain
COPD
Opioids
Anxiety
Other MSK
United Arab Emirates
Back pain
MDD
Opioids
Diabetes
Neck pain
Iron
Anxiety
Migraine
COPD
Schizophrenia
Yemen
Iron
Back pain
MDD
Anxiety
Migraine
Neck pain
COPD
Dermatitis
Diarrhoea
Conduct
Sub-Saharan Africa
MDD
Iron
Back pain
Oth HIV
Neck pain
Hearing
Schisto
COPD
Anxiety
Malaria
Central sub-Saharan Africa
Iron
MDD
Oncho
Back pain
Neck pain
Hearing
Schisto
Malaria
Diarrhoea
COPD
Angola
MDD
Iron
Back pain
Schisto
Neck pain
Diarrhoea
Malaria
COPD
Migraine
Anxiety
Central African Republic
Iron
MDD
Back pain
Oncho
Malaria
Neck pain
COPD
Oth HIV
Hearing
Anxiety
Congo
MDD
Iron
Back pain
Neck pain
Malaria
COPD
Schisto
Hearing
Migraine
Anxiety
Democratic Republic of the Congo
Iron
MDD
Oncho
Back pain
Hearing
Neck pain
Malaria
Diarrhoea
COPD
Schisto
Equatorial Guinea
MDD
Back pain
Iron
Neck pain
Malaria
Oth HIV
COPD
Hearing
Migraine
Anxiety
Gabon
MDD
Iron
Back pain
Schisto
Neck pain
Malaria
Oth HIV
COPD
Hearing
Anxiety
Eastern sub-Saharan Africa
MDD
Iron
Back pain
Neck pain
Oth HIV
Hearing
Schisto
Anxiety
COPD
Malaria
Burundi
MDD
Iron
War
Back pain
Neck pain
Hearing
COPD
Anxiety
Diarrhoea
Migraine
Comoros
MDD
Iron
Back pain
Neck pain
Hearing
COPD
Malaria
Anxiety
Migraine
Refraction
Djibouti
MDD
Iron
Back pain
Neck pain
Hearing
COPD
Anxiety
Other MSK
Migraine
Schisto
Eritrea
Iron
MDD
War
Back pain
Schisto
Neck pain
Hearing
Anxiety
COPD
Migraine
Ethiopia
MDD
Iron
Back pain
Anxiety
Neck pain
Hearing
Schisto
COPD
Refraction
Diarrhoea
Kenya
MDD
Iron
Back pain
Oth HIV
Schisto
Neck pain
Hearing
COPD
Anxiety
Migraine
Madagascar
MDD
Iron
Hearing
Back pain
Schisto
Neck pain
COPD
Malaria
Anxiety
LF
Malawi
MDD
Oth HIV
Iron
Back pain
Malaria
Neck pain
Hearing
COPD
Anxiety
Diarrhoea
Mauritius
Back pain
Diabetes
Hearing
MDD
Migraine
COPD
Other MSK
Neck pain
Schizophrenia
Anxiety
Mozambique
Oth HIV
MDD
Iron
Back pain
Schisto
Hearing
Neck pain
Malaria
COPD
Anxiety
Rwanda
War
MDD
Iron
Back pain
Neck pain
Hearing
COPD
Anxiety
Asthma
Schisto
Seychelles
Diabetes
Back pain
Hearing
MDD
Migraine
COPD
Neck pain
Schizophrenia
Anxiety
Other MSK
Somalia
MDD
Iron
Back pain
Schisto
Hearing
Neck pain
COPD
Anxiety
War
Diarrhoea
South Sudan
MDD
Oncho
Iron
Back pain
Schisto
Hearing
Neck pain
COPD
Anxiety
Refraction
Tanzania
MDD
Iron
Back pain
Oth HIV
Neck pain
COPD
Anxiety
Hearing
Malaria
LF
Uganda
MDD
Iron
Malaria
Oth HIV
Back pain
War
Hearing
Neck pain
COPD
Diarrhoea
Zambia
MDD
Oth HIV
Iron
Migraine
Back pain
Neck pain
Hearing
Schisto
Malaria
COPD
Southern sub-Saharan Africa
Oth HIV
MDD
Back pain
Neck pain
Iron
COPD
TB
Anxiety
Diabetes
Migraine
Botswana
MDD
Oth HIV
Back pain
Iron
Neck pain
Anxiety
COPD
TB
Migraine
Hearing
Lesotho
Oth HIV
MDD
Iron
Back pain
Neck pain
Anxiety
COPD
TB
ID
Migraine
Namibia
MDD
Iron
Oth HIV
Back pain
Neck pain
Anxiety
COPD
TB
Migraine
ID
South Africa
Oth HIV
Back pain
MDD
Neck pain
Iron
COPD
TB
Anxiety
Diabetes
Migraine
Swaziland
Oth HIV
MDD
Iron
Neck pain
Back pain
Anxiety
TB
COPD
Oth NTD
ID
Zimbabwe
Oth HIV
MDD
Iron
Back pain
Neck pain
TB
Anxiety
ID
COPD
Schisto
Western sub-Saharan Africa
Iron
Back pain
MDD
Malaria
Hearing
Neck pain
Schisto
COPD
Migraine
Oth HIV
Benin
Iron
MDD
Back pain
Malaria
Schisto
Neck pain
Hearing
COPD
Migraine
Anxiety
Burkina Faso
Iron
MDD
Malaria
Back pain
Neck pain
Hearing
COPD
Migraine
Anxiety
Diarrhoea
Cameroon
MDD
Iron
Back pain
Oth HIV
Oncho
Malaria
Neck pain
Hearing
COPD
Migraine

40
Articles
10
Cape Verde
MDD
Iron
Back pain
Neck pain
Hearing
COPD
Diabetes
Migraine
Anxiety
Other MSK
Chad
Iron
Back pain
MDD
Neck pain
Diarrhoea
Hearing
Malaria
COPD
Migraine
Anxiety
Cte dIvoire
Iron
MDD
Back pain
Malaria
Neck pain
Hearing
Oth HIV
Schisto
COPD
Migraine
Ghana
MDD
Iron
Back pain
Neck pain
Malaria
COPD
Hearing
Migraine
Schisto
Anxiety
Guinea
Iron
MDD
Back pain
Neck pain
Malaria
Hearing
COPD
Schisto
Migraine
Anxiety
Guinea-Bissau
Iron
MDD
Back pain
Oth HIV
Neck pain
Hearing
COPD
Migraine
Anxiety
Diarrhoea
Liberia
Oncho
Iron
MDD
Back pain
Malaria
Schisto
Neck pain
Hearing
COPD
War
Mali
Iron
MDD
Malaria
Back pain
Neck pain
Hearing
COPD
Migraine
Diarrhoea
Anxiety
Mauritania
Iron
MDD
Back pain
Neck pain
Hearing
COPD
Migraine
Refraction
Anxiety
Diarrhoea
Niger
Iron
MDD
Back pain
Diarrhoea
Neck pain
Hearing
Malaria
COPD
Migraine
Anxiety
Nigeria
Back pain
Iron
MDD
Hearing
Malaria
Schisto
Oth HIV
Neck pain
COPD
Migraine
So Tom and Prncipe
MDD
Iron
Back pain
Neck pain
Hearing
COPD
Migraine
Anxiety
Diarrhoea
Other MSK
Senegal
Iron
MDD
Back pain
Neck pain
Hearing
COPD
Diabetes
Migraine
Diarrhoea
Anxiety
Sierra Leone
Iron
MDD
Back pain
Neck pain
Malaria
Oncho
COPD
Migraine
Anxiety
Hearing
The Gambia
MDD
Iron
Back pain
Neck pain
Hearing
Diarrhoea
Migraine
COPD
Anxiety
Schisto
Togo
Iron
MDD
Back pain
Malaria
Neck pain
Diarrhoea
Hearing
Oth HIV
COPD
Migraine
Low back pain
Back pain
MDD
Iron
Neck pain
Neck pain
Hearing
Migraine
Migraine
Diabetes mellitus
Diabetes
Chronic obstructive pulmonary disease
COPD
Anxiety disorders
Anxiety
Other MSK
Figure 4: Top ten causes of years lived with disability by location in 2013
numbers. It is not clear whether this increase in rates was

due to improvements in case ascertainment or indicates a
true increase in disease prevalence. Among the headache
disorders, only medication overuse headache had a
signicant change in rates of 433%.
Overall, the YLDs for mental and substance use disorders
increased 450% from 1990 to 2013, but there was only a
10% increase in the age-standardised rate (table 10). For
all disorders in this group, including autism, Aspergers
syndrome, anorexia nervosa, and bulimia, there were
increases and decreases in age-standardised rates of less
than 10%. Diabetes mellitus YLDs increased by 1357%,
but age-standardised rates increased only 434%. By
contrast, chronic kidney disease YLDs increased 495%
but rates declined by 28%. Patterns in age-standardised
rates were dierent between specic causes of chronic
kidney disease with an increase in chronic kidney disease
due to diabetes but a reduction in chronic kidney disease
due to hypertension and glomerulonephritis. Among
urinary diseases, the increase in numbers and agestandardised rates for urolithiasis was notable. For most
gynaecological diseases, numbers increased, but the
changes in age-standardised rates were small; the category
uterine broids was an exception with a reduced rate and
only a small increase in numbers.
YLDs for the large category of musculoskeletal disorders
increased by 607%, but there was no change in the agestandardised rate (table 10). The only exception to this
general pattern was rheumatoid arthritis for which agestandardised rates declined signicantly by 46%. YLDs
due to congenital disorders, as a group, increased 614%
and age-standardised rates by 197%. These large

increases in numbers and age-standardised rates were
noted for all congenital causes except Klinefelters
syndrome, for which the rate did not increase signicantly.
The reason for the large increases in prevalence and YLDs
was the improved survival because birth prevalence for
congenital disorders remained stable or declined (data not
shown). Although skin diseases, as a group, did not show
a signicant pattern for age-standardised YLDs, some
causes including cellulitis, bacterial skin diseases, and
decubitus ulcer declined signicantly. Most causes of
vision and hearing loss included in the sense organ
category increased in absolute numbers of YLDs but the
age-standardised rates declined.
Injury age-standardised YLD rates decreased
substantially from 1990 to 2013. There were reductions of
more than 30% in age-standardised YLD rates for road
injuries, drowning, re, heat, and hot substances,
poisoning, venomous animal contact, non-venomous
animal contact, and self-harm (table 10).
The main disorders that drove changes in rates varied
with age (appendix pp 776811). In childhood, most
infectious diseases and iron-deciency anaemia showed
decreases in YLD rates, whereas neonatal disorders and
congenital disorders showed increases, largely due to
lower initial case fatality and better long-term survival, and
in the case of preterm birth complications an increase in
the birth prevalence (data not shown). For ages 1549 years,
large increases from 1990 to 2013 were noted in disability
associated with diabetes (appendix pp 776811), HIV, and
medication overuse headache, whereas there were large
41
Articles
decreases in the YLD rates of iron-deciency anaemia,

falls, and collective violence. In adults aged 5069 years,
reductions in YLD rates for all injuries (appendix pp 776
811) and increase in diabetes YLD rates were notable.
Figure 4 shows the ten leading causes of YLDs for each
country. Causes are colour coded by their global rank to
emphasise where they vary substantially in the leading
set. There was substantial consistency in the top causes.
Low back pain and major depressive disorder were among
the top ten causes of YLDs in every country. 40 causes
were in the top ten list across all countries but only 16 of
these causes were in the top ten of more than 20 countries.
Low back pain was the leading cause in 45 of 50 developed
countries and major depressive disorder was the leading
cause in three countries, with neck pain and diabetes
leading in one country each. Across developing country
regions, there was more variation in leading causes. Low
back pain or major depressive disorder was the leading
cause in 94 of 138 developing countries. But other causes
such as iron-deciency anaemia, HIV, and war were
leading causes in more than one country. Regional
patterns emerged such as the more prominent role of
falls in central Europe where they were ranked second in
11 of 13 countries. The category other musculoskeletal
which includes disorders such as shoulder problems,
pathological fractures from osteoporosis, osteomyelitis,
pyogenic arthritis, and systemic lupus erythematous
was prominent in high-income Asia and high-income
North America. Anxiety disorders ranked more highly in
many Caribbean nations and diabetes was prominent in
Mexico, Nicaragua, Panama, and Venezuela. In Oceania,
some soil-based helminths were highly prevalent,
pushing them into the top ve of the YLD rank list.
Onchocerciasis, predominantly the onchocercal skin
sequela, was ranked highly in Liberia, Cameroon, and
South Sudan. The disability from past war and conict
ranked as the top cause of YLDs in Cambodia, Nicaragua,
and Rwanda, and number two in Vietnam.
The gure appendix provides an analysis of the change
in the YLDs per person from 1990 to 2013 by country and
region. The countries were ordered by YLDs per person in
1990. Across countries in 1990, YLDs per person ranged
from 0072 to more than double at 0170. Generally,
developed countries with higher mean age for the
population had higher YLDs per person, but there were
many exceptions to this pattern. Changes in the YLDs per
person were decomposed into contributing causes for
YLDsfor convenience these cause groups were chosen
to represent the major causes of YLDs at the global level.
The gure provides a summary of what causes contributed
to increases or decreases in YLDs per person for each
country.
From 1990 to 2013, 139 of 188 countries had increases in
the YLDs per person. Although the drivers of increased
YLDs per person varied by region and country, generally,
musculoskeletal, mental, substance use, neurological, and
chronic respiratory disorders played important parts across
42
most of the regions and countries. In sub-Saharan Africa,

increases were largely driven by HIV/AIDS. Declining
levels of iron-deciency anaemia contributed to a decline in
YLDs per person in many countries. In the subset of
countries where the overall YLDs per person declined,
specic factors such as long-term disability due to war were
important factorsmost strikingly evident in Lebanon.
However, declines due to neglected tropical diseases and
malaria, as well as diarrhoea and lower respiratory
infections (represented as other communicable diseases in
the gure appendix) also pushed YLD per person lower in
some countries. Mostly increasing YLDs per person meant
that by 2013 the range across countries was from 0076 to
0153. It is important to note that the gure appendix
shows YLDs per person and not age-standardised YLD
rates; therefore, changes in YLD rates were aected by
changes in population age structure and changes in agespecic disease rates.
From 1990 to 2013, YLDs per person rose in most
countries and YLLs per person declined. Both trends led to
a shift towards greater disability as a share of the overall
burden. Figure 5 shows the shift from 1990 to 2013 towards
greater disability as the ratio of YLDs to YLDs plus YLLs76
(namely disability-adjusted life years [DALYs]). 30 countries
as of 2013 had the most DALYs due to YLDs, representing
a major change from historical patterns of premature
mortality being the dominant set of health issues. In 1990,
premature mortality still represented more than half of
DALYs in every country. By 2013, the lowest YLD to DALY
ratio outside of sub-Saharan Africa was in Afghanistan,
but most developing countries outside of sub-Saharan
Africa had ratios of greater than 35%. In sub-Saharan
Africa, however, the ratio of YLDs to DALYs ranged from
104% in Mali to 389% in Cape Verde.
Discussion
We analysed more than 35 620 epidemiological sources
from 188 countries spanning the past three decades to
provide the most up-to-date empirical assessment of the
leading causes of acute disease incidence, chronic disease
prevalence, and YLDs for 6 years (1990, 1995, 2000, 2005,
2010, and 2013) for 188 countries using consistent and
comparable methods. Importantly, our study provides the
rst comprehensive assessment of the extent, pattern,
and trend of non-fatal health loss in countries, with
important implications not only for health policy, but also
for the provision and nancing of health services (panel).
A wide array of disease and injury sequelae aects the
worlds population. Globally, only 43% of the population
had no burden of disease or injury sequelae in 2013, up
slightly from 42% in 1990. There were 59 diseases and
injuries with a global prevalence of greater than 1%, but
each caused little disability. These disorders comprised
various causes of mild to moderate vision impairment,
hearing loss, soil-transmitted helminths, mild anaemia,
caries, and many others. For many of these common but
fairly mild disorders, there are eective interventions.8992
Articles
<10%
1015%
1520%
2025%
2530%
3035%
3540%
4045%
4550%
>50%
ATG
VCT
Barbados
Comoros
West Africa
Dominica
Caribbean
Grenada
Maldives
Mauritius
LCA
TTO
TLS
Seychelles
ATG
VCT
Barbados
Comoros
Marshall Isl
Kiribati
Solomon Isl
FSM
Vanuatu
Samoa
Fiji
Tonga
Marshall Isl
Kiribati
Solomon Isl
FSM
Vanuatu
Samoa
Fiji
Tonga
Eastern
Mediterranean
Malta
Persian Gulf
Singapore
West Africa
Eastern
Mediterranean
Balkan Peninsula
Dominica
Caribbean
LCA
Grenada
TTO
Maldives
TLS
Mauritius
Seychelles
Malta
Persian Gulf
Singapore
Balkan Peninsula
Figure 5: Percentage of disability-adjusted life years due to years lived with disability in 1990 (A) and 2013 (B) in 188 countries
ATG=Antigua and Barbuda. FSM=Federated States of Micronesia. LCA=Saint Lucia. TLS=Timor-Leste. TTO=Trinidad and Tobago. VCT=Saint Vincent and the Grenadines. Isl=Islands.
43
Articles
Panel: Research in context

Systematic review
The GBD 2013 assessment of morbidity is a major
improvement in the evidence base compared with GBD 2010
through the inclusion of new data from surveys, disease
registries, and hospital inpatient and outpatient registrations.
GBD 2013 also benets from improvements in the Bayesian
meta-regression tool DisMod-MR. The fty-fold increase in
computational speed allowed consistent estimation of
prevalence and incidence for each country and time period.
Interpretation
This study provides a comprehensive description of morbidity
levels and patterns worldwide. Because the study provides a
complete re-analysis of trends for each cause from 1990 to
2013, it supersedes the results of the GBD 2010 study. This is
the rst time that country-specic results for all
188 countries with populations of more than 50 000 people
have been comprehensively published. In all countries, the
share of disability in total burden is increasing because of
ageing populations and a slower decline in disability rates
compared to the decline in mortality.
The GBD provides several insights into the health of

dierent populations by quantifying the prevalence of a
wide range of disorders and YLDs that take into account
the general publics view of severity.
Of the 240 GBD causes that led to mortality, Naghavi
and colleagues76 reported that global age-standardised
death rates were declining by 80%. For YLDs, the
distribution of causes where age-standardised rates were
declining, stagnant, or increasing was dierent. For
140 causes, distributed across communicable diseases,
non-communicable diseases, and injuries, agestandardised rates declined signicantly from 1990 to
2013. For 89 causes, changes in age-standardised rates
were statistically indistinguishable from zero over the
same period. For 72 causes, including epidemic disorders
like HIV and dengue but also cancers, diabetes, and
COPD, age-standardised rates increased signicantly. Of
301 causes, the percentage change in the age-standardised
rate for YLDs was higher than the percentage change in
the age-standardised YLLs for 213 causes. Divergence in
rates for diseases and injuries between mortality and
morbidity could be because of reductions in case-fatality
rates due to treatment or improved background risks
such as malnutrition. To the extent that mortality is
declining faster than disease prevalence due to treatment,
access to care might be a crucial driver of trends in health.
The mortalitydisability temporal disconnect, however, is
further evidence of the importance of paying attention to
trends in disease incidence, prevalence, and YLDs and
not simply focusing on mortality. Diabetes is an important
example in which age-standardised prevalence rates
increased 43% while death rates increased only 9%.
Stagnant or increasing age-standardised rates combined
44
with rising mean age of the worlds population implies

substantial future increases in burden from these causes.
The documented shift in many developed and developing
countries to a larger fraction of DALYs due to YLDs is
another manifestation of this global shift. Despite the
evidence for this shift, global health policy discussion
remains focused mostly on premature mortality. For
example, in the Sustainable Development Goals Open
Working Group proposal93 with 13 targets for the health
goal, only one on narcotic drug abuse and harmful use of
alcohol was focused on a disability.
Although the general pattern of the past 23 years has
been for infectious disease mortality and morbidity,
measured through incidence or prevalence, to decline,
there are some very notable exceptions that stress that
such trends are not inevitable with rising income per
person and educational attainment. Compared with
1990, both HIV and malaria YLDs increased in 2013.
More careful examination of our estimates for the six
periods shows that malaria and HIV YLDs have been
declining since at least 2005. Increases for dengue
(nearly 450%) and for cutaneous and mucocutaneous
leishmaniasis have continued throughout the period.
Increases in dengue have been ascribed to the rise of
breeding sites for the mosquito vector in urban and
periurban areas.94 Increases for cutaneous leishmaniasis
have been related to the expansion of previously
non-endemic areas as a result of urbanisation and
deforestation with domestic animals as potential
reservoirs. Additionally, economic hardship, natural
disasters, armed conict, movement of seasonal workers,
development of new projects, and bringing non-immune
labour forces into endemic areas are contributing causes.
Also, pressure on populations throughout the world is
pushing migration into areas where the infection is
endemic, thereby bringing many more humans into
contact with the natural vectors and resulting in increased
infection rates.9598 These counter trends for infectious
diseases are a reminder that active surveillance of
infectious diseases at a ne-grained geospatial level are
essential to detect changes that might run against the
general trend towards lower rates.
The GBD 2010 reported that the burden of
musculoskeletal disorders was much larger than
previously appreciated.7,8,19,20,37,38 In this analysis, we show
that musculoskeletal disorders ranged from 96% of
YLDs to 289% of YLDs between 188 countries. Low
back pain was the leading cause of YLDs in 86 countries
and the second or third leading cause in 67 countries.
Although the GBD 2010 analysis brought more
attention to these disorders, there remains little policy
discussion of the options available to address and
prevent these disorders.1,99 From a health service point
of view, it is important to note that there is a connection
between the injury analysis of fractures and soft tissue
injury and musculoskeletal disorders. We estimated
22 million YLDs from fractures, most of which were
Articles
long-term disabilities. Most of the individuals aicted

would present with a musculoskeletal chief complaint
in surveys and therefore to avoid double counting we
subtracted the long-term disability from fractures and
dislocations out of the estimates of the category of other
musculoskeletal disorders. Musculoskeletal disorders
combined with fractures and soft tissue injuries
reached a total of 208% of global YLDs in 2013; across
countries this total ranged from 108% in Mali to
300% in South Korea. Our analysis of time trends
showed that this category of disorders was an important
driver of rising YLD rates per person. Increases were
driven by ageing of the population in most countries
with trends in obesity and physical inactivity likely
exacerbating
the
problem.100,101
Musculoskeletal
disorders were not only an important contributor to the
burden of disease but were also a crucial component of
health expenditure in many high-income and middleincome countries.102106
Mental and substance abuse disorders accounted for
212% of YLDs, ranging from 154% in Germany to
367% in Qatar. Major depressive disorder was a crucial
contributor in developed and developing countries alike:
it is the leading cause of YLDs in 56 countries, the second
leading cause in 56 countries, and the third in
34 countries. Although major depressive disorder, anxiety
disorders, schizophrenia, and bipolar disorder are
leading causes in nearly all countries, there is much
greater country variation in substance use disorders
including alcohol. YLDs from alcohol use disorders
ranged from a high of 29% in Russia to a low of 03% in
Iran; YLDs from drug use disorders ranged from a high
of 135% in Qatar to a low of 06% in Slovenia. New data
in the GBD 2013 suggested that Iran and Afghanistan
had particular problems with opioid dependence. The
GBD 2013 analysis conrmed that common mental
disorders had well established sex patterns in most
countries: higher rates in women for major depressive
disorder and anxiety and similar rates for bipolar and
schizophrenia for men and women. Treatments if widely
and appropriately deployed could lead to substantial
reductions in the burden of these disorders; some studies
suggest that up to half of YLDs could be averted in some
countries.1,107,108 As new studies accumulate on the role of
childhood sexual abuse, intimate partner violence, nonsexual child abuse, and bullying, the possibility of
prevention programmes is increasing.109113 Systematic
quantication of these risks will help establish where
prevention programmes could be developed and tested.
For the rst time in the GBD studies, we provide a
systematic quantication of the geographical and
temporal coverage of the input epidemiological data for
nearly all sequelae. For several diseases with sequelae
representing dierent levels of severity such as major
depressive disorder (mild, moderate, and severe
sequelae), the data representativeness metrics show
there are often more data for overall disease prevalence
than for determining the distribution of severity for a

cause. Sequelae with the highest DRI tend to be those
where administrative data such as notiable disease
reporting or hospital discharge data can be corrected for
completeness or selection bias, or both. For some
sequelae, such as drug use disorders only one study was
available to ascertain the distribution of cases by level of
severity. Despite attempts to quantify uncertainty from
various sources in the estimates (see limitations below),
it is highly likely that for sequelae with low DRIs
uncertainty might be larger than estimated. At the global
level, 12 of the top causes of YLDs had a DRI of less than
025. Priorities for further data collection in a country
might usefully be informed by comparison of the
estimated YLDs and the DRI for the country for each
cause. Examining countries, the fraction of sequelae with
any data available in a country, shows marked variation
across countries within a region or within income
groupeg, Nigeria with a DRI of 47% and Mauritania at
10% or the UK at 81% and Greece at 52%. Our
computation of the DRI was based on the data available
to the GBD through published studies or reports, publicly
released datasets, and unpublished data. In view of our
experience in China and Mexico with subnational burden
of disease estimation, it is likely data coverage could be
improved through detailed national burden of disease
studies, which often lead to several unpublished sources.
Ministries of health and national statistics authorities in
countries with low coverage should carefully assess
which high burden disorders with low data availability
would benet from new data collection eorts.
With each iteration of the GBD, the cause and sequelae
list has expanded. Expansion involves taking an existing
cause and splitting it into more detailed component
causeseg, eating disorders were broken down into
anorexia nervosa and bulimia. Residual categories, such
as other mental disorders, other neurological disorders
or other musculoskeletal disorders contain many rarer
causes and some common causes that have very low
levels of disability. One of the key values of the GBD was
the comprehensive and systematic nature of the analysis;
it is likely that in future iterations based on health service
use data or new epidemiological studies or policy
demand, the cause and sequelae list will be expanded
further. The GBD cause list, even in the current expanded
form, still has only 301 causes compared with the 11 299
four-digit ICD-10 codes. The GBD cause list provided a
more manageable public health and health service
planning focused approach to the complexity of disease
coding. The sequelae list also had many potential
applications, such as facilitating the mapping of data
collected through dierent studies and typologies into a
common framework.
For GBD 2013, the study beneted from use of a larger
computational cluster than for GBD 2010 (22 teraops
compared with 8 teraops). The optimised recoding of
DisMod-MR 1.0 to DisMod-MR 2.0, combined with
45
Articles
greater computational capacity, allowed us to generate

country-specic posterior estimates for incidence,
prevalence, remission, and excess mortality for each of
the six periods. We estimated and reported internal
validity of dierent models and conducted crossvalidation studies for ten of the models. We believe
DisMod-MR 2.0 is a substantial improvement over
DisMod-MR 1.0, but there is still much opportunity to
improve these data synthesis programs in the future. In
particular, work is underway to develop the next iteration
of DisMod-MR that would allow for variation of incidence,
remission, excess mortality rates simultaneously over
age, geography, and time unlike the present approach, in
which variation in rates over time is captured by
independent estimation of the available data for six
dierent periods. Despite progress in the estimation
software, a fundamental challenge in epidemiological
synthesis of sparse and heterogeneous data is
distinguishing between true variation in the underlying
rates and study heterogeneity due to variation in, for
example, case denitions, assays, instruments, and
sampling frames. DisMod-MR 2.0 allows explicit
modelling of these factors, but true resolution of this
challenge requires more data to be collected with
consistent denitions and study design.
The
comorbidity
microsimulation
for
each
countryagesexyear has been used to both quantify
comorbidity and allocate to contributing causes of each
disability weight. By weighting each countryagesexyear
microsimulation by the true population in each age
group, we have created a working model of individual
health for all 73 billion individuals in the world
consistent with the entire GBD non-fatal health outcome
results. With future iterations of the GBD, we intend to
incorporate data for risk factors into the global
microsimulation providing an even more comprehensive
working model of each countrys population. This global
and national microsimulation has many potential
applications from inequality measurement to
comprehensive forecasting of multiple interventions. For
example, the GBD microsimulations provide an ideal
environment for modelling the eect of interventions
that would represent the complex interplay between
disorders that is often missing in many intervention
impact assessments. The distribution of functional
health status across individuals in each country for
dierent timepoints can also be used to compute
measures of individual inequality in functional health. If
the correlations between socioeconomic indicators
within each countryagesexyear group with health
outcomes and risk factors can be estimated, then the
microsimulation environment could also be used to look
at the relation between health and income inequality.
Disability weights through the inclusion of new data
from national surveys in Italy, Hungary, Sweden, and the
Netherlands and revisions in lay descriptions for selected
health states have changed from those used in the GBD
46
2010. The severe hearing loss disability weight increased

from 005 to 018 with similar increases for profound
hearing loss and deafness. Through the inclusion of
incontinence in the lay descriptions for spinal cord lesion
below the neck, the disability weight increased from
0047 to 0296. These ndings draw attention to the
importance of the exact wording of lay descriptions for
use in population surveys. We revised lay descriptions in
the latest round of data collection based on commentary
in the literature and a careful review of all lay descriptions
checking for symmetry and consistency. We believe that
future iterations of the GBD will benet from further
data collection and vigorous scrutiny and debate by the
scientic community of the exact lay descriptions in
usethe full listing is provided in the appendix
pp 68893 and further details are provided in Salomon
and colleagues.85 In many countries undertaking
subnational burden of disease studies, there may be
opportunities to collect further disability weight data
using the latest iteration of the GBD lay descriptions and
measurement protocol. Such data would help establish
whether there was any notable national variation in
disability weights from the global average and strengthen
the global empirical database for disability weight
measurement.
Another important component determining average
disability weight was the empirical analysis of the
distribution of severity controlling for comorbidity. The
number of studies or data sources that allowed for
teasing apart functional health limitations from a
particular cause from other comorbid causes were few.
Very low DRIs for many sequelae in table 1 document
this limitation. More datasets like the US MEPS that
include both functional health limitation measurement
and ICD-coded diagnoses would be extremely helpful in
strengthening the empirical assessment of severity
controlling for comorbidity. This must be regarded as
one of the most important data gaps for the quantication
of many chronic disorders.
Because the GBD 2013 has re-estimated prevalence and
YLDs for all disease and injury sequelae for 1990, 1995,
2000, 2005, 2010, and 2013, we can compare the results of
GBD 2013 directly with GBD 2010. The leading global
causes of YLDs estimated for 2010 in this study (low back
pain, major depressive disorder, iron-deciency anaemia,
neck pain, and age-related and other hearing loss) were
similar to those reported in GBD 2010 (low back pain,
major depressive disorder, iron-deciency anaemia, neck
pain, and COPD) for 2010. For 97 diseases or injuries,
global YLDs from GBD 2013 for 2010 were signicantly
dierent from the GBD 2010 estimates for 2010. For
27 diseases and injuries, there were changes in YLDs
greater than 30% but these changes were not signicantly
dierent from GBD 2010. Generally, changes stemmed
from the inclusion of new data, exclusion of studies used
in GBD 2010 due to changes of inclusion criteria for each
sequela that emerged through the process of replicating
Articles
many GBD 2010 systematic reviews, the shift to

DisMod-MR 2.0, which reduced the eect of large sample
size outlier studies, changes in covariates, changes in
disability weights, or changes in severity distributions.
The appendix pp 3354 provides a more detailed account
for each of these cases including changes in inclusion
criteria where relevant. At the level of global YLDs, the
most notable eect of these changes was the inclusion of
age-related and other hearing loss in the top ten causes of
global YLDs; this change was almost exclusively due to
the revision of the hearing loss disability weights. The
yearly updating cycle for GBD provides a much more
rapid cycle for incorporating new data and scientic
feedback from GBD collaborators and the broader
scientic community. We expect that with each iteration
there will be important changes driven by the collection
and release of new data, but that the number of changes
driven by uncovering older studies, exclusion of older
studies on quality grounds, or changes in modelling
strategy will tend to get smaller with each iteration.
A study of this scope has several limitations, many of
which were detailed in the GBD 2010 analysis.1 Here we
focus on selected major limitations that are not specic
to the data sources or analysis of a specic sequela. First,
for comorbidity simulation to work eectively, especially
with the assumption of independence, individuals with a
disease need to be uniquely mapped to a single sequela.
For some diseases that have several distinct functional
impairments such as motor and cognitive dysfunction
for some neonatal disorders, several combinations are
possible. In some cases, to map all of the possible
combinations was not feasible because of increased
computational load and the lack of epidemiological data
to accurately describe these combinations. In a very
small number of cases, we did not follow the principle of
mapping one individual to a unique sequela including
schistosomiasis, lymphatic lariasis, and onchocerciasis.
Second, a major limitation that might aect many
sequelae is that important unpublished data sources
might be missing. The collaborations with investigators
in Mexico, China, and England to generate subnational
burden of disease estimates for 2013 identied
unpublished data sources or more detailed age and time
breakdowns for published studies. Other countries are
likely to have similar data sources, which after being
identied could enrich the estimation of the burden of
disease for a country.
Third, in this analysis of prevalence and YLDs, we
attempted to capture uncertainty from model estimation
and available data but 95% uncertainty intervals might be
too narrow because we cannot capture uncertainty that
comes from the possibility that countries with data might
in some way be dierent for a given sequela from
countries with data. Further, unlike the GBD analysis of
causes of death, we do not capture uncertainty that
comes from model specication. We undertook crossvalidation studies for a few models but the move to using
out of sample validity testing to then create ensembles of

good models will require further advances in
computational speed of DisMod-MR to make this viable.76
Fourth, for GBD 2013 we made a substantial eort to
enhance the transparency in all aspects of the estimation.
In GBD 2010, in some cases contributors who undertook
systematic reviews provided results but without study
references. For GBD 2013, we have included in the Global
Health Data Exchange 31 950 citations with metadata
covering essentially all sources used in any aspect of this
analysis. We have provided more detail about modelling
strategies and internal validity of model ts. In view of the
complexity of the GBD analysis spanning so many
sequelae, estimation requires a tremendous investment
across the network of collaborators measured in
person-years. Replication of the entire eort was possible
but would have required many resources and negotiated
access to the few datasets provided to the GBD through
data use agreements that are not in the public domain.
With the public release of the Epi Viz tool, everyone will
be able to examine the specic studies and datapoints
used for each disease sequela and the model t. To further
satisfy the reasonable scientic curiosity of academics
about particular sequelae, the GBD collaborators remain
committed to answering detailed questions about all
steps of the analysis and many disease-specic
publications will follow in which much greater detail of
the modelling assumptions and data for each sequela can
be provided.
Fifth, when data for a sequela are collected using
dierent denitions, assays, or instrument items, we
have cross-walked between these dierences using xed
eects in the meta-regressions. For example, in the
DisMod-MR 2.0 model for major depressive disorder, the
coecient for symptom scale measures as opposed to a
diagnostic interview schedule was 083 (95% uncertainty
interval 064104) in log space and 230 (190283)
after exponentiation. By dividing symptom scale
prevalence datapoints by 23, we predicted the
corresponding values for the reference case. Another
example of an important cross-walk was between data for
opioid dependence from household surveys and the
more inclusive estimates from triangulation of data from
treatment centres, needle exchange programmes, and
the justice system.9 DisMod-MR 2.0 estimated a
coecient of 031 (015074) after exponentiation
indicating the household survey prevalence was an
underestimate by more than a factor of three. Several
factors could account for this large dierence including
lack of a steady residence, lower response to surveys, and
fear of reprisals for admitting to illegal behaviours.114 We
used a similar covariate for triangulated data for cocaine
and amphetamine dependence but did not note
systematic bias compared with household survey data.
There is no equivalent approach to address the potential
bias from non-response to surveys or the eect of stigma
on responses for cannabis and alcohol dependence. In
47
Articles
the DisMod-MR 2.0 model of alcohol dependence we use

several study characteristics such as the type of survey
and the measurement questionnaire. A review of
Chinese studies on alcohol dependence showed that
variation in prevalence between studies was strongly
related to such study characteristics.115 Of particular
interest in the Chinese review was the nding that large
surveys often rely on proxy reporting for absent
household members to improve the response rate and
that these surveys tend to underestimate the prevalence
of alcohol dependence. Although there is substantial
evidence for stigma and alcohol dependence, there was
no quantication of the magnitude and direction of the
bias on population prevalence estimates, probably
because a gold standard measurement that would be
unaected by stigma is dicult to dene.116118 Experience
in the GBD 2013 compared with GBD 2010 shows that
these xed-eect coecients for study level characteristics
can be substantially aected by the inclusion of new data
sources. For large cross-walks, new data in one country
can alter results in many other countries. This sensitivity
of statistical cross-walks in models with sparse data
draws attention to the value of standardising case
denitions, assays, and instruments in future data
collection. The comprehensive nature of GBD provides
an opportunity to identify what is the reference case
approach to measurement with the current knowledge
for each sequela. We plan to summarise our assessment
of best practice for each sequela in a future publication.
Sixth, in models using DisMod-MR 2.0 or natural
history models, the associations between incidence,
remission, excess mortality, prevalence, and causespecic mortality are modelled simultaneously. However,
if there are no models for the age pattern and level
of excess mortality across countries, simultaneous
estimation does not ensure any correlation in the agespecic rates of prevalence and cause-specic mortality
across countries. In this iteration of the GBD, we have
devoted much more attention to this estimation challenge
by incorporating into many models more direct
information about the credible range of excess mortality
across age, sex, and country. However, country variation
in excess mortality has not been as extensively debated in
the literature about burden of disease estimation as it has
for incidence, prevalence, or causes of death. More
attention to these associations and the determinants of
excess mortality such as access to care will be benecial
in future iterations of the GBD.
Seventh, comorbidity simulation, used for quantifying
the burden of disease and undertaking intervention
analysis, has a major limitation, namely that we assume
that within a countryagesexyear group prevalence
values are independent. For some disorders such as
diabetes and ischaemic heart disease or anxiety disorders,
depression, and alcohol dependence, we expect probabilities
are dependent. Empirical assessments119,120 of comorbidity
tend to show that age is the dominant driver of comorbidity,
48
ignoring dependent comorbidity, for example in the MEPS

data, leads to minimal errors in estimated burden.1
Incorporating dependent comorbidity into the microsimulation environment is not technically challenging; the
issue is that there are insucient data to generally estimate
the age-specic correlation matrix of all 2337 sequelae. As
compelling and albeit incomplete evidence on dependence
accumulates, we intend to incorporate this into the
comorbidity simulation microsimulations.
Eighth, in the current version of DisMod-MR 2.0, we
were unable to incorporate estimates of the subnational
units for China, Mexico, and the UK as a fth level in the
estimation cascade (gure 2). Instead, subnational units
were modelled as though they were independent
countries. If data were sparse, that meant that subnational
units might borrow strength from the regional estimate
rather than the country estimate. In some cases, when
only national data were available, we used these data for
each subnational unit after dividing the eective sample
size of each datapoint by the number of subnational
units to avoid overemphasising the national data used in
each unit in the overall estimation. A fth level of the
cascade will be added in the next version of DisMod-MR.
Ninth, there was a steady drop in the age-standardised
rates of YLDs for all injury categories between 1990 and
2013. For the unintentional injury categories, with the
exception of falls, the steady drop was partly driven by a
downward trend in case fatality rates accompanied by a
drop in incident cases. The larger change aecting the
downward trend in YLD rates was related to the
dierence between disability with and without treatment.
In the absence of robust national data for the injury
treatment rates, we have assumed access to treatment
scales according to the indicator health system access.76
The health system access indicator was based on a
principal component analysis of coverage of mostly
maternal and child health interventions and health
system infrastructure. There have been steady global
improvements in health system access as captured in
this indicator reducing the estimated injury YLDs.
Tenth, substantial eorts have been made in the data
preparation and analysis to address issues of
ascertainment bias that might aect trends. In another
example of dealing with ascertainment bias we crosswalked between diagnostic assays from creatine kinasemyocardial band enzymes to troponins for the detection
of acute myocardial infarction. Despite these eorts,
there are some upward trends that might still relate to
residual issues of ascertainment including multiple
sclerosis and prostate cancer.
Eleventh, in a study with more than half a million YLD
estimates generated from sometimes sparse and always
disparate data sources there remain areas where
additional evidence or a change in the modelling strategy
could lead to better estimates. Yearly updates of GBD
allowed for a continued eort to search for new data and
improve methods, particularly for disorders with sparse
Articles
data or inconsistencies between data sources. We are

already compiling a list of issues to address in the next
iteration. For example, with our collaborators in Qatar,
we are searching for data to verify the high YLD estimate
for opioid dependence, which in the models is aected
by data from studies in Iran and Afghanistan. In other
cases, further data for the clinical severity associated with
paragonimiasis would help determine the relevance of
the health state used to select the disability weight for
this sequela. Generally, we will search for additional
evidence of the severity of all disorders for the next
iteration of GBD.
Despite the limitations, the implications of our ndings
are substantial. By extending the GBD analysis to report
the commonly understood measures of morbidity and
disability in populations, by age, by sex, by country, and
over time, this study represents an enormous resource
for national, regional, and global policy debates about
health priorities, not just to keep people alive well into
old age, but to also keep them healthy. Without this
health intelligence, large, preventable causes of health
loss in populations, particularly mental and behavioural
disorders and serious musculoskeletal disorders, have
thus far not received the attention that they deserve in
national health debates.
The GBD 2013 covers a comprehensive, exhaustive, and
mutually exclusive set of causes and their sequelae at the
country level over 23 years. By shifting to a process of
yearly updating, the GBD provides a rapid mechanism for
incorporating new data, development of methods, and
new insights into old data or disease mechanisms. By
steadily increasing the transparency of input sources,
documenting in detail the methods used, sharing crucial
code such as DisMod-MR 2.0, and facilitating online
exploration of new results using dynamic data
visualisations, we believe GBD can progressively become
a means for global health surveillance, not just for
mortality but also for reducing health loss among
populations everywhere. As a group of investigators, we
seek to accommodate within the GBD framework
epidemiological debate about each cause, and based on
scientic principles, describe the functional health of all
individuals in the world. Studies such as this provide the
important comprehensive, comparative, and consistent
evidence to guide policy and practice, evidence that will
become progressively more reliable as more data and
information are identied and included as part of the
global collaboration.
Contributors
TV, ADL, MN, and CJLM prepared the rst draft. TV, CJLM, MFM, GH,
and CS nalized the draft based on comments from other authors and
reviewer feedback. TV, ADL, MN, and CJLM conceived of the study and
provided overall guidance. TF, RB, SB, DD, LS, and JW performed nal
statistical analyses. All other authors provided data, developed models,
reviewed results, provided guidance on methodology, and reviewed the
manuscript.
Global Burden of Disease Study 2013 Collaborators
Theo Vos, Ryan M Barber, Brad Bell, Amelia Bertozzi-Villa,
Stan Biryukov, Ian Bolliger, Fiona Charlson, Adrian Davis,

Louisa Degenhardt, Daniel Dicker, Leilei Duan, Holly Erskine,
Valery L Feigin, Alize J Ferrari, Christina Fitzmaurice, Thomas Fleming,
Nicholas Graetz, Caterina Guinovart, Juanita Haagsma,
Gillian M Hansen, Sarah Wulf Hanson, Kyle R Heuton, Hideki Higashi,
Nicholas Kassebaum, Hmwe Kyu, Evan Laurie, Xiofeng Liang,
Katherine Lofgren, Rafael Lozano, Michael F MacIntyre,
Maziar Moradi-Lakeh, Mohsen Naghavi, Grant Nguyen, Shaun Odell,
Katrina Ortblad, David Allen Roberts, Gregory A Roth, Logan Sandar,
Peter T Serina, Jerey D Stanaway, Caitlyn Steiner, Bernadette Thomas,
Stein Emil Vollset, Harvey Whiteford, Timothy M Wolock, Pengpeng Ye,
Maigeng Zhou, Marco A vila*, Gunn Marit Aasvang*,
Cristiana Abbafati*, Ayse Abbasoglu Ozgoren*, Foad Abd-Allah*,
Muna I Abdel Aziz*, Semaw F Abera*, Victor Aboyans*,
Jerry P Abraham*, Biju Abraham*, Ibrahim Abubakar*,
Laith J Abu-Raddad*, Niveen ME Abu-Rmeileh*, Tania C Aburto*,
Tom Achoki*, Ilana N Ackerman*, Ademola Adelekan*,
Zanna Ademi*, Arsne K Adou*, Josef C Adsuar*, Johan Arnlov*,
Emilie E Agardh*, Mazin J Al Khabouri*, Sayed Saidul Alam*,
Deena Alasfoor*, Mohammed I Albittar*, Miguel A Alegretti*,
Alicia V Aleman*, Zewdie A Alemu*, Rafael Alfonso-Cristancho*,
Samia Alhabib*, Raghib Ali*, Francois Alla*, Peter Allebeck*,
Peter J Allen*, Mohammad AbdulAziz AlMazroa*, Ubai Alsharif*,
Elena Alvarez*, Nelson Alvis-Guzman*, Omid Ameli*, Heresh Amini*,
Walid Ammar*, Benjamin O Anderson*, H. Ross Anderson*,
Carl Abelardo T Antonio*, Palwasha Anwari*, Henry Apfel*,
Valentain S Arsic Arsenijevic *, Al Artaman*, Rana J Asghar*,
Reza Assadi*, Lydia S Atkins*, Charles Atkinson*, Alaa Badawi*,
Maria C Bahit*, Talal Bakfalouni*, Kalpana Balakrishnan*,
Shivanthi Balalla*, Amitava Banerjee*, Suzanne L Barker-Collo,
Simon Barquera*, Lars Barregard*, Lope H Barrero*, Sanjay Basu*,
Arindam Basu*, Amanda Baxter*, Justin Beardsley*, Neeraj Bedi*,
Ettore Beghi*, Tolesa Bekele*, Michelle L Bell*, Corina Benjet*,
Derrick A Bennett*, Isabela M Bensenor*, Habib Benzian*,
Eduardo Bernabe*, Tariku J Beyene*, Neeraj Bhala*, Ashish Bhalla*,
Zulqar Bhutta*, Kelly Bienho*, Boris Bikbov*, Aref Bin Abdulhak*,
Jed D Blore*, Fiona M Blyth*, Megan A Bohensky*,
Berrak Bora Basara*, Guilherme Borges*, Natan M Bornstein*,
Dipan Bose*, Souane Boufous*, Rupert R Bourne*, Lindsay N Boyers*,
Michael Brainin*, Michael Brauer*, Carol EG Brayne*,
Alexandra Brazinova*, Nicholas JK Breitborde*, Hermann Brenner*,
Adam DM Briggs*, Peter M Brooks*, Jonathan Brown*,
Traolach S Brugha*, Rachelle Buchbinder*, Georey C Buckle*,
Gene Bukhman*, Andrew G Bulloch*, Michael Burch*,
Richard Burnett*, Rosario Cardenas*, Norberto L Cabral*,
Ismael R Campos Nonato*, Julio C Campuzano*, Jonathan R Carapetis*,
David O Carpenter*, Valeria Caso*, Carlos A Castaneda-Orjuela*,
Ferran Catala-Lopez*, Vineet K Chadha*, Jung-Chen Chang*,
Honglei Chen*, Wanqing Chen*, Peggy P Chiang*,
Odgerel Chimed-Ochir*, Rajiv Chowdhury*, Hanne Christensen*,
Costas A Christophi*, Sumeet S Chugh*, Massimo Cirillo*,
Megan Coggeshall*, Aaron Cohen*, Valentina Colistro*,
Samantha M Colquhoun*, Alejandra G Contreras*, Leslie T Cooper*,
Cyrus Cooper*, Kimberly Cooperrider*, Josef Coresh*,
Monica Cortinovis*, Michael H Criqui*, John A Crump*,
Lucia Cuevas-Nasu*, Rakhi Dandona*, Lalit Dandona*,
Emily Dansereau*, Hector G Dantes*, Paul I Dargan*, Gail Davey*,
Dragos V Davitoiu*, Anand Dayama*, Vanessa De la Cruz-Gongora*,
Shelley F de la Vega*, Diego De Leo*, Borja del Pozo-Cruz* ,
Robert P Dellavalle*, Kebede Deribe*, Sarah Derrett*,
Don C Des Jarlais*, Muluken Dessalegn*, Gabrielle A deVeber*,
Samath D Dharmaratne*, Cesar Diaz-Torne*, Eric L Ding*,
Klara Dokova*, E R Dorsey*, Tim R Driscoll*, Herbert Duber*,
Adnan M Durrani*, Karen M Edmond*, Richard G Ellenbogen*,
Matthias Endres*, Sergey P Ermakov*, Babak Eshrati*,
Alireza Esteghamati*, Kara Estep*, Saman Fahimi*, Farshad Farzadfar*,
Derek FJ Fay*, David T Felson*, Seyed-Mohammad Fereshtehnejad*,
Jeerson G Fernandes*, Cluesa P Ferri*, Abraham Flaxman*,
Nataliya Foigt*, Kyle J Foreman*, F Gerry R Fowkes*,
Richard C Franklin*, Thomas Furst*, Neal D Futran*, Belinda J Gabbe*,
Fortune G Gankpe*, Francisco A Garcia-Guerra*, Johanna M Geleijnse*,
For GBD Data Visualizations see

http://www.healthdata.org/gbd/
data-visualizations
49
Articles
Bradford D Gessner*, Katherine B Gibney*, Richard F Gillum*,

Ibrahim A Ginawi*, Maurice Giroud*, Giorgia Giussani*,
Shifalika Goenka*, Ketevan Goginashvili*, Philimon Gona*,
Teresita Gonzalez de Cosio*, Richard A Gosselin*, Carolyn C Gotay*,
Atsushi Goto*, Hebe N Gouda*, Richard l Guerrant*,
Harish C Gugnani*, David Gunnell*, Rajeev Gupta*, Rahul Gupta*,
Reyna A Gutierrez*, Nima Hafezi-Nejad*, Holly Hagan*, Yara Halasa*,
Randah R Hamadeh*, Hannah Hamavid*, Mouhanad Hammami*,
Graeme J Hankey*, Yuantao Hao*, Hilda L Harb*, Josep Maria Haro*,
Rasmus Havmoeller*, Roderick J Hay*, Simon Hay*,
Mohammad T Hedayati*, Ileana B Heredia Pi*, Pouria Heydarpour*,
Martha Hijar*, Hans W Hoek*, Howard J Homan*,
John C Hornberger*, H. Dean Hosgood*, Mazeda Hossain*,
Peter J Hotez*, Damian G Hoy*, Mohamed Hsairi*, Howard Hu*,
Guoqing Hu*, John J Huang*, Cheng Huang*, Laetitia Huiart*,
Abdullatif Husseini*, Marissa Iannarone*, Kim M Iburg*, Kaire Innos*,
Manami Inoue*, Kathryn H Jacobsen*, Simerjot K Jassal*,
Panniyammakal Jeemon*, Paul N Jensen*, Vivekanand Jha*,
Guohong Jiang*, Ying Jiang*, Jost B Jonas*, Jonathan Joseph*,
Knud Juel*, Haidong Kan*, Andre Karch*, Chante Karimkhani*,
Ganesan Karthikeyan*, Ronit Katz*, Anil Kaul*, Norito Kawakami*,
Dhruv S Kazi*, Andrew H Kemp*, Andre P Kengne*, Yousef S Khader*,
Shams Eldin AH Khalifa*, Ejaz A Khan*, Gulfaraz Khan*,
Young-Ho Khang*, Irma Khonelidze*, Christian Kieling*, Daniel Kim*,
Sungroul Kim*, Ruth W Kimokoti*, Yohannes Kinfu*, Jonas M Kinge*,
Brett M Kissela*, Miia Kivipelto*, Luke Knibbs*, Ann Kristin Knudsen*,
Yoshihiro Kokubo*, Soewarta Kosen*, Alexander Kramer*,
Michael Kravchenko*, Rita V Krishnamurthi*, Sanjay Krishnaswami*,
Barthelemy Kuate Defo*, Burcu Kucuk Bicer*, Ernst J Kuipers*,
Veena S Kulkarni*, Kaushalendra Kumar*, G Anil Kumar*,
Gene F Kwan*, Taavi Lai*, Ratilal Lalloo*, Hilton Lam*, Qing Lan*,
Van C Lansingh*, Heidi Larson*, Anders Larsson*,
Alicia EB Lawrynowicz*, Janet L Leasher*, Jong-Tae Lee*, James Leigh*,
Ricky Leung*, Miriam Levi*, Bin Li*, Yichong Li*, Yongmei Li*,
Juan liang*, Stephen Lim*, Hsien-Ho Lin*, Margaret Lind*,
M Patrice Lindsay*, Steven E Lipshultz*, Shiwei Liu*, Belinda K Lloyd*,
Summer Lockett Ohno*, Giancarlo Logroscino*, Katharine J Looker*,
Alan D Lopez*, Nancy Lopez-Olmedo*, Joannie Lortet-Tieulent*,
Paulo A Lotufo*, Nicola Low*, Robyn M Lucas*,
Raimundas Lunevicius*, Ronan A Lyons*, Jixiang Ma*, Stefan Ma*,
Mark T Mackay*, Marek Majdan*, Reza Malekzadeh*,
Christopher C Mapoma*, Wagner Marcenes*, Lyn M March*,
Chris Margono*, Guy B Marks*, Melvin B Marzan*, Joseph R Masci*,
Amanda J Mason-Jones*, Richard G Matzopoulos*, Bongani M Mayosi*,
Tasara T Mazorodze*, Neil W McGill*, John J McGrath*,
Martin McKee*, Abby McLain*, Brian J McMahon*, Peter A Meaney*,
Man Mohan Mehndiratta*, Fabiola Mejia-Rodriguez*,
Wubegzier Mekonnen*, Yohannes A Melaku*, Michele Meltzer*,
Ziad A Memish*, George Mensah*, Atte Meretoja*,
Francis A Mhimbira*, Renata Micha*, Ted R Miller*, Edward J Mills*,
Philip B Mitchell*, Charles N Mock*, Terrie E Mott*,
Norlinah Mohamed Ibrahim*, Karzan A Mohammad*, Ali H Mokdad*,
Glen L Mola*, Lorenzo Monasta*, Marcella Montico*,
Thomas J Montine*, Ami R Moore*, Andrew E Moran*,
Lidia Morawska*, Rintaro Mori*, Joanna Moschandreas*,
Wilkister N Moturi*, Madeline Moyer*, Dariush Mozaarian*,
Ulrich O Mueller*, Mitsuru Mukaigawara*, Michele E Murdoch*,
Joseph Murray*, Kinnari S Murthy*, Paria Naghavi*, Ziad Nahas*,
Aliya Naheed*, Kovin S Naidoo*, Luigi Naldi*, Devina Nand*,
Vinay Nangia*, K.M. Venkat Narayan*, Denis Nash*, Chakib Nejjari*,
Sudan P Neupane*, Lori M Newman*, Charles R Newton*, Marie Ng*,
Frida N Ngalesoni*, Nguyen T Nhung*, Muhammad I Nisar*,
Sandra Nolte*, Ole F Norheim*, Rosana E Norman*, Bo Norrving*,
Luke Nyakarahuka*, In Hwan Oh*, Takayoshi Ohkubo*, Saad B Omer*,
John Nelson Opio*, Alberto Ortiz*, Jeyaraj D Pandian*,
Carlo Irwin A Panelo*, Christina Papachristou*, Eun-Kee Park*,
Charles D Parry*, Angel J Paternina Caicedo*, Scott B Patten*,
Vinod K Paul*, Boris I Pavlin*, Neil Pearce*, Lilia S Pedraza*,
Carlos A Pellegrini*, David M Pereira*, Fernando P Perez-Ruiz*,
Norberto Perico*, Aslam Pervaiz*, Konrad Pesudovs*,
Carrie B Peterson*, Max Petzold*, Michael R Phillips*, David Phillips*,
50
Bryan Phillips*, Frederic B Piel*, Dietrich Plass*, Dan Poenaru*,

Guilherme V Polanczyk*, Suzanne Polinder*, C A Pope*,
Svetlana Popova*, Richie G Poulton*, Farshad Pourmalek*,
Dorairaj Prabhakaran*, Noela M Prasad*, Dima Qato*, D A Quistberg*,
Anwar Rafay*, Kazem Rahimi*, Vafa Rahimi-Movaghar*,
Sajjad ur Rahman*, Murugesan Raju*, Ivo Rakovac*, Saleem M Rana*,
Homie Razavi*, Amany Refaat*, Jurgen Rehm*, Giuseppe Remuzzi*,
Serge Resniko*, Antonio L Ribeiro*, Patricia M Riccio*,
Lee Richardson*, Jan Hendrik Richardus*, Anne M Riederer*,
Margot Robinson*, Anna Roca*, Alina Rodriguez*, David Rojas-Rueda*,
Luca Ronfani*, Dietrich Rothenbacher*, Nobhojit Roy*,
George M Ruhago*, Nsanzimana Sabin*, Ralph L Sacco*,
Kjetil Ksoreide*, Sukanta Saha*, Ramesh Sahathevan*,
Mohammad Ali Sahraian*, Uchechukwu Sampson*, Juan R Sanabria*,
Lidia Sanchez-Riera*, Itamar S Santos*, Maheswar Satpathy*,
James E Saunders*, Monika Sawhney*, Mete I Saylan*,
Peter Scarborough*, Ben Schoettker*, Ione JC Schneider*,
David C Schwebel*, James G Scott*, Soraya Seedat*, Sadaf G Sepanlou*,
Berrin Serdar*, Edson E Servan-Mori*, Katya Shackelford*,
Amira Shaheen*, Saeid Shahraz*, Teresa Shamah Levy*, Siyi
Shangguan*, Jun She*, Sara Sheikhbahaei*, Donald S Shepard*,
Peilin Shi*, Kenji Shibuya*, Yukito Shinohara*, Rahman Shiri*,
Kawkab Shishani*, Ivy Shiue*, Mark G Shrime*, Inga D Sigfusdottir*,
Donald H Silberberg*, Edgar P Simard*, Shireen Sindi*,
Jasvinder A Singh*, Lavanya Singh*, Vegard Skirbekk*, Karen Sliwa*,
Michael Soljak*, Samir Soneji*, Sergey S Soshnikov*, Peter Speyer*,
Luciano A Sposato*, Chandrashekhar T Sreeramareddy*,
Heidi Stoeckl*, Vasiliki Kalliopi Stathopoulou*, Nadine Steckling*,
Murray B Stein*, Dan J Stein*, Timothy J Steiner*, Andrea Stewart*,
Eden Stork*, Lars J Stovner*, Konstantinos Stroumpoulis*,
Lela Sturua*, Bruno F Sunguya*, Mamta Swaroop*, Bryan L Sykes*,
Karen M Tabb*, Ken Takahashi*, Feng Tan*, Nikhil Tandon*,
David Tanne*, Marcel Tanner*, Mohammad Tavakkoli*, Hugh R Taylor*,
Braden J Te Ao*, Awoke Misganaw Temesgen*, Margreet Ten Have*,
Eric Yeboah Tenkorang*, Abdullah Sulieman Terkawi*,
Alice M Theadom*, Elissa Thomas*, Andrew L Thorne-Lyman*,
Amanda G Thrift*, Imad M Tleyjeh*, Marcello Tonelli*, Fotis Topouzis*,
Jerey A Towbin*, Hideaki Toyoshima*, Jeerson Traebert*,
Bach X Tran*, Leonardo Trasande*, Matias Trillini*, Thomas Truelsen*,
Ulises Trujillo*, Miltiadis Tsilimbaris*, Emin M Tuzcu*,
Kingsley N Ukwaja*, Eduardo A Undurraga*, Selen B Uzun*,
Wim H van Brakel*, Steven van de Vijver*, Rita Van Dingenen*,
Coen H van Gool*, Yuri Y Varakin*, Tommi J Vasankari*,
Monica S Vavilala*, Lennert J Veerman*, Gustavo Velasquez-Melendez*,
Narayanaswamy Venketasubramanian*, Lakshmi Vijayakumar*,
Salvador Villalpando*, Francesco S Violante*, Vasiliy V Vlassov*,
Stephen Waller*, Mitchell T Wallin*, Xia Wan*, Linhong Wang*,
JianLi Wang*, Yanping Wang*, Tati S Warouw*, Scott Weichenthal*,
Elisabete Weiderpass*, Robert G Weintraub*, Andrea Werdecker*,
K. Ryan R Wessells*, Ronny Westerman*, James D Wilkinson*,
Hywel C Williams*, Thomas N Williams*, Solomon M Woldeyohannes*,
Charles DA Wolfe*, John Q Wong*, Haidong Wong*,
Anthony D Woolf*, Jonathan L Wright*, Brittany Wurtz*, Gelin Xu*,
Gonghuan Yang*, Yuichiro Yano*, Muluken A Yenesew*,
Gokalp K Yentur*, Paul Yip*, Naohiro Yonemoto*, Seok-Jun Yoon*,
Mustafa Younis*, Chuanhua Yu*, Kim Yun Kim*,
Maysaa El Sayed Zaki*, Yong Zhang*, Zheng Zhao*, Yong Zhao*,
Jun Zhu*, David Zonies*, Joseph R Zunt*, Joshua A Salomon,
Christopher JL Murray. *Authors listed alphabetically. Joint senior
authors.
Aliation
Institute for Health Metrics and Evaluation (Prof T Vos PhD,
R M Barber BS, B Bell PhD, A Bertozzi-Villa BA, S Biryukov BS,
I Bolliger BA, D Dicker BS, C Fitzmaurice MD, T Fleming BS,
N Graetz BS, J Haagsma PhD, G M Hansen MSW,
S Wolf Hansen MPH, K R Heuton BChe, H Higashi PhD,
H H Kyu PhD, E Laurie BS, K T Lofgren MPH, R Lozano PhD,
M F MacIntyre EdM, M Moradi-Lakeh MD, M Naghavi PhD,
G Nguyen BA, S Odell MD, K Ortblad MPH, D A Roberts BS,
G A Roth MD, L Sandar BS, P T Serina MPH, J D Stanaway PhD,
C Steiner MPH, A Stewart MPH, B Thomas MD, S E Vollset MD,
Articles
T M Wolock BA, T Achoki PhD, H Apfel BA, C Atkinson BS,

K Bienho MA, J D Blore PhD, J C Brown MAIS, M Coggeshall BA,
K Cooperrider BA, L Dandona MD, E Dansereau MPH, H C Duber MD,
K Estep MPA, A Flaxman PhD, K J Foreman MPH, H Hamavid BA,
M L Iannarone MS, J Joseph BS, Prof S S Lim PhD, M L Lind BS,
S Lockett Ohno BA, Prof A D Lopez PhD, C Margono BS, A McLain MA,
A H Mokdad PhD, M L Moyer BS, P Naghavi BESc, M Ng PhD,
B K Phillips BA, D E Phillips BS, L Richardson BS, M Robinson BA,
K Shackelford BA, L Singh BS, P Speyer MBA, E Stork MSLIS,
E Thomas MLS, H Wong PhD, B Wurtz MPH, C JL Murray DPhil),
Harborview Hospital and Department of Medicine
(R G Ellenbogen MD), Childrens Hospital (N Kassebaum MD), Kidney
Research Institute (R Katz DPhil), School of Medicine (J L Wright MD),
University of Washington (R Alfonso-Cristancho MD,
Prof B O Anderson MD, N D Futran MD, P N Jensen PhD,
C N Mock PhD, T J Montine PhD, C A Pellegrini MD,
D A Quistberg PhD, A M Riederer ScD, M S Vavilala MD, J R Zunt MD)
Seattle, WA, USA; School of Population Health (D G Hoy PhD), Centre
for Clinical Research (J G Scott PhD), University of Queensland,
Brisbane, Australia (F C Charlson MPH, H E Erskine BPsySc,
A J Ferrari BPsySc, H N Gouda PhD, L Knibbs PhD,
Prof J J McGrath MD, R E Norman PhD, L J Veerman PhD,
Prof H A Whiteford MD), Public Health England, London, UK
(Prof A Davis PhD, D FJ Fay MSc); Transport and Road Safety (TARS)
Research (S Boufous PhD) University of New South Wales, Sydney
(Prof L Degenhardt PhD, Prof P B Mitchell MD, M Satpathy PhD),
Australia; National Centers for Chronic and Noncommunible Disease
Control and Prevention, Chinese Center for Disease Control, China
(L Duan Master, X Liang, Y Li MD, S Liu PhD, J Ma PhD,
Prof L Wang MD, P Ye PhD, Prof M Zhou PhD); National Institute for
Stroke and Applied Neurosciences (V L Feigin PhD, S Balalla MPH)
Auckland University of Technology (B J Te Ao MPH, A M Theadom
PhD, R V Krishnamurthi PhD), Auckland, New Zealand; PATH, Seattle,
WA, USA (C Guinovart PhD); National Institute of Public Health,
Mexico City, Mexico (M A vila BS, T C Aburto MSc, S Barquera PhD,
I R Campos-Nonato PhD, Prof J C Campuzano PD, A G Contreras MsC,
L Cuevas-Nasu MsC, V De la Cruz-Gongora
MsC, T Gonzalez de Cosio PhD, H G Dantes MsC,
Prof F A Garcia-Guerra MS, I B Heredia Pi, T Shamah Levy PhD,
N Lopez-Olmedo MSc, Prof Rafael Lozano PhD, F Mejia-Rodriguez MSc,
L S Pedraza MSc, E E Servan-Mori MSc, S Villalpando PhD); Norwegian
Institute of Public Health, Oslo, Norway (G Aasvang PhD,
J M Kinge PhD, A K Knudsen PhD, Prof V Skirbekk PhD); La Sapienza
University of Rome, Rome, Italy (C Abbafati PhD); Hacettepe University
Institute of Population Studies, Turkey (A Abbasoglu Ozgoren MSc);
Faculty of Medicine, Cairo University, Cairo, Egypt (Prof F Abd-Allah
MD) Public Health Institute, Sudan (M I Abdel Aziz); Mekelle
University, College of Health Sciences, School of Public Health, Ethiopia
(S F Abera MSc, Y A Melaku MPH); Dupuytren University Hospital,
Limoges, France (Prof V Aboyans MD); Oslo and Akershus University
College of Applied Sciences (HiOA), Oslo, Norway (B Abraham MPhil);
University of Texas School of Medicine, San Antonio, Texas, USA
(J P Abraham MD); Department of Epidemiology and Public Health
(H Benzian), University College (Prof I Abubakar FRCP), London, UK;
Weill Cornell Medical College Qatar, Doha, Qatar (L J Abu-Raddad PhD);
Institute of Community and Public Health-Birzeit University, Birzeit,
Palestine (N ME Abu-Rmeileh PhD); General Practice and Primary
Health Care Academic Centre (P P Chiang PhD), Centre for
International Child Health (S M Colquhoun PhD), Melbourne School of
Population and Global Health (Prof H R Taylor MD), University of
Melbourne (I N Ackerman PhD, Z Ademi PhD, M A Bohensky PhD,
Prof P M Brooks MD, Prof A D Lopez PhD, A Meretoja MD,
R G Weintraub MB), Melbourne, Australia; Public Health Promotion
Alliance, Osogbo, Nigeria (A Adelekan MPH); Association Ivoirienne
pour le Bien-Etre Familial, Abidjan, Cote DIvoire (A K Adou Masters);
University of Extremadura, Cceres, Spain (Prof J C Adsuar PhD);
Institution of Public Health Sciences, Stockholm, Sweden (E E Agardh
PhD); Ministry of Health, Muskat, Oman (M J Al Khabouri PhD,
D Alasfoor MSc); International Centre for Diarrhoeal Diseases Research,
Bangladesh, Dhaka, Bangladesh (S Alam MSc, A Naheed PhD); Public
Health Consultant, Syria (M I Albittar MSc); Faculty of Medicine,
Departamento de Medicina Preventiva y Social (M A Alegretti), School of

Medicine (A V Aleman MD), Department of Medicine (V Colistro MSc),
University of the Republic, Montevideo, Uruguay; Debre Markos
University, Debre Markos, Amhara, Ethiopia (Z A Alemu MPH),
National Guard Health Aairs, Riyadh, Saudi Arabia (S Alhabib PhD);
University of Oxford, Oxford, UK (R Ali FRCP, D A Bennett PhD,
A DM Briggs MRCP, S I Hay DSc, F B Piel PhD, K Rahimi DM,
P Scarborough DPhil); School of Public Health, University of Lorraine,
Nancy, France (Prof F Alla PhD); Department of Public Health Sciences
(Prof P Allebeck PhD), Department of Neurobiology, Care Sciences and
Society (NVS) (S Fereshtehnejad MD), Department of Medical
Epidemiology and Biostatistics (Prof E Weiderpass MD), Aging Research
Center (Prof M Kivipelto PhD), Karolinska Institutet (R Havmoeller
PhD, S Sindi PhD), Stockholm, Sweden; Ministry of Health, Belmopan,
Belize (P J Allen DDS); Saudi Ministry of Health, Riyadh, Saudi Arabia
(M A AlMazroa MD, Prof Z A Memish MD); Charit Universittsmedizin Berlin, Berlin, Germany (U Alsharif DMD,
Prof M Endres MD, S Nolte PhD, C Papachristou PhD); Government of
Spain, Spain (E Alvarez PhD); Universidad de Cartagena, Cartagena de
Indias, Colombia (Prof N Alvis-Guzman PhD, A J Paternina Caicedo
MSc); Department of Epidemiology, College of Medicine and Health
Sciences (A T Amare MPH), University Medical Center Groningen
(Prof H W Hoek MD) University of Groningen, Groningen,
Netherlands, Bahir Dar University (M A Yenesew), Bahir Dar, Ethiopia;
Boston University, Boston, MA, USA (O Ameli MD,
Prof D T Felson MD); Kurdistan Environmental Health Research Center,
Kurdistan University of Medical Sciences, Sanandaj, Kurdistan, Iran
(H Amini MSPH); Department of Epidemiology and Public Health,
Swiss Tropical and Public Health Institute, Basel, Switzerland
(H Amini MSPH, Prof M Tanner PhD); University of Basel, Basel,
Switzerland (H Amini MSPH); Ministry of Public Health, Beirut,
Lebanon (W Ammar PhD, H L Harb MPH); St Georges
(Prof H R Anderson MD), Queen Mary (Prof W Marcenes PhD),
University of London, London, UK; College of Public Health, University
of the Philippines, Manila, Philippines (C T Antonio MD,
C A Panelo MD); United Nations Population Fund, Kabul, Afghanistan
(P Anwari MSc); Uppsala University, Uppsala, Norway (J Arnlov PhD,
Prof A Larsson); University of Belgrade, School of Medicine, Institute of
Microbiology and Immunology, Belgrade, Serbia (Prof V S Arsic
Arsenijevic PhD); Evidera Inc, Lexington, KY, USA (A Artaman PhD);
South Asian Public Health Forum, Pakistan (R J Asghar MBBS);
Mashhad University of Medical Sciences, Mashhad, Iran (R Assadi MD);
Ministry Of Health, Wellness, Human Services and Gender Relations,
Castries, St. Lucia (L S Atkins MPH); Public Health Agency of Canada,
Toronto, ON, Canada (A Badawi PhD); INECO Neurociencias, Rosario,
Santa Fe, Argentina (M C Bahit MD); Ministry of Health, Damascus,
Syria (T Bakfalouni MD); Sri Ramachandra University, Chennai, Tamil
Nadu, India (K Balakrishnan PhD); University of Birmingham,
Birmingham, UK (A Banerjee DPhil); School of Psychology
(S L Barker-Collo PhD), University of Auckland (B del Pozo-Cruz PhD),
Auckland, New Zealand; Department of Occupational and
Environmental Health (Prof L Barregard PhD), Health Metrics at
Sahlgrenska Academy (Prof M Petzold PhD), University of Gothenburg,
Gothenburg, Sweden; Department of Industrial Engineering, Ponticia
Universidad Javeriana, Bogota, Colombia (L H Barrero ScD); School of
Health Sciences, University of Canterbury, Christchurch, New Zealand
(A Basu PhD); Stanford University, Stanford, CA, USA (S Basu PhD);
A Baxter; Oxford University, Ho Hi Minh City, Vietnam
(J Beardsley MBChB); College of Public Health and Tropical Medicine,
Jazan, Saudi Arabia (N Bedi MD); Mario Negri, Milan (E Beghi MD,
Prof G Remuzzi MD), Burlo Garofolo, Trieste (L Ronfani PhD), IRCCSIstituto di Ricerche Farmacologiche, Italy; Madawalabu University,
Bale Robe, Ethiopia (T Bekele MPH, M Cortinovis Biotech D,
G Giussani BiolD, L Monasta DSc, M Montico MSc, N Perico MD,
M Trillini MD); Yale University, New Haven, CT, USA (Prof M L Bell,
J J Huang MD); National Institute of Psychiatry Ramon de la Fuente
Muniz, Mexico City, Mexico (C Benjet PhD, Prof G Borges DSc;
R A Gutierrez PhD); Hospital Universitrio (I M Bensenor PhD)
University of Sao Paulo (Prof A Kemp PhD, Prof P A Lotufo DrPh,
Prof G V Polanczyk PhD, Prof I S Santos PhD), Sao Paulo, Brazil; Kings
College, London, UK (E Bernabe PhD, Prof C DA Wolfe MD); Addis
51
Articles
Ababa University, Addis Ababa, Ethiopia (T J Beyene MSc,

K Deribe MPH, W Mekonnen PhD); Wellington Hospital, Wellington,
New Zealand (N Bhala DPhil); Post Graduate Institute of Medical
Education and Research, Chandigarh, UT, India (A Bhalla MD); Medical
Center (Z A Bhutta PhD), Aga Khan University, Karachi, Pakistan
(M I Nisar MSc); I. Evdokimov Moscow State University of Medicine and
Dentistry, Moscow, Russia (B Bikbov MD); University of MissouriKansas City, Kansas City, KS, USA (A Bin Abdulhak MD); Sydney School
of Public Health (T R Driscoll PhD), Woolcock Institute of Medical
Research (G B Marks PhD), University of Sydney (F M Blyth PhD,
J Leigh PhD, Prof L March PhD), Sydney, Australia; Ministry of Health
(S B Uzun MSc), General Directorate of Health Research, Ankara,
Turkey (B Bora Basara PhD); Tel Aviv Saurasky Medical Center, Tel Aviv,
Israel (Prof N M Bornstein MD); World Bank, Washington DC, DC, USA
(D Bose PhD); Vision & Eye Research Unit, Anglia Ruskin University,
Cambridge, UK (Prof R R Bourne FRCOphth); School of Medicine
(L N Boyers BA), Neurology Department (M T Wallin MD), Georgetown
University, Washington DC, DC, USA; Danube-University Krems,
Krems an der Donau, Austria (Prof M Brainin MD); University of British
Columbia, Vancouver, Canada (M Brauer ScD, C C Gotay PhD,
F Pourmalek PhD); Cambridge Institute of Public Health, Cambridge,
UK (Prof C EG Brayne MD), Trnava University, Faculty of Health
Sciences and Social Work, Trnava, Slovakia (A Brazinova PhD,
M Majdan PhD); University of Arizona, Tucson, AZ, USA
(Prof N J K Breitborde PhD); Division of Clinical Epidemiology and
Aging Research (B Schoettker PhD), German Cancer Research Center,
Heidelberg, Germany (Prof H Brenner MD); University of Leicester,
Leicester, UK (Prof T S Brugha MD); Monash University and Cabrini
Institute, Melbourne, Australia (Prof R Buchbinder PhD); University of
Massachusetts Medical School, Worcester, MA, USA (G C Buckle MPH,
Prof P Gona PhD); Harvard Medical School (G Bukhman PhD), Harvard
School of Public Health (E L Ding ScD, S Fahimi MD, S Shangguan
MD), Harvard University (M G Shriem MD, Prof J A Salomon PhD),
Cambridge, MA, USA; University of Calgary, Calgary, Alberta, Canada
(A G Bulloch PhD, Prof S B Patten PhD, J Wang PhD); Great Ormond
Street Hospital for Children, London, UK (M Burch MD); R Burnett;
University of Joinville, Brazil (N L Cabral PhD); Telethon Institute for
Child Health Research, West Perth, Australia (Prof J R Carapetis PhD);
Universidad Autonoma Metropolitana, Mexico City, Mexico
(R Cardenas ScD); University at Albany, Albany, NY, USA
(Prof D O Carpenter MD); Stroke Unit, University of Perugia, Perugia,
Italy (V Caso MD); Colombian National Health Observatory, Instituto
Nacional de Salud, Bogota, Colombia (C A Castaneda-Orjuela EcoMSc);
Division of Pharmacoepidemiology and Pharmacovigilance, Spanish
Medicines and Healthcare Products Agency (AEMPS), Ministry of
Health, Madrid, Spain (F Catala-Lopez PhD); National Tuberculosis
Institute, Bangalore, India (V K Chadha MD); Institute of Epidemiology
and Preventive Medicine (H-H Lin ScD), National Taiwan University
(Prof J-C Chang PhD), Taipei City, Taiwan, Province of China; Cancer
Institute, Chinese Academy of Medical Sciences, Beijing, China
(W Chen MD, PhD); Division of Intramural Research, National Institute
of Environmental Health Sciences, National Institutes of Health,
Department of Health and Human Services, RTP, NC, USA
(H Chen PhD); Department of Health Development, Institute of
Industrial Ecological Sciences (Y Jiang PhD, Prof K Takahashi MD),
Department of Environmental Department of Environmental
Epidemiology (N Chimed-Ochir MD), University of Occupational and
Environmental Health, Kitakyushu City, Fukuoka Prefecture, Japan;
University of Cambridge, Cambridge, UK (R Chowdhury PhD,
J Murray PhD); Bispebjerg University Hospital, Copenhagen, Denmark
(Prof H Christensen DMSci); Cyprus University of Technology,
Limassol, Cyprus (C A Christophi PhD; Cedars-Sinai Medical Center,
Los Angeles, CA, USA (Prof S S Chugh MD); University of Salerno,
Salerno, Italy (Prof M Cirillo MD; Health Eects Institute, Boston, MA,
USA (A J Cohen DSc); Mayo Clinic, Rochester, MN, USA
(L T Cooper MD, Prof I M Tleyjeh MD); MRC Lifecourse Epidemiology
Unit, University of Southampton, Southampton, UK
(Prof C Cooper FMedSci); Johns Hopkins Bloomberg School of Public
Health, Baltimore, MD, USA (J Coresh PhD, B X Tran PhD) VA San
Diego (S K Jassal MD), University of California (M H Criqui MD,
M B Stein MD), San Diego, CA, USA; Centre for International Health,
52
Dunedin School of Medicine (Prof J A Crump MD), University of Otago

(Prof R G Poulton PhD),Dunedin, New Zealand; Indian Institute of
Public Health (S Goenka PhD), Public Health Foundation of India
(R Dandona PhD, G A Kumar PhD, K S Murthy MPH), Delhi, India;
Guys and St Thomas NHS Foundation Trust, London, UK
(P I Dargan FRCP); Brighton & Sussex Medical School, Brighton, UK
(G Davey MD); University of Medicine and Pharmacy Bucharest,
Bucharest, Romania (D V Davitoiu PhD); Department of Surgery, Jacobi
Medical Center, New York, NY, USA (A Dayama MD); Institute on Aging
(S F de la Vega MD), Institute of Health Policy and Development Studies
(Prof H Lam PhD), National Institutes of Health, Manila, Philippines;
Grith University, Nathan, QLD, Australia (Prof D De Leo DSc); U.S.
Department of Veterans Aairs, Eastern Colorado Healthcare System,
Denver, CO, USA (R P Dellavalle MD); Massey University, Palmerston
North, New Zealand (S Derrett PhD); Beth Israel Medical Center, New
York, NY, USA (D C Des Jarlais PhD); Africa Medical and Research
Foundation in Ethiopia, Addis Ababa, Ethiopia (M Dessalegn MPH);
Hospital for Sick Children, University of Toronto, Toronto, Canada
(G A deVeber MD); University of Peradeniya, Peradeniya, Sri Lanka
(S D Dharmaratne MD); Hospital de la Santa Creu i Sant Pau, Barcelona,
Spain (C Diaz-Torne MD, PhD); Department of Social Medicine, Faculty
of Public Health, Medical University of Varna, Varna, Bulgaria
(K Dokova PhD); University of Rochester Medical Center, Rochester, NY,
USA (Prof E R Dorsey MD); National Institute on Deafness and Other
Communication Disorders (H J Homan MA), National Institutes of
Health (A M Durrani MD), Bethesda, MD, USA; School of Medicine and
Pharmacology (Prof G J Hankey MD), University of Western Australia,
Crawley, WA, Australia (Prof K M Edmond PhD); The Institute of Social
and Economic Studies of Population at the Russian Academy of
Sciences, Chernogolovka, Russia (Prof S P Ermakov DrSc); Arak
University of Medical Sciences & Health Aairs, Arak, Markazi, Iran
(B Eshrati PhD); Non-Communicable Diseases Research Center,
Endocrine and Metabolic Research Institute (Prof A Esteghamati MD,
F Farzadfar MD, N Hafezi-Nejad MD, S Sheikhbahaei MD), Digestive
Disease Research Center (Prof R Malekzadeh MD, S G Sepanlou MD),
Sina Trauma and Surgery Research Center (Prof V Rahimi-Movaghar
MD), MS Research Center (M Sahraian MD), Tehran University of
Medical Sciences (P Heydarpour MD), Tehran, Iran; German Hospital
Oswaldo Cruz, Institute of Education and Sciences, Sao Paulo, Brazil
(Prof J G Fernandes PhD); Federal University of Sao Paulo, Sao Paulo,
Brazil (C P Ferri MD); Institute of Gerontology, Acad Med Sci, Kyiv,
Ukraine (N Foigt PhD); University of Edinburgh, Edinburgh,UK
(Prof F R Fowkes FRCPE); James Cook University, Townsville, QLD,
Australia (R C Franklin PhD); Centre for Health Policy & Department of
Infectious Disease Epidemiology (T Furst PhD), Imperial College
London, London, UK (Prof A Rodriguez PhD, M Soljak PhD); Eastern
Health Clinical School (B K Lloyd PhD), Monash University, Malvern
East, VIC, Australia (B J Gabbe PhD, K B Gibney FRACP,
Prof A G Thrift PhD); Clinique Cooperative de Parakou, Parakou,
Borgou, Benin (F G Gankpe MD); Wageningen University, Division of
Human Nutrition, Wageningen, Netherlands (J M Geleijnse PhD);
Agence de Medecine Preventive, Paris, France (B D Gessner MD);
Howard University, Washington, DC, DC, USA (R F Gillum MD);
University of Hail, College of Medicine, Hail, Saudi Arabia
(I A Ginawi MD); University Hospital of Dijon, Dijon, France
(Prof M Giroud MD); Ministry of Labour, Health and Social Aairs,
Tbilisi, Georgia (K Goginashvili MPH); University of California in San
Francisco, San Francisco, CA, USA (R A Gosselin MD, D S Kazi MD);
Department of Diabetes Research, National Center for Global Health
and Medicine, Tokyo, Japan (A Goto MD); University of Virginia School
of Medicine (R L Guerrant MD), Department of Anesthesiology
(A S Terkawi MD), University of Virginia, Charlottesville, VA, USA;
Saint James School of Medicine, Netherlands Antilles (Prof H C
Gugnani PhD); University of Bristol, Bristol, UK (Prof D Gunnell DSc,
K J Looker PhD); Fortis Escorts Hospital, New Delhi, Delhi, India
(R Gupta MD); Kanawha Charleston Health Department, Charleston,
WV, USA (R Gupta PhD); School of Medicine (L Trasande MD), New
York University, New York, NY, USA (Prof H Hagan PhD); Brandeis
University, Waltham, MA, USA (Y Halasa MS, S Shahraz Ph,
Prof D S Shepard PhD, E A Undurraga PhD); Arabian Gulf University,
Manama, Bahrain (Prof R R Hamadeh DPhil); Wayne County
Articles
Department of Health and Human Services, Wayne, MI, USA

(M Hammami MD); School of Public Health, Sun Yae-Sen University,
Guangzhou, Guangdong, China (Prof Y Hao PhD); Parc Sanitari Sant
Joan de Deu, CIBERSAM, University of Barcelona, Barcelona, Spain
(Prof J M Haro MD); International Foundation for Dermatology,
London, UK (Prof R J Hay MD); Mazandaran University of Medical
Sciences, Sari, Mazandaran, Iran (Prof M T Hedayati PhD); Fundacion
Entornos AC, Cuernavaca, Morelos, Mexico (M Hijar PhD); Parnassia
Psychiatric Institute, The Hague, Netherlands, (Prof H W Hoek MD);
Cedar Associates, Menlo Park, CA, USA (J C Hornberger MD); Albert
Einstein College of Medicine, Bronx, NY, USA (Prof H Hosgood PhD);
London School of Hygiene & Tropical Medicine, London, UK (M
Hossain MSc, H Larson PhD, Prof M McKee DSc, Prof N Pearce PhD,
H Stoeckl PhD); Baylor College of Medicine, Waco, TX, USA
(P J Hotez MD); National Institute of Public Health, Ministry of Health,
Tunis, Tunisia (Prof M Hsairi MD); Public Health Division, Secretariat
of the Pacic Community, Noumea, New Caledonia, Australia
(D G Hoy PhD); Central South University, Changsha, China
(G Hu PhD); University of Toronto, Toronto, ON, Canada (H Hu MD);
George Washington University, Washington DC, USA; Centre
Hospitalier Universitaire de La Runion (L Huiart PhD); Public Health
Program, Qatar University, Doha, Qatar (A Husseini PhD); Aarhus
University, Aarhus, Denmark (K M Iburg PhD); National Institute for
Health Development, Tallinn, Estonia (K Innos PhD); Graduate School
of Medicine (M Inoue PhD), School of Public Health (Prof N Kawakami
DMSc), The University of Tokyo, Tokyo, Japan; George Mason
University, Fairfax, VA, USA (K H Jacobsen PhD); Centre for Chronic
Disease Control, New Delhi, India (P Jeemon PhD, D Prabhakaran DM);
Postgraduate Institute of Medical Education and Research, Chandigarh,
India (Prof V Jha DM); Tianjin Centers for Diseases Control and
Prevention, Tianjin, China (G Jiang MPH); Department of
Ophthalmology, Medical Faculty Mannheim of the University of
Heidelberg, Heidelberg, Germany (Prof J B Jonas MD); The National
Institute of Public Health, Copenhagen, Denmark (Prof K Juel PhD);
Zhongshan Hospital (J She PhD), Fudan University, Shanghai, China
(H Kan PhD); Holtz Centre for Infection Research, Braunschweig,
Germany and German Center for Infection Research (DZIF), HannoverBraunschweig site, Hannover-Braunschweig, Germany (A Karch MD);
College of Physicians and Surgeons (C Karimkhani BA), Columbia
University, New York, NY, USA (A E Moran MD); All India Institute of
Medical Sciences, New Delhi, India (Prof G Karthikeyan DM,
Prof V K Paul MD PhD, Prof N Tandon PhD); Oklahoma State
University, Stillwater, OK, USA (A Kaul MD); South African Medical
Research Council, Cape Town, South Africa (A P Kengne PhD); Jordan
University of Science and Technology, AlRamtha, Irbid, Jordan
(Prof Y S Khader ScD); Supreme Council of Health, Doha, Qatar
(AH Khalifa MSc); Health Services Academy, Islamabad, Punjab,
Pakistan (E A Khan MPH); UAE University, Al Ain, Abu Dhabi, United
Arab Emirates (G Khan PhD); Institute of Health Policy and
Management, Seoul National University College of Medicine, Seoul,
South Korea (Prof Y Khang MD); National Center for Disease Control
and Public Health, Tbilisi, Georgia (I Khonelidze MP, L Sturua PhD);
Federal University of Rio Grande do Sul, Rio Grande do Sul, Curitiba,
Paran, Brazil (C Kieling MD); Northeastern University, Boston, MA,
USA (Prof D Kim DrPH); Soonchunhyang University, Asan, South
Korea (Prof S Kim PhD); Simmons College, Boston, MA, USA
(R W Kimokoti MD); University of Canberra, Canberra, ACT Australia
(Y Kinfu PhD); University of Cincinnati, Cincinnati, OH, USA
(B M Kissela MD); Department of Preventive Cardiology, National
Cerebral and Cardiovascular Center, Suita, Japan (Y Kokubo PhD) Center
for Community Empowerment, Health Policy & Humanities
(S Kosen MD), NIHRD, MoH Indonesia, Indonesia
(Prof T S Warouw PhD); School of Public Health (Prof A Kramer PhD),
Department of Public Health Medicine (D Plass PhD), University of
Bielefeld, Bielefeld, Germany; Research Center of Neurology, Moscow,
Russia (M Kravchenko PhD); Oregon Health and Science University,
Portland, OR, USA (S Krishnaswami MD); Univeristy of Montreal,
Montreal, Quebec, Canada (Prof B Kuate Defo PhD); Hacettepe
University, Ankara, Turkey (B Kucuk Bicer PhD); Department of Public
Health (S Polinder PhD), University Medical Center
(Prof E J Kuipers PhD, J Richardus PhD) Erasmus MC, Rotterdam,
Netherlands; Arkansas State University, Jonesboro, AR, USA

(V S Kulkarni PhD); International Institute for Population Sciences,
Mimbai, India (K Kumar MPS); Boston Medical Center, Boston, MA,
USA (G F Kwan MD); Fourth View Consulting, Tallinn, Estonia
(T Lai PhD); Australian Research Centre for Population Oral Health
(ARCPOH), School of Dentistry, The University of Adelaide, Gold Coast,
ALD, Australia (Prof R Lalloo PhD); National Cancer Institute, Rockville,
MD, USA (Q Lan PhD); IAPB and Vision 2020 LA, Weston, FL, USA
(V C Lansingh PhD); Instituto Nacional de Epidemiologia
Dr. Juan H Jara, Mar del Plata, Buenos Aires, Argentina
(A EB Lawrynowicz MD); Nova Southeastern University, Ft. Lauderdale,
FL, USA (J L Leasher OD); Korea University, Seoul, South
Korea(Prof JT Lee PhD, S Yoon PhD); State University of New York,
Albany, NY, USA (R Leung PhD); Tuscany Regional Centre for
Occupational Injuries and Diseases, Florence, Italy (M Levi MD);
Genentech, Inc., South San Francisco, CA, USA (Y Li MD); Department
of Gerontology (Y Zhang PhD), Jinan Central Hospital, Jinan, Shandong,
China (B Li MD); National Oce for Maternal and Child Health
Surveillance, West China Second University Hospital, Sichuan
University, Chengdu, Sichuan, China (Prof J Liang MD); Heart and
Stroke Foundation Canada, Ottawa, ON, Canada (M P Lindsay PhD);
Wayne State University, Detroit, MI, USA (S E Lipshultz MD); Turning
Point, Alcohol & Drug Centre, Eastern Health, Fitzroy, Victoria, Australia
(B K Lloyd PhD); University of Bari, Bari, Italy (Prof G Logroscino PhD);
American Cancer Society, Atlanta, GA, USA (J Lortet-Tieulent MSc);
University of Bern, Switzerland (Prof N Low MD); The Australian
National University, Canberra, ACT, Australia (Prof R M Lucas PhD);
Aintree University Hospital NHS Foundation Trust, Liverpool, UK
(Prof R Lunevicius PhD); Swansea University, Swansea, UK
(Prof R A Lyons MD); Ministry of Health Singapore, Singapore
(S Ma PhD, Z Zhao); Murdoch Childrens Research Institute
(R G Weintraub MB), Royal Childrens Hospital, Melbourne, Australia
Royal Childrens Hospital Melbourne, Melbourne, Australia
(M T Mackay MBBS); University of Zambia, Lusaka, Zambia
(C C Mapoma PhD); University of the East Ramon Magsaysay Medical
Center, Quezon City, Philippines (M B Marzan MSc); Elmhurst Hospital
Center, Mount Sinai Services, Elmhurst, NY, USA (J R Masci MS);
University of York, York, UK (A J Mason-Jones PhD); Medical Research
Council, Cape Town, Western Cape, South Africa (R G Matzopoulos
PhD, Prof C D Parry PhD); Faculty of Health Sciences, Hatter Institute
for Cardiovascular Research in Africa (Prof K Sliwa PhD), University of
Cape Town, Cape Town, South Africa (Prof B M Mayosi DPhil,
Prof D J Stein PhD); AIDC EC, Port Elizabeth, Eastern Cape, South
Africa (T T Mazorodze MA); Royal Prince Alfred Hospital, Sydney,
Australia (N W McGill MBBS); Alaska Native Tribal Health Consortium,
Anchorage, AK, USA (B J McMahon MD); Pereleman School of
Medicine (P A Meaney MD), University of Pennsylvania, Philadelphia,
PA (D Silberberg MD); Janakpuri Superspecialty Hospital, New Delhi,
Delhi, India (Prof M M Mehndiratta DM); Thomas Jeerson University,
Philadelphia, PA, USA (M Meltzer MD); National Institutes of Health,
Bethesda, MD, USA (G Mensah MD); Ifakara Health Institute,
Dar es Salaam, Tanzania (F A Mhimbira MSc); Friedman School of
Nutrition Science and Policy (R Micha PhD, D Mozaarian DrPH), Tufts
University, Medford, MA, USA (P Shi PhD); Pacic Institute for
Research & Evaluation, Calverton MD, USA and Centre for Population
Health Research, Curtin University, Perth, Australia (T R Miller PhD);
University of Ottawa, Ottawa, ON, Canada (E J Mills PhD); Duke
University, Durham, NC, USA (Prof T E Mott PhD); Department of
Medicine, Universiti Kebangsaan Malaysia Medical Center, Kuala
Lampur, Malaysia (Prof N Mohamed Ibrahim MBBch); University of
Salahaddin, Erbil, Iraq (K A Mohammad PhD); University of Papua New
Guinea, Port Moresby, NCD, Papua New Guinea
(Prof G L Mola FRCDG); University of North Texas, Denton, TX, USA
(Prof A R Moore PhD); International Laboratory for Air Quality and
Health, Queensland University of Technology, Brisbane, Australia
(L Morawska PhD); National Center for Child Health and Development,
Setagaya, Tokyo, Japan (R Mori MD); Department of Medicine
(Prof M K Tsilimbaris MD), University of Crete, Crete, Greece
(J Moschandreas PhD); Egerton University, Egerton, Rift Valley, Kenya
(W N Moturi PhD); Philipps-University Marburg, Marburg, Germany
(Prof U O Mueller PhD); Tokyo Medical and Dental University,
53
Articles
Bunkyo-ku, Tokyo, Japan (M Mukaigawara MD); West Hertfordshire

Hospitals NHS Trust, Hertfordshire, UK (M E Murdoch FRCP);
American University of Beirut Medical Center, Beirut, Lebanon
(Prof Z Nahas MD); University of KwaZulu-Natal, Durban,
KwaZulu-Natal, South Africa (Prof K S Naidoo PhD); Azienda
Ospedaliera papa Giovanni XXIII, Bergamo, Italy (Prof L Naldi MD);
Ministry of Health Fiji, Suva, Republic of Fiji (D Nand MPH); Suraj Eye
Institute, Nagpur, Maharashtra, India (Prof V Nangia FRCS); Rollins
School of Public Health (E P Simard PhD), Emory University, Atlanta,
GA, USA (Prof KM V Narayan MD, B Omer PhD, Prof M R Phillips
MD); School of Public Health, City University of New York, New York,
NY, USA (D Nash PhD); Faculty of Medicine, Fez, Morocco
(Prof C Nejjari PhD); Norwegian Center for Addiction Research
(SERAF), University of Oslo, Oslo, Norway (S P Neupane Mphil); WHO
Regional Oce for Europe in Denmark (I Rakovac PhD), World Health
Organization, Geneva, Switzerland (L Newman MD); KEMRI Wellcome
Trust, Kili, Kenya (Prof C R Newton MD); Ministry of Health and Social
Welfare, Dar es Salaam,Tanzania (F N Ngalesoni MSc); Hanoi School of
Public Health, Hanoi, Vietnam (N T Nhung MPH); University of
Bergen, Bergen, Norway (Prof O F Norheim PhD); Department of
Clinical Sciences, Medical Faculty, Lund University, Lund, Sweden
(Prof B Norrving PhD); Makerere University, Kampala, Uganda
(L Nyakarahuka MPH); Kyung Hee University, Seoul, Korea
(I-H Oh PhD); Teikyo University School of Medicine, Itabashi, Tokyo,
Japan (Prof T Ohkubo MD); Lira District Local Government, Lira
Municipal Council, Northern Uganda, Uganda (J Opio MPH); IISFundacion Jimenez Diaz, Madrid, Spain (Prof A Ortiz PhD); Christian
Medical College Ludhiana, Ludhiana, India (J D Pandian MD); Kosin
University College of Medicine, Busan, South Korea (E-K Park PhD);
Independent Researcher, Port Moresby, Papua New Guinea
(B I Pavlin MD); REQUIMTE/Laboratario de Farmacognosia,
Departamento de Quamica, Faculdade de Farmacia, Universidade do
Porto, Portugal (Prof D M Pereira PhD); Hospital Universitario Cruces
and Biocruces Health Research Institute, Barakaldo, Bizkaia, Spain
(F P Perez-Ruiz PhD); Postgraduate Medical Institute, Lahore, Pakistan
(A Pervaiz MHA); Flinders University, Bedford Park, SA, Australia
(Prof K Pesudovs PhD); Aalborg University, Aalborg, Denmark
(C B Peterson PhD); School of Public Health, Faculty of Health Sciences,
University of the Witwatersrand, Johannesburg, South Africa
(Prof M Petzold PhD); Shanghai Jiao Tong University, Shanghai, China
(Prof M R Phillips MD); McMaster University, Hamilton, ON, Canada
(D Poenaru MD); Brigham Young University, Provo, UT, USA
(Prof C A Pope III PhD); Centre for Addiction and Mental Health,
Toronto, ON, Canada (S Popova MD, Prof J Rehm PhD); The Fred
Hollows Foundation, Sydney, Australia (N M Prasad MD); College of
Pharmacy, University of Illinois, Chicago, IL, USA (D Qato PhD);
Contech International, Lahore, Pakistan (A Rafay MBBS); Hamad
Medical Corporation, Doha, Qatar (S ur Rahman FRCPCH); University
of Missouri, Columbia, MO, USA (M Raju PhD); Department of Public
Health, University of the Punjab, Lahore, Pakistan (M Rana PhD);
Center for Disease Analysis, Louisville, CO, USA (H Razavi PhD);
Walden University, Minneapolis, MN, USA (Prof A Refaat PhD);
International Health and Development, Switzerland (Prof S Resniko
PhD); Hospital das Clinicas (Prof A L Ribeiro MD), Escola de
Enfermagem (Prof G Velasquez-Melendez PhD), Universidade Federal
de Minas Gerais, Belo Horizonte, Brazil; Department of Clinical
Neurological Sciences, London Health Sciences Centre, University of
Western Ontario, London, ON, Canada (P M Riccio MD); MRC Unit,
Fajara, The Gambia (A Roca PhD); Centre of Research in Environmental
Epidemiology (CREAL), Barcelona, Spain (D Rojas-Rueda PhD);
Institute of Epidemiology and Medical Biometry, Ulm University, Ulm,
Germany (Prof D Rothenbacher MD); BARC Hospital, Mumbai,
Maharashtra, India (N Roy MD); Muhimbili University of Health and
Allied Sciences, Dar es Salaam, Tanzania (G M Ruhago MA,
B F Sunguya PhD); Rwanda Bio-Medical Center, Kigali, Rwanda
(N Sabin MD); University of Miami, Miller School of Medicine, Miami,
FL, USA (R L Sacco MD); Queensland Centre for Mental Health
Research, The Park for Centre for Mental Health, Wacol, QLD, Australia
(S Saha PhD); Universiti Kebangsaan Malaysia Medical Centre, Bangi,
Selangor, Malaysia (R Sahathevan PhD); Vanderbilt University, Nashville,
TN, USA (U Sampson MPH); Case Western Reserve University,
54
Cleveland, OH, USA (J Sanabria MD); Mafraq Hospital-SEHA,

Abu Dhabi, United Arab Emirates (L Sanchez-Riera MD); Dartmouth
Hitchcock Medical Center, Lebanon, NH, USA (J E Saunders MD);
Marshall University, Huntington, WV, USA (M Sawhney PhD); Novartis,
Istanbul, Turkey (M I Saylan MD); Federal University of Santa Catarina,
Florianpolis, SC, Brazil (I JC Schneider PhD); University of Alabama at
Birmingham, Birmingham, AL, USA (D C Schwebel PhD,
J A Singh MD); Stellenbosch University, Stellenbosch, South Africa
(Prof S Seedat PhD); University of Colorado, Boulder, CO, USA
(B Serdar PhD); An-Najah University, Nablus, Palestine
(A Shaheen PhD); Tokyo University, Tokyo, Japan (K Shibuya MD);
Tachikawa Hospital, Tokyo, Japan (Y Shinohara MD); Finnish Institute
of Occupational Health, Finland (R Shiri PhD); Washington State
University, Pullman, WA, USA (K Shishani PhD); Heriot-Watt
University, Edinburgh, Scotland, UK (I Shiue PhD); Reykjavik
University, Reykjavik, Iceland (I D Sigfusdottir PhD); Dartmouth
College, Hannover, NH, USA (S Soneji PhD); Stavanger University
Hospital, Stavanger, Norway (K Soreide PhD); Federal Research Institute
for Health Organization and Informatics of Ministry of Health of the
Russian Federation, Moscow, Russia (S S Soshnikov PhD); Department
of Clinical Neurological Sciences. Western University, London, ON,
Canada (L A Sposato MD); Faculty of Medicine and Health Sciences,
University Tunku Abdul Rahman, Selangor, Malaysia
(C T Sreeramareddy MD); Centre Hospitalier Nord Deux-Sevres,
Bressuire, France (V K Stathopoulou MD); University Hospital Munich,
Institute and Outpatient Clinic for Occupational, Social and
Environmental Medicine, Munich, Germany (N Steckling MSc);
Department of Neuroscience (Prof L J Stovner PhD), Norwegian
University of Science and Technology, Trondheim, Norway
(Prof T J Steiner PhD); KEELPNO, Centre for Disease Control, Greece,
dispatched to Alexandra General Hospital of Athens, Athens, Greece
(K Stroumpoulis PhD); Northwestern University, Evanston, IL, USA
(M Swaroop MD); Department of Criminology, Law and Society and
Sociology, University of California-Irvine, Irvine, CA, USA
(B L Sykes PhD); University of Illinois, Urbana, IL, USA
(K M Tabb PhD); National Institute of Occupational Health and Poison
Control, China CDC, China (Prof F Tan MD); Chaim Sheba Medical
Center and Tel Aviv University, Tel Aviv, Israel (Prof D Tanne MD);
Westchester Medical Center, Valhalla, NY, USA (M Tavakkoli MD);
Jhpiego, an alate of Johns Hopkins University, Addis Ababa, Ethiopia
(A M Temesgen PhD); Netherlands Institute of Mental Health and
Addiction, Utrecht, Netherlands (M Ten Have PhD); Memorial
University, St Johns, Newfoundland, Canada (E Y Tenkorang PhD);
Department of Anesthesiology (A S Terkawi MD), College of Medicine
(Prof I M Tleyjeh MD), King Fahad Medical City, Riyadh, Saudi Arabial
WorldFish, Penang, Malaysia (A L Thorne-Lyman ScD); University of
Alberta, Edmonton, AL, Canada (M Tonelli MD; Aristotle University of
Thessaloniki, Thessaloniki, Greece (Prof F Topouzis PhD); Cincinnati
Childrens Hospital Medical Center, Cincinnati, OH, USA
(Prof J A Towbin MD); Health Care Center of Anjo Kosei Hospital, Anjo
City, Aichi Prefecture, Japan (H Toyoshima MD); University of Southern
Santa Catarina, Palhoa, Santa Catarina, Brazil (Prof J Traebert PhD);
Department of Neurology, Copenhagen University Hospital Herlev,
Herlev, Copenhagen, Denmark (T Truelsen DMSc); Servicio Canario de
Salud, Santa Cruz de Tenerife, Tenerife, Spain (U Trujillo MD);
Cleveland Clinic, Cleveland, OH, USA (Prof E M Tuzcu MD);
Department of Internal Medicine, Federal Teaching Hospital Abakaliki,
Abakailiki, Ebonyi State, Nigeria (K N Ukwaja MBBS); Netherlands
Leprosy Relief, Netherlands (W H van Brakel PhD); African Population
and Health Research Center, Nairobi, Kenya (S van de Vijver MD);
European Commission, Joint Research Centre, Ispra, Italy
(R Van Dingenen PhD); National Institute for Public Health and the
Environment, Bilthoven, Netherlands (C H van Gool PhD); Research
Center of Neurology, Moscow, Russia (Prof Y Y Varakin MD); UKK
Institute for Health Promotion Research, Tampere, Finland
(Prof T J Vasankari PhD); Neuroscience Centre, Raes Hospital,
Singapore (N Venketasubramanian FRCP); Voluntary Health Services,
Sneha, India (Prof L Vijayakumar PhD); University of Bologna, Bologna
, Italy (Prof F S Violante MD); Higher School of Economics, Moscow,
Russia (Prof V V Vlassov MD); Uniformed Services University of Health
Sciences, Bethesda, MD, USA (S Waller MD); VA Medical Center,
Articles
Washington, DC, USA (M T Wallin MD) ; Institute of Basic Medical

Sciences, Chinese Academy of Medical Sciences, Beijing, China
(X Wan PhD); National Oce for Maternal and Childs Health
Surveillance, China (Prof Y Wang MD); Health Canada, Ottawa, ON,
Canada (S Weichenthal PhD); Institute of Medical Sociology and Social
Medicine, Germany (A Werdecker Dipl.oec.troph); University of
California at Davis, Davis, CA, USA (K R Wessells PhD); University of
Marburg, Hessen, Germany (R Westerman PhD); University of Miami,
Miami, FL, USA (Prof J D Wilkinson MD); Imperial College, London,
UK (Prof T N Williams MBBS); University of Nottingham, Nottingham,
UK (Prof H C Williams DSc); Institute of Public Health, University of
Gondar, Amhara, Ethiopia (S M Woldeyohannes MPH); Ateneo School
of Medicine and Public Health, Pasig City, Manila, Philippines
(J Q Wong MD); Royal Cornwall Hospital, Truro, Cornwall, UK
(Prof A D Woolf FRCP) ; Nanjing University School of Medicine, Jinling
Hospital, Nanjing, China (Prof G Xu MD); G Yang MD; Division of
Cardiovascular Medicine, Jichi Medical University School of Medicine,
Shimotsuke, Tochigi, Japan (Y Yano MD); General Directorate of Health
Research, Ankara, Turkey (G K Yentur PhD);The University of Hong
Kong, Hong Kong, China (Prof P Yip PhD); National Center of
Neurology and Psychiatry, Kodaira, Tokyo, Japan (N Yonemoto MPH);
Jackson State University, Jackson, MS, USA (Prof M Younis PhD);
Department of Epidemiology and Biostatistics, School of Public Health,
Wuhan University and Global Health Institute, Wuhan University,
Wuhan, Hubei, China (Prof C Yu PhD); TCM Medical TK SDN BHD
TCM, Nusajaya, Johor Bahru, Malaysia (K Yun Kin PhD); Mansoura
School of Medicine, Mansoura, Egypt (Prof M ES Zaki MD); Chongqing
Medical University, China (Prof Y Zhao Masters); National Oce of
MCH Surveillance of China, China (Prof J Zhu MD); Landstuhl
Regional Medical Center, USA (D Zonies MD)
Declaration of interests
FP-R has consulted for Astra-Zeneca, Menarini, and Pzer, honoraria for
developing educational materials from Astra-Zeneca, and Menarini,
been a speaker for Astra-Zeneca, Menarini, Sociedad Espanola de
Reumatologia, and has received investigational grants from Fundacion
Espanola de Reumatologia, Ministerio de Sanidad (Gobierno de Espana),
Asociacion de Reumatologos del Hospital de Cruces. JC reports grants
from National Kidney Foundation, is a board member of the Kidney
Disease Improving Global Outcomes, and has a patent on glomerular
ltration rate estimation using a panel of biomarkers pending. The other
authors declare no competing interests.
Acknowledgments
This study was funded by the Bill & Melinda Gates Foundation. VF and
RK were partly supported by the unrestricted educational grant from
Lundbeck and Auckland University of Technology University. RM
received funding from Ministry of Health, Labour and Welfare of Japan.
LD is supported by an Australian National health and Medical Research
Council (NHMRC) Principal Research Fellowship (#1041742). Work by
NY was supported by funding from the Japan Society of Clinical
Pharmacology and Therapeutics. YK would like to thank the National
Heart Foundation, Australia, for extending a special grant to the
University of Canberra that enabled him to participate in the GBD 2013
study and more broadly engage in research on cardiovascular conditions
in Australia. TW would like to acknowledge the Wellcome Trust, through
whom he is supported through a Senior Research Fellowship number
091758. During the study, KJL received funding from Health Protection
Scotland, the National Institute for Health Research (NIHR) Health
Protection Research Unit (HPRU) in Evaluation of Interventions, and
Sexual Health 24. KJL received funding from WHO to conduct the
review of HSV.2 seroprevalence data that informed this study. GRs
contribution to this paper has been on behalf of the International Society
of Nephrology (ISN), as a follow-up of the activities of the GBD 2010
Genitourinary Diseases Expert Group. KTD would like to acknowledge
the following funding source of institutional support: University of
Illinois, Lemann Institute for Brazilian Studies Faculty Research Grant.
KR is supported by the NIHR Oxford BRC and an NIHR Career
Development Fellowship. FC-L would like to thank funding support by
CIBERSAM, Instituto de Salud Carlos III, Spanish Ministry of Economy
and Competitiveness, Madrid, Spain. LJAR would like to acknowledge
the support of Qatar National Research Fund (NPRP 04-924-3-251) who
provided the main funding for generating the data provided to the GBDIHME eort. MBS is a member of the board of directors of the Anxiety
and Depression Association of America (a non-prot professional and
consumer organization). He has in the past 24 months been a consultant
for companies that either market or are conducting research involving
antidepressant or antianxiety medications: Janssen, Pzer, and Tonix
Pharmaceuticals. JAC is supported by the joint US National Institutes of
Health-National Science Foundation Ecology and Evolution of Infectious
Disease program (R01 TW009237) and the UK Biotechnology and
Biological Sciences Research Council (BBSRC) (BB/J010367/1), and by
UK BBSRC Zoonoses in Emerging Livestock Systems awards BB/
L017679, BB/L018926, and BB/L018845. HW, AF, FC, and HE are
aliated with the Queensland Centre for Mental Health Research,
which receives funding from the Queensland Department of Health. EB
has received money for board membership by VIROPHARMA and
EISAI; funding for travel and speaker honoraria from UCB-Pharma and
GlaxoSmithKline and funding for educational presentations from
GlaxoSmithKline; grants for research activities from the Italian Drug
Agency, Italian Ministry of Health, Sano-Aventis, and the American
ALS Association. ML would like to acknowledge the institutional support
received from CeRIMP, Centro Regionale Infortuni e Malattie
Professionali Regione Toscana (via S.Salvi, 12 - 50135 Firenze Italy).
AB would like to acknowledge funding from the Wellcome Trust. CW
was supported by the NIHR Biomedical Research Centre at Guys and
St Thomas National Health Service Foundation Trust and Kings College
London, funded by the NIHR. DS has received research grants or
consultancy honoraria from Abbott, ABMRF, Astrazeneca, Biocodex,
Eli-Lilly, GlaxoSmithKline, Jazz Pharmaceuticals, Johnson & Johnson,
Lundbeck, National Responsible Gambling Foundation, Novartis, Orion,
Pzer, Pharmacia, Roche, Servier, Solvay, Sumitomo, Sun, Takeda,
Tikvah, and Wyeth. DS would like to acknowledge support by the
Medical Research Council of South Africa. DAQ was supported by the
Eunice Kennedy Shriver National Institute of Child Health and Human
Development of the National Institutes of Health under award number
5T32HD057822. The content of this report is solely the responsibility of
the authors and does not necessarily represent the ocial views of the
National Institutes of Health. PJ is supported by a career development
fellowship from the Wellcome Trust, Public Health Foundation of India
and a consortium of UK universities. CK receives research grants from
Brazilian public funding agencies Conselho Nacional de
Desenvolvimento Cientico e Tecnolgico (CNPq), Coordenao de
Aperfeioamento de Pessoal de Nvel Superior (CAPES), and Fundacao
de Amparo a Pesquisa do Estado do Rio Grande do Sul (FAPERGS). He
has also received authorship royalties from publishers Artmed and
Manole. RAL is partly funded through the Farr Institute at CIPHER. The
Farr Institute at CIPHER is supported by a ten-funder consortium:
Arthritis Research UK, the British Heart Foundation, Cancer Research
UK, the Economic and Social Research Council, the Engineering and
Physical Sciences Research Council, the Medical Research Council, the
National Institute of Health Research, the National Institute for Social
Care and Health Research (Welsh Assembly Government), the Chief
Scientist Oce (Scottish Government Health Directorates), the
Wellcome Trust, (MRC Grant No:MR/K006525/1). JAS has received
research grants from Takeda and Savient and consultant fees from
Savient, Takeda, Regeneron and Allergan. JAS is a member of the
executive of OMERACT, an organisation that develops outcome
measures in rheumatology and receives arms-length funding from
36 companies; a member of the American College of Rheumatologys
Guidelines Subcommittee of the Quality of Care Committee; and a
member of the Veterans Aairs Rheumatology Field Advisory
Committee. SIH is funded by a Wellcome Trust Grant (#095066). JM is
funded as a Research Career Development Fellow from the Wellcome
Trust (#089963/Z/09/Z). RL is supported by a National Health and
Medical Research of Australia Fellowship. KK thanks the Director of
International Institute for Population Sciences (IIPS) for giving KK the
opportunity to do PhD at the IIPS, during which KK got the chance to
become a GBD Study 2013 collaborator. HC is supported by the
Intramural Research Program of the NIH, the National Institute of
Environmental Health Sciences. The GBD Vision Loss Expert Group
received additional funding from Brien Holden Vision Institute. NP has
an honorary position with the University of Melbourne, through the
55
Articles
Centre for Eye Research Australia (CERA), and is employed by the Fred
Hollows Foundation (FHF). Access to information on population-based
prevalence studies from the countries they support work in was
primarily as a result of her work at FHF, and the review of the
manuscript and revisions suggested were a part of her position at CERA.
CERA receives Operational Infrastructure CERA receives Operational
Infrastructure Support funding from the Victorian Articles 56
Government. I-HO and S-JYs work was funded by a grant of the Korean
Health Technology research and development project, Ministry of Health
and Welfare, North Korea (grant number HI13C0729). SS is supported
by grants from the NIH and employed by NRF and has honoraria from
pharmaceutical companies. KD is supported by a Wellcome Trust
Fellowship in Public Health and Tropical Medicine (grant number
099876). LM would like to acknowledge the Commonwealth
Government of Australia and the Institute of Bone and Joint Research as
funders of this work as all the original data collection for
musculoskeletal was funded by these sources. BDG works for Agence de
Mdecine Prventive which receives grant specic support from Crucell,
GlaxoSmithKline, Merck, Novartis, and Sano Pasteur. None of these
sources contributed to the current work. MGS previously served as a
consultant for Ellicon. DCDJ was supported by NIH grant R01 DA
003574. LJA-R would like to acknowledge the Qatar National Research
Fund (NPRP 04-924-3-251) who provided the main funding for
generating the data he provided to the GBD-IHME eort. The GBD
Genitourinary Diseases Expert Groups activities with the GBD 2013
have been made on behalf of the International Society of Nephrology. AK
would like to acknowledge funding support from Oklahoma Center for
the Advancement of Science and Technology. KR is supported by the
NIHR Oxford BRC and an NIHR Career Development Fellowship. KD is
supported by a Wellcome Trust Training Fellowship (grant number
099876). KS would like to acknowledge funding from the South African
Medical Research Council. IR and WHO sta acknowledge that the
authors alone are responsible for the views expressed in this article and
they do not necessarily represent the views, decisions or policies of the
institutions with which they are aliated.
References
1
Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability
(YLDs) for 1160 sequelae of 289 diseases and injuries 19902010:
a systematic analysis for the Global Burden of Disease Study 2010.
Lancet 2012; 380: 216396.
2
Baxter AJ, Brugha TS, Erskine HE, Scheurer RW, Vos T, Scott JG.
The epidemiology and global burden of autism spectrum disorders.
Psychol Med 2014; 45: 113.
3
Blencowe H, Vos T, Lee ACC, et al. Estimates of neonatal
morbidities and disabilities at regional and global levels for 2010:
introduction, methods overview, and relevant ndings from the
Global Burden of Disease study. Pediatr Res 2013;
74 (suppl 1): 416.
4
Boyers LN, Karimkhani C, Hilton J, Richheimer W, Dellavalle RP.
Global Burden of Eye and Vision Disease as Reected in the
Cochrane Database of Systematic Reviews. JAMA Ophthalmol
2014; published online Sept 18. DOI:10.1001/
jamaophthalmol.2014.3527.
5
Charlson FJ, Ferrari AJ, Flaxman AD, Whiteford HA. The
epidemiological modelling of dysthymia: application for the Global
Burden of Disease Study 2010. J Aect Disord 2013; 151: 11120.
6
Chugh SS, Havmoeller R, Narayanan K, et al. Worldwide
epidemiology of atrial brillation: a Global Burden of Disease 2010
Study. Circulation 2014; 129: 83747.
7
Cross M, Smith E, Hoy D, et al. The global burden of rheumatoid
arthritis: estimates from the global burden of disease 2010 study.
Ann Rheum Dis 2014; 73: 131622.
8
Cross M, Smith E, Hoy D, et al. The global burden of hip and knee
osteoarthritis: estimates from the global burden of disease 2010
study. Ann Rheum Dis 2014; 73: 132330.
9
Degenhardt L, Charlson F, Mathers B, et al. The global
epidemiology and burden of opioid dependence: results from the
global burden of disease 2010 study. Addiction 2014; 109: 132033.
10 Degenhardt L, Ferrari AJ, Calabria B, et al. The global epidemiology
and contribution of cannabis use and dependence to the global
burden of disease: results from the GBD 2010 study. PLoS One 2013;
8: e76635.
56
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
Degenhardt L, Whiteford HA, Ferrari AJ, et al. Global burden of

disease attributable to illicit drug use and dependence: ndings from
the Global Burden of Disease Study 2010. Lancet 2013; 382: 156474.
Driscoll T, Jacklyn G, Orchard J, et al. The global burden of
occupationally related low back pain: estimates from the Global
Burden of Disease 2010 study. Ann Rheum Dis 2014; 73: 97581.
Erskine HE, Ferrari AJ, Nelson P, et al. Epidemiological modelling
of attention-decit/hyperactivity disorder and conduct disorder for
the Global Burden of Disease Study 2010.
J Child Psychol Psychiatry 2013; 54: 126374.
Erskine HE, Ferrari AJ, Polanczyk GV, et al. The global burden of
conduct disorder and attention-decit/hyperactivity disorder in
2010. J Child Psychol Psychiatry 2014; 55: 32836.
Feigin VL, Forouzanfar MH, Krishnamurthi R, et al, and the Global
Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD
2010) and the GBD Stroke Experts Group. Global and regional
burden of stroke during 1990-2010: ndings from the Global
Burden of Disease Study 2010. Lancet 2014; 383: 24554.
Hay RJ, Johns NE, Williams HC, et al. The global burden of skin
disease in 2010: an analysis of the prevalence and impact of skin
conditions. J Invest Dermatol 2014; 134: 152734.
Higashi H, Barendregt JJ, Kassebaum NJ, Weiser TG, Bickler SW,
Vos T. The burden of selected congenital anomalies amenable to
surgery in low and middle-income regions: cleft lip and palate,
congenital heart anomalies and neural tube defects. Arch Dis Child
2014; published online Sept 26. DOI:10.1136/
archdischild-2014-306175.
Hotez PJ, Alvarado M, Basez M-G, et al. The global burden of
disease study 2010: interpretation and implications for the neglected
tropical diseases. PLoS Negl Trop Dis 2014; 8: e2865.
Hoy D, March L, Brooks P, et al. The global burden of low back
pain: estimates from the Global Burden of Disease 2010 study.
Ann Rheum Dis 2014; 73: 96874.
Hoy D, March L, Woolf A, et al. The global burden of neck pain:
estimates from the global burden of disease 2010 study.
Ann Rheum Dis 2014; 73: 130915.
Hoy DG, Smith E, Cross M, et al. The global burden of
musculoskeletal conditions for 2010: an overview of methods.
Ann Rheum Dis 2014; 73: 98289.
IHME. The Global Burden of Disease: Generating Evidence,
Guiding Policy East Asia and Pacic Regional Edition. Seattle,
WA: Institute for Health Metrics and Evaluation, Human
Development Network, World Bank, 2013.
Guiding Policy Europe and Central Asia Regional Edition. Seattle,
WA: Institute for Health Metrics and Evaluation, Human
Guiding Policy Latin America and Caribbean Regional Edition.
Seattle, WA: Institute for Health Metrics and Evaluation, Human
Guiding Policy Middle East and North Africa Regional Edition.
Seattle, WA: Institute for Health Metrics and Evaluation, Human
Guiding Policy South Asia Regional Edition. Seattle, WA: Institute
for Health Metrics and Evaluation, Human Development Network,
World Bank, 2013.
Guiding Policy Sub-Saharan Africa Regional Edition. Seattle, WA:
Institute for Health Metrics and Evaluation, Human Development
Network, World Bank, 2013.
Leonardi M, Raggi A. Burden of migraine: international
perspectives. Neurol Sci 2013; 34 (suppl 1): S11718.
Mensah GA, Forouzanfar MH, Naghavi M, et al. Comparable
estimates of mortality and trends for cardiovascular disease
including congenital heart disease in 21 world regions in 1990 and
2010: the Global Burden of Diseases, Injuries and Risk Factors
Study. J Am Coll Cardiol 2013; 61: E1406.
Moran AE, Forouzanfar MH, Roth GA, et al. Temporal trends in
ischemic heart disease mortality in 21 world regions, 1980 to 2010:
the Global Burden of Disease 2010 study. Circulation 2014;
129: 148392.
Articles
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
Moran AE, Forouzanfar MH, Roth GA, et al. The global burden of
ischemic heart disease in 1990 and 2010: the Global Burden of
Disease 2010 study. Circulation 2014; 129: 1493501.
Murray CJL, Richards MA, Newton JN, et al. UK health
performance: ndings of the Global Burden of Disease Study 2010.
Lancet 2013; 381: 9971020.
Pederson H, Okland T, Boyers LN, et al. Identifying
Otolaryngology Systematic Review Research Gaps: Comparing
Global Burden of Disease 2010 Results With Cochrane Database of
Systematic Review Content. JAMA Otolaryngol Head Neck Surg
2015; 141: 6772.
Powles J, Fahimi S, Micha R, et al, and the Global Burden of
Diseases Nutrition and Chronic Diseases Expert Group
(NutriCoDE). Global, regional and national sodium intakes in 1990
and 2010: a systematic analysis of 24 h urinary sodium excretion
and dietary surveys worldwide. BMJ Open 2013; 3: e003733.
Pullan RL, Smith JL, Jasrasaria R, Brooker SJ. Global numbers of
infection and disease burden of soil transmitted helminth
infections in 2010. Parasit Vectors 2014; 7: 37.
Risal A, Manandhar K, Steiner TJ, Holen A, Koju R, Linde M.
Estimating prevalence and burden of major disorders of the brain
in Nepal: cultural, geographic, logistic and philosophical issues of
methodology. J Headache Pain 2014; 15: 51.
Smith E, Hoy D, Cross M, et al. The global burden of gout:
estimates from the Global Burden of Disease 2010 study.
Ann Rheum Dis 2014; 73: 147076.
Smith E, Hoy DG, Cross M, et al. The global burden of other
musculoskeletal disorders: estimates from the Global Burden of
Disease 2010 study. Ann Rheum Dis 2014; 73: 146269.
Whiteford HA, Degenhardt L, Rehm J, et al. Global burden of
disease attributable to mental and substance use disorders: ndings
from the Global Burden of Disease Study 2010. Lancet 2013;
382: 157586.
Ferrari AJ, Charlson FJ, Norman RE, et al. Burden of depressive
disorders by country, sex, age, and year: ndings from the global
burden of disease study 2010. PLoS Med 2013; 10: e1001547.
Karimkhani C, Boyers LN, Prescott L, et al. Global burden of skin
disease as reected in Cochrane Database of Systematic Reviews.
JAMA Dermatol 2014; 150: 94551.
Krishnamurthi RV, Feigin VL, Forouzanfar MH, et al, and the
Global Burden of Diseases, Injuries, Risk Factors Study 2010
(GBD 2010), and the GBD Stroke Experts Group. Global and
regional burden of rst-ever ischaemic and haemorrhagic stroke
during 1990-2010: ndings from the Global Burden of Disease
Study 2010. Lancet Glob Health 2013; 1: e25981.
Kassebaum NJ, Jasrasaria R, Naghavi M, et al. A systematic analysis
of global anemia burden from 1990 to 2010. Blood 2014; 123: 61524.
Kassebaum NJ, Bernab E, Dahiya M, Bhandari B, Murray CJL,
Marcenes W. Global burden of severe periodontitis in 19902010:
a systematic review and meta-regression. J Dent Res 2014;
93: 104553.
Moran A, Forouzanfar M, Sampson U, Chugh S, Feigin V,
Mensah G. The epidemiology of cardiovascular diseases in
sub-Saharan Africa: the Global Burden of Diseases, Injuries and
Risk Factors 2010 Study. Prog Cardiovasc Dis 2013; 56: 23439.
Stovner LJ, Ho JM, Svalheim S, Gilhus NE. Neurological
disorders in the Global Burden of Disease 2010 study.
Acta Neurol Scand Suppl 2014; 129: 16.
Pasricha S-R. Anemia: a comprehensive global estimate. Blood 2014;
123: 61112.
Bittles AH. Genetics and global healthcare.
J R Coll Physicians Edinb 2013; 43: 710.
Byass P, de Courten M, Graham WJ, et al. Reections on the global
burden of disease 2010 estimates. PLoS Med 2013; 10: e1001477.
Gabbe BJ, Lyons RA, Harrison JE, et al. Validating and Improving
Injury Burden Estimates Study: the Injury-VIBES study protocol.
Inj Prev 2013; published online Aug 6. DOI:10.1136/injuryprev-2013040936.
Spencer S. Global Burden of Disease 2010 Study: a personal
reection. Glob Cardiol Sci Pract 2013; 2013: 11526.
Hser Y-I, Evans E, Grella C. Commentary on Degenhardt et al.
(2014): Regional variation in the global burden of disease
attributable to opioid dependence-where do the data come from and
does population size matter? Addiction 2014; 109: 133435.
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
Nord E. Disability weights in the Global Burden of Disease 2010:

unclear meaning and overstatement of international agreement.
Health Policy 2013; 111: 99104.
Taylor HR, Jonas JB, Keee J, et al. Disability weights for vision
disorders in Global Burden of Disease study. Lancet 2013; 381: 23.
Voigt K, King NB. Disability weights in the global burden of disease
2010 study: two steps forward, one step back?
Bull World Health Organ 2014; 92: 22628.
GBD 2010 Country Collaboration. GBD 2010 country results:
a global public good. Lancet 2013; 381: 96570.
Gilmour S, Liao Y, Bilano V, Shibuya K. Burden of disease in Japan:
using national and subnational data to inform local health policy.
J Prev Med Public Health 2014; 47: 13643.
Public Health Policy & Strategy Unit/NHS Commissioning Unit.
Living well for longer: a call to action to reduce avoidable premature
mortality. UK Department of Health, 2013.
The global burden of disease and its implications for U.S. Policy.
Council on Foreign Relations. http://www.cfr.org/world/globalburden-disease-its-implications-us-policy/p35394 (accessed
May 11, 2015).
Yu SC, Tan F, Zhou MG, Liu SW, Zhu XJ, Zhu YL. Global Burden
of Disease, Injury and Risk Factor Study 2010: its policy
implications for China. Biomed Environ Sci 2014; 27: 4548.
Murray CJL, Ortblad KF, Guinovart C, et al. Global, regional, and
national incidence and mortality for HIV, tuberculosis, and malaria
during 1990-2013: a systematic analysis for the Global Burden of
Disease Study 2013. Lancet 2014; 384: 100570.
Flaxman A, Murray C, Vos T, eds. Integrated meta-regression
framework for descriptive epidemiology. Seattle, WA: University of
Washington Press, 2014.
Bhatt S, Gething PW, Brady OJ, et al. The global distribution and
burden of dengue. Nature 2013; 496: 50407.
London School of Hygiene and Tropical Medicine. GAHI: Global
Atlas of Helminth Infections. 2014; published online Oct 25.
http://www.thiswormyworld.org/ (accessed Oct 25, 2014).
Forouzanfar MH, Foreman KJ, Delossantos AM, et al. Breast and
cervical cancer in 187 countries between 1980 and 2010: a systematic
analysis. Lancet 2011; 378: 146184.
Lozano R, Naghavi M, Foreman K, et al. Global and regional
mortality from 235 causes of death for 20 age groups in 1990 and
2010: a systematic analysis for the Global Burden of Disease Study
2010. Lancet 2012; 380: 2095128.
National Cancer Institute (United States). United States SEER
Cancer Statistics Review (CSR) 19752011. Bethesda, MD: National
Cancer Institute, 2014 http://ghdx.healthdata.org/record/unitedstates-seer-cancer-statistics-review-csr-1975-2011 (accessed Nov 19,
2014).
Sankaranarayanan R, Swaminathan R, Lucas E. Cancer survival in
Africa, Asia, the Caribbean and Central America (SurvCan). IARC
Scientic Publications, number 162. Lyon, France: International
Agency for Research on Cancer, 2011.
Agency for Healthcare Research and Quality. Agency for Healthcare
Research and Quality. United States Medical Expenditure Panel
Survey 19962012. Rockville, MD: Agency for Healthcare Research
and Quality.
Centers for Disease Control and Prevention (CDC), Medical
University of South Carolina, South Carolina Department of
Disabilities and Special Needs, South Carolina Department of
Health and Environmental Control. United States - South
Carolina Traumatic Brain Injury Follow-up Registry 19992013.
USA.
Haagsma JA. Posttraumatic Stress Disorder Following Injury:
Trajectories and Impact on Health-Related Quality of Life.
J Depress Anxiety 2013; 14: 124249.
Johns Hopkins Bloomberg School of Public Health, University of
Washington, Westat. United States national study on the costs and
outcomes of trauma care 20012003.
Polinder S, van Beeck EF, Essink-Bot ML, et al. Functional outcome
at 2.5, 5, 9, and 24 months after injury in the Netherlands.
J Trauma 2007; 62: 13341.
Ringburg AN, Polinder S, van Ierland MCP, et al. Prevalence and
prognostic factors of disability after major trauma. J Trauma 2011;
70: 91622.
57
Articles
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
58
Van Loey NE, van Beeck EF, Faber BW, van de Schoot R,
Bremer M. Health-Related Quality of Life After Burns: A
Prospective Multicentre Cohort Study With 18 Months Follow-Up.
J Trauma 2011; published online Oct 24. DOI:10.1097/
TA.0b013e3182199072.
GBD 2013 Mortality and Causes of Death Collaborators. Global,
regional, and national age-sex specic all-cause and cause-specic
mortality for 240 causes of death, 1990-2013: a systematic analysis
for the Global Burden of Disease Study 2013. Lancet 2014; published
online Dec 17. DOI:10.1016/S0140-6736(14)61682-2.
Australian Bureau of Statistics. National Survey of Mental Health
and Wellbeing of Adults 1997. Canberra: Australian Bureau of
Statistics.
Rastogi T, Mathers C. Global burden of iron deciency anaemia in
the year 2000. Geneva: World Health Organization, 2002.
Kates EH, Kates JS. Anemia and polycythemia in the newborn.
Pediatr Rev 2007; 28: 3334.
Bishop YM, Fienberg SE, Holland PW. Discrete Multivariate
Analysis Theory and Practice. Cambridge, MA: MIT Press, 1975.
Pearson K. Mathematical contributions to the theory of evolution.
London: Dulau and Co, 1904.
Edmond K, Clark A, Korczak VS, Sanderson C, Griths UK,
Rudan I. Global and regional risk of disabling sequelae from
bacterial meningitis: a systematic review and meta-analysis.
Lancet Infect Dis 2010; 10: 31728.
Bluestone CD. Epidemiology and pathogenesis of chronic
suppurative otitis media: implications for prevention and treatment.
Int J Pediatr Otorhinolaryngol 1998; 42: 20723.
Minja BM, Machemba A. Prevalence of otitis media, hearing
impairment and cerumen impaction among school children in
rural and urban Dar es Salaam, Tanzania.
Int J Pediatr Otorhinolaryngol 1996; 37: 2934.
Salomon JA, Vos T, Hogan DR, et al. Common values in assessing
health outcomes from disease and injury: disability weights
measurement study for the Global Burden of Disease Study 2010.
Lancet 2012; 380: 212943.
Salomon JA. New disability weights for the global burden of
disease. Bull World Health Organ 2010; 88: 879.
Haagsma JA, Noordhout C, Polinder S, et al. The European
disability weights study: assessing disability weights based on the
responses of 30,660 people from four European countries.
Popul Health Metr 2015; 13: 10.
Salomon JA, Haagsma JA, Davis A, et al. Disability weights for the
Global Burden of Disease 2013 Study. Lancet Global Health (in
press).
Aregawi M, Cibulskis RE, Otten M, Williams R. Chapter 3
Interventions to control malaria. In: World malaria report 2009.
Geneva: World Health Organization, 2009.
Baltussen R, Knai C, Sharan M. Iron fortication and iron
supplementation are cost-eective interventions to reduce iron
deciency in four subregions of the world. J Nutr 2004;
134: 267884.
Casey GJ, Montresor A, Cavalli-Sforza LT, et al. Elimination of iron
deciency anemia and soil transmitted helminth infection: evidence
from a fty-four month iron-folic acid and de-worming program.
PLoS Negl Trop Dis 2013; 7: e2146.
Yeung CA. A systematic review of the ecacy and safety of
uoridation. Evid Based Dent 2008; 9: 3943.
Sustainable Development. Proposal for sustainable development
goals: sustainable development knowledge platform. 2014;
published online Nov 25. http://sustainabledevelopment.un.org/
focussdgs.html (accessed Nov 25, 2014).
Llyod LS. Best Practices for Dengue Prevention and Control in
the Americas. Washington, DC: Environmental Health Project,
2003.
Desjeux P. The increase in risk factors for leishmaniasis worldwide.
Trans R Soc Trop Med Hyg 2001; 95: 23943.
Desjeux P. Leishmaniasis: current situation and new perspectives.
Comp Immunol Microbiol Infect Dis 2004; 27: 30518.
Franke CR, Staubach C, Ziller M, Schlter H. Trends in the
temporal and spatial distribution of visceral and cutaneous
leishmaniasis in the state of Bahia, Brazil, from 1985 to 1999.
Trans R Soc Trop Med Hyg 2002; 96: 23641.
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
Reithinger R, Dujardin J-C, Louzir H, Pirmez C, Alexander B,

Brooker S. Cutaneous leishmaniasis. Lancet Infect Dis 2007;
7: 58196.
Hoy D, Geere JA, Davatchi F, Meggitt B, Barrero LH. A time for
action: Opportunities for preventing the growing burden and
disability from musculoskeletal conditions in low- and middle-income
countries. Best Pract Res Clin Rheumatol 2014; 28: 37793.
Blagojevic M, Jinks C, Jeery A, Jordan KP. Risk factors for onset of
osteoarthritis of the knee in older adults: a systematic review and
meta-analysis. Osteoarthritis Cartilage 2010; 18: 2433.
Hart DJ, Spector TD. The relationship of obesity, fat distribution
and osteoarthritis in women in the general population: the
Chingford Study. J Rheumatol 1993; 20: 33135.
AIHW. Health-care expenditure on arthritis and other
musculoskeletal conditions 200809. Canberra: Australian Institute
of Health and Welfare, 2014.
Statistics Norway. Norway survey of living conditions 2002. Olso,
Norway: Statistics Norway, 2004.
Statistics Norway. Norway survey of living conditions 20052006.
Olso: Statistics Norway, 2006.
Statistics Norway. Norway survey of living conditions 20082009.
Olso: Statistics Norway, 2009.
Statistics Norway. Norway survey of living conditions 2012. Olso,
Norway: Statistics Norway, 2013.
Andrews G, Issakidis C, Sanderson K, Corry J, Lapsley H. Utilising
survey data to inform public policy: comparison of the costeectiveness of treatment of ten mental disorders.
Br J Psychiatry 2004; 184: 52633.
Vos T, Haby MM, Barendregt JJ, Kruijshaar M, Corry J, Andrews G.
The burden of major depression avoidable by longer-term treatment
strategies. Arch Gen Psychiatry 2004; 61: 1097103.
Devries KM, Mak JYT, Garca-Moreno C, et al. Global health. The
global prevalence of intimate partner violence against women.
Science 2013; 340: 152728.
Forero R, McLellan L, Rissel C, Bauman A. Bullying behaviour and
psychosocial health among school students in New South Wales,
Australia: cross sectional survey. BMJ 1999; 319: 34448.
Hansen AM, Hogh A, Persson R, Karlson B, Garde AH, rbaek P.
Bullying at work, health outcomes, and physiological stress
response. J Psychosom Res 2006; 60: 6372.
Hillberg T, Hamilton-Giachritsis C, Dixon L. Review of
meta-analyses on the association between child sexual abuse and
adult mental health diculties: a systematic approach.
Trauma Violence Abuse 2011; 12: 3849.
Norman RE, Byambaa M, De R, Butchart A, Scott J, Vos T. The
long-term health consequences of child physical abuse, emotional
abuse, and neglect: a systematic review and meta-analysis.
PLoS Med 2012; 9: e1001349.
Degenhardt L, Bucello C, Calabria B, et al, and the GBD illicit drug
use writing group. What data are available on the extent of illicit
drug use and dependence globally? Results of four systematic
reviews. Drug Alcohol Depend 2011; 117: 85101.
Cheng H, Deng F, Xiong W, Phillips MR. Prevalence of alcohol use
disorders in mainland China: a systematic review. Addiction 2015;
published online Feb 10. DOI:10.1111/add.12876.
Pescosolido BA, Martin JK, Long JS, Medina TR, Phelan JC,
Link BG. A disease like any other? A decade of change in public
reactions to schizophrenia, depression, and alcohol dependence.
Am J Psychiatry 2010; 167: 132130.
Schomerus G, Lucht M, Holzinger A, Matschinger H, Carta MG,
Angermeyer MC. The stigma of alcohol dependence compared with
other mental disorders: a review of population studies.
Alcohol Alcohol 2011; 46: 10512.
Schomerus G, Corrigan PW, Klauer T, Kuwert P, Freyberger HJ,
Lucht M. Self-stigma in alcohol dependence: consequences for
drinking-refusal self-ecacy. Drug Alcohol Depend 2011; 114: 1217.
Mathers CD, Iburg KM, Begg S. Adjusting for dependent
comorbidity in the calculation of healthy life expectancy.
Popul Health Metr 2006; 4: 4.
van Baal PH, Hoeymans N, Hoogenveen RT, de Wit GA,
Westert GP. Disability weights for comorbidity and their inuence
on health-adjusted life expectancy. Popul Health Metr 2006; 4: 1.

Articles: Background

Uploaded by

Copyright:

Available Formats

Articles: Background

Uploaded by

Document Information

Original Title

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Articles: Background

Uploaded by

Copyright:

Available Formats

Articles

Global, regional, and national incidence, prevalence, and

289 diseases and injuries across 21 regions.1 National

www.thelancet.com Published online June 8, 2015 http://dx.doi.org/10.1016/S0140-6736(15)60692-4

See Online for appendix

over time, age, sex, and geography.1 Results for specic

period from 1990 to 2013 were reanalysed using

Cause and sequelae list changes

www.thelancet.com Published online June 8, 2015 http://dx.doi.org/10.1016/S0140-6736(15)60692-4

hospital discharges. For others, most of the data were

188 countries between 1990 and 2013. The DRI values

For the Global Health Data

HIV/AIDS resulting in mycobacterial infection

Intestinal infectious diseases

Lower respiratory infections

Upper respiratory infections

HIV/AIDS resulting in other diseases

Haemophilus inuenzae type B meningitis

Varicella and herpes zoster

Cutaneous and mucocutaneous leishmaniasis

www.thelancet.com Published online June 8, 2015 http://dx.doi.org/10.1016/S0140-6736(15)60692-4

(Table 1 continues on next page)

(Continued from previous page)

Sequelae incidence and prevalence

Maternal hypertensive disorders

Other maternal disorders

Preterm birth complications

Neonatal encephalopathy due to birth asphyxia

The appendix pp 65484 provides a brief description of

Neonatal sepsis and other infections

Other nutritional deciencies

Other communicable, maternal, neonatal, and

Other sexually transmitted diseases

Liver cancer due to hepatitis B

Liver cancer due to hepatitis C

Liver cancer due to alcohol use

Liver cancer due to other causes

(Table 1 continues on next page)

variation within regions; for example, Kenya had 49%,

www.thelancet.com Published online June 8, 2015 http://dx.doi.org/10.1016/S0140-6736(15)60692-4

computational time. For GBD 2013, we generated ts

(Continued from previous page)

Tracheal, bronchus, and lung cancer

Colon and rectum cancer

Lip and oral cavity cancer

Other pharynx cancer

Gallbladder and biliary tract cancer

Malignant skin melanoma

Non-melanoma skin cancer

Brain and nervous system cancer

Ischaemic heart disease

Hypertensive heart disease

Cardiomyopathy and myocarditis

Atrial brillation and utter

Peripheral vascular disease

Other cardiovascular and circulatory diseases

Coal workers pneumoconiosis

Cirrhosis due to hepatitis B

Cirrhosis due to hepatitis C